<SEC-DOCUMENT>0001104659-23-104830.txt : 20230928
<SEC-HEADER>0001104659-23-104830.hdr.sgml : 20230928
<ACCEPTANCE-DATETIME>20230928172557
ACCESSION NUMBER:		0001104659-23-104830
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20230928
DATE AS OF CHANGE:		20230928

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inventiva S.A.
		CENTRAL INDEX KEY:			0001756594
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-258369
		FILM NUMBER:		231291012

	BUSINESS ADDRESS:	
		STREET 1:		50 RUE DE DIJON
		CITY:			DAIX
		STATE:			I0
		ZIP:			21121
		BUSINESS PHONE:		33380447500

	MAIL ADDRESS:	
		STREET 1:		50 RUE DE DIJON
		CITY:			DAIX
		STATE:			I0
		ZIP:			21121
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm2327093-1_424b4.htm
<DESCRIPTION>424B4
<TEXT>
<html>
  <head>
    <title>tm2327093-1_424b4 - none - 8.64066s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:right; width:456pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#8202; Filed pursuant to Rule&#160;424(b)(5)</font>
          <br >
          <font style="letter-spacing:-0.2pt;">&#8202;Registration No. 333-258369</font>&#8203;</div>
        <div style="margin-top:9.81pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS SUPPLEMENT</font> <br ><font style="letter-spacing:-0.2pt;">(To Prospectus Dated August&#160;6, 2021)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font></div>
        <div style="position:relative;margin-top:14pt; text-align:center; width:456pt;">
          <img src="lg_inventiva-4c.jpg" alt="[MISSING IMAGE: lg_inventiva-4c.jpg]" height="86" width="229" >
        </div>
        <div style="margin-top:14.31pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Up to $58,000,000</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">American Depositary Shares representing Ordinary Shares</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have entered into a sale agreement, or Sales Agreement, with Cowen and Company, LLC, or TD&#160;Cowen, relating to the sale of American Depositary Shares, or ADSs, each ADS representing one ordinary share, offered by this prospectus supplement. In accordance with the terms of the Sales Agreement, we may offer and sell ADSs having an aggregate offering price of up to $58.0 million from time to time through TD Cowen, acting as sales agent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our ordinary shares will be sold in the form of ordinary shares represented by American Depositary Shares, or ADSs. Each ADS represents one ordinary share. Our ADSs are listed on the Nasdaq Global Market under the symbol &#8220;IVA&#8221;. On September&#160;27, 2023, the last reported sale price of our ADSs was $4.16 per ADS. Our ordinary shares are listed on Euronext Paris under the symbol &#8220;IVA.&#8221; On September&#160;27, 2023, the closing price of our ordinary shares on Euronext Paris was &euro;4.02 per ordinary share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sales of our ADSs, if any, under this prospectus supplement may be made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act, from time to time. TD Cowen is not required to sell any specific number or dollar amount of securities, but will act as sales agent and use commercially reasonable efforts to arrange on our behalf for the sale of all ADSs requested to be sold by us, consistent with its normal sales practices, on mutually agreed terms between us and TD Cowen. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">TD Cowen will be entitled to compensation at a commission rate of up to 3.0% of the gross sales price per ADS sold under the Sales Agreement. See &#8220;Plan of Distribution&#8221; beginning on page S-27 of this prospectus supplement for additional information regarding the compensation to be paid to TD Cowen. In connection with the sale of the ADSs on our behalf, TD Cowen will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act, and the compensation of TD Cowen will be deemed to be underwriting commissions. We have also agreed to provide indemnification and contribution to TD Cowen with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the authority granted by our shareholders, the ADSs may only be purchased initially by (i)&#160;persons, legal entities (including companies), trusts or investment funds, or other investment vehicles, regardless of their form, under French or foreign law, investing on a regular basis in the pharmaceutical, biotechnology or medical technology sectors; and/or (ii) French or foreign companies, institutions or entities, regardless of their form, carrying out a significant part of their activities in the pharmaceutical, cosmetic or chemical sectors or in medical devices and/or technologies or in research in these fields. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; on page <a href="#tRIFA">S-6</a> of this prospectus supplement and in the documents that are incorporated by reference into this prospectus supplement.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:21.92pt; text-align:center; width:456pt; line-height:20pt;font-weight:bold;font-size:18pt;">
          <font style="letter-spacing:-0.36pt;">TD Cowen</font><font style="font-weight:normal;letter-spacing:0.36pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The date of this prospectus supplement is September 28, 2023.</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a><a name="TOC2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Prospectus Supplement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:235pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATPS"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS SUPPLEMENT </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATPS">S-ii</a></font> <a href="#tATPS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOFA"><font style="letter-spacing:0.2pt;">PRESENTATION OF FINANCIAL AND OTHER INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOFA">S-iii</a></font> <a href="#tPOFA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPSS"><font style="letter-spacing:0.2pt;">PROSPECTUS SUPPLEMENT SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPSS">S-1</a></font> <a href="#tPSS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTHOF"><font style="letter-spacing:0.2pt;">THE OFFERING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTHOF">S-4</a></font> <a href="#tTHOF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">S-6</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF"><font style="letter-spacing:0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSNRF">S-13</a></font> <a href="#tSNRF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">S-15</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDIL"><font style="letter-spacing:0.2pt;">DILUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDIL">S-16</a></font> <a href="#tDIL"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMUFI"><font style="letter-spacing:0.2pt;">MATERIAL U.S. FEDERAL INCOME AND FRENCH TAX CONSIDERATIONS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMUFI">S-18</a></font> <a href="#tMUFI"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD">S-27</a></font> <a href="#tPOD"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMACH"><font style="letter-spacing:0.2pt;">MATERIAL CHANGES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMACH">S-29</a></font> <a href="#tMACH"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEOJ"><font style="letter-spacing:0.2pt;">ENFORCEMENT OF JUDGMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEOJ">S-30</a></font> <a href="#tEOJ"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA1"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA1">S-31</a></font> <a href="#tLEMA1"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">S-31</a></font> <a href="#tEXP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">S-31</a></font> <a href="#tWYCF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:425.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIOCI"><font style="letter-spacing:0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIOCI">S-32</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Prospectus</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:308.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATP">ii</a></font> <a href="#tATP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRSU1"><font style="letter-spacing:0.2pt;">PROSPECTUS SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPRSU1">1</a></font> <a href="#tPRSU1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA1"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA1">6</a></font> <a href="#tRIFA1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF1"><font style="letter-spacing:0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSNRF1">7</a></font> <a href="#tSNRF1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tOSAE1"><font style="letter-spacing:0.2pt;">OFFER STATISTICS AND EXPECTED TIMETABLE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tOSAE1">9</a></font> <a href="#tOSAE1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCAP1"><font style="letter-spacing:0.2pt;">CAPITALIZATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCAP1">10</a></font> <a href="#tCAP1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tOALD1"><font style="letter-spacing:0.2pt;">OFFER AND LISTING DETAILS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tOALD1">11</a></font> <a href="#tOALD1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP1"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP1">12</a></font> <a href="#tUOP1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD1"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD1">13</a></font> <a href="#tPOD1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOSC1"><font style="letter-spacing:0.2pt;">DESCRIPTION OF SHARE CAPITAL </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOSC1">14</a></font> <a href="#tDOSC1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLASO1"><font style="letter-spacing:0.2pt;">LIMITATIONS AFFECTING SHAREHOLDERS OF A FRENCH COMPANY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLASO1">35</a></font> <a href="#tLASO1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOAD1"><font style="letter-spacing:0.2pt;">DESCRIPTION OF AMERICAN DEPOSITARY SHARES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOAD1">37</a></font> <a href="#tDOAD1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOW1"><font style="letter-spacing:0.2pt;">DESCRIPTION OF WARRANTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOW1">45</a></font> <a href="#tDOW1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTAX1"><font style="letter-spacing:0.2pt;">TAXATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTAX1">46</a></font> <a href="#tTAX1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">47</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP1"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP1">47</a></font> <a href="#tEXP1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEOCL1"><font style="letter-spacing:0.2pt;">ENFORCEMENT OF CIVIL LIABILITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEOCL1">48</a></font> <a href="#tEOCL1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF1"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF1">49</a></font> <a href="#tWYCF1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIODB1"><font style="letter-spacing:0.2pt;">INCORPORATION OF DOCUMENTS BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIODB1">50</a></font> <a href="#tIODB1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEAWR1"><font style="letter-spacing:0.2pt;">EXPENSES ASSOCIATED WITH REGISTRATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEAWR1">51</a></font>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tATPS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:120pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS SUPPLEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement is part of a registration statement on Form F-3 that we filed with the Securities and Exchange Commission, or SEC, utilizing a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may from time to time sell ADSs representing our ordinary shares having an aggregate offering price of up to $58.0 million under this prospectus supplement at prices and on terms to be determined by market conditions at the time of the offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein or therein include important information about us, the securities being offered and other information you should know before investing in our securities. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained or incorporated by reference in the accompanying prospectus or any document incorporated by reference in this prospectus supplement that was filed with the SEC before the date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date (for example, a document incorporated by reference in this prospectus supplement), the statement in the document having the later date modifies or supersedes the earlier statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should rely only on the information contained in or incorporated by reference in this prospectus supplement and in any free writing prospectus that we authorized for use in connection with this offering. We have not, and the sales agent has not, authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and the sales agent is not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein or therein, and any free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein or therein, and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making an investment decision. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus supplement were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise indicated, all references in this prospectus supplement to &#8220;Inventiva,&#8221; &#8220;the company,&#8221; &#8220;our company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Inventiva S.A. and its consolidated subsidiary. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-ii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPOFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:472pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PRESENTATION OF FINANCIAL AND OTHER INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We present our consolidated financial statements in euros and in accordance with IFRS. None of the financial statements incorporated by reference into this prospectus supplement were prepared in accordance with generally accepted accounting principles in the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise specified, all monetary amounts are in euros. All references in this prospectus supplement to &#8220;$,&#8221; &#8220;US$,&#8221; &#8220;U.S.$,&#8221; &#8220;U.S. dollars,&#8221; &#8220;dollars&#8221; and &#8220;USD&#8221; mean U.S. dollars and all references to &#8220;&euro;&#8221; and &#8220;euros,&#8221; mean euros, unless otherwise noted. Throughout this prospectus supplement, references to ADSs mean ADSs or ordinary shares represented by such ADSs, as the case may be. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have made rounding adjustments to some of the figures included in this prospectus supplement. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-iii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPSS">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUPPLEMENT SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by reference into this prospectus supplement, and does not contain all of the information that you need to consider in making your investment decision. For a more complete understanding of our business and this offering, you should carefully read the entire prospectus supplement, the accompanying prospectus and the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, including our historical financial statements and the notes thereto, which are incorporated herein by reference. You should read section titled &#8220;Risk Factors&#8221; beginning on page S-6 of this prospectus supplement and Item&#160;3D. &#8220;Risk Factors&#8221; in our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1756594/000110465923038571/iva-20221231x20f.htm">Annual Report on Form 20-F for the year ended December&#160;31, 2022</a>, as well as the other documents incorporated by reference into this prospectus supplement and the accompanying prospectus, for more information about important risks that you should consider before making a decision to invest in our securities.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Company Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH and other diseases with significant unmet medical need. We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, we are advancing lanifibranor for the treatment of NASH, as well as a pipeline of earlier stage programs in oncology and other diseases with significant unmet medical need. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Lanifibranor for the Treatment of NASH</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;We are developing our lead product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a progressive, chronic liver disease for which there are currently no approved therapies. NASH is believed to affect 12% of the United States adult population and is a leading cause of cirrhosis, liver transplantation and liver cancer. Compared to the general population, patients with NASH have a ten-fold greater risk of liver-related mortality. NASH is characterized by a metabolic process known as steatosis, or the excessive accumulation of fat in the liver, inflammation and ballooning of liver cells and progressive liver fibrosis that can ultimately lead to cirrhosis. Lanifibranor is an orally-available small molecule in development for the treatment of NASH that acts to induce anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor, or PPAR, isoforms. PPARs are well-characterized nuclear receptor proteins that regulate gene expression, and their relevance for the fibrotic, inflammatory, vascular and metabolic processes that characterize NASH is well-established. While there are other PPAR agonists that target only one or two PPAR isoforms, lanifibranor is the only pan-PPAR agonist, meaning that it targets the three isoforms, in clinical development. We believe that this pan-PPAR approach provides for a combination of anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic effects that cannot be obtained with single and dual PPAR agonists. Currently, lanifibranor is our only product candidate in clinical development. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Odiparcil for the Treatment of MPS</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Our second clinical-stage asset is odiparcil, which we were previously developing for the treatment of patients with mucopolysaccharidoses, or MPS, a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells. As announced in 2020, we have decided to focus our clinical efforts on the development of lanifibranor for the treatment of NASH and as part of this decision, we are reviewing available options for potential further development of odiparcil for the treatment of MPS VI and may seek a third-party partner to help pursue the development and commercialization of odiparcil. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Discovery Engine</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;We have a scientific team of approximately 90 people with deep biology, medicinal and computational chemistry, pharmacokinetics, pharmacology and clinical development expertise. We also own a library of approximately 240,000 pharmacologically relevant molecules, 60% of which are proprietary, as well as a wholly-owned research and development facility. Using these assets and this expertise, we have built a discovery engine focused on small molecule compounds that target nuclear receptors, transcription factors and epigenetic modulation. We are leveraging this discovery engine to identify and develop compounds addressing a wide range of indications. Our Hippo signaling pathway program </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:18.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">aims to disrupt the interaction between yes-associated protein, or YAP, and transcription enhancer associated domain transcription factors, or TEAD, an interaction that plays a key role in oncogenic and fibrotic processes. In xenograft and orthotopic models of malignant pleural mesothelioma, or MPM, we observed that YAP-TEAD inhibition was associated with reduced tumor growth and we are in the process of selecting development candidate for our Hippo program, which we anticipate entering pre-clinical development in 2024. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are also advancing a pre-clinical program for the treatment of idiopathic pulmonary fibrosis and have validated a new target within the transforming growth factor beta, or TGF-&beta;, signaling pathway. We aim to find an agonist of NR4A1 that could modulate the TGF-&beta;1 pathway, which is the main driver of the fibrogenesis. Even though the TGF-&beta;1 pathway appears to be central in the development of fibrosis, prior strategies targeting it directly were unsuccessful and even deleterious. We believe NR4A1 has anti-fibrotic properties coming from its ability to regulate the TGF-&beta;1 signaling. We are evaluating the anti-fibrotic properties of agonist compounds that directly bind to NR4A1 and keep it in an active form to inhibit the TGF-&beta;1 signaling. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Pipeline</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
            <img src="fc_deeppipeline-4clr.jpg" alt="[MISSING IMAGE: fc_deeppipeline-4clr.jpg]" height="275" width="605" >
          </div>
          <div style=" float:left; line-height:10pt; margin-top:7.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:7.1pt; margin-bottom:0pt; line-height:10pt; text-align:left; margin-left:20pt;font-size:8pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.16pt;">Licensing agreement giving Chia Tai Tianqing Pharmaceutical Group, Co., LTD. (&#8220;CTTQ&#8221;), an affiliate of Sino Biopharm, exclusive rights to develop and commercialize in China, Hong-Kong, Macao and Taiwan. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:10pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">(2)</font>
            <br >
          </div>
          <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:10pt; text-align:left; margin-left:20pt;font-size:8pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.16pt;">We suspended all MPS-related research and development activities in 2020, and continue to evaluate our options for potential further development of odiparcil for the treatment of MPS. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:10pt; margin-top:4.09pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">(3)</font>
            <br >
          </div>
          <div style=" margin-top:4.09pt; margin-bottom:0pt; line-height:10pt; text-align:left; margin-left:20pt;font-size:8pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.16pt;">Lead generation means identifying molecules in anticipation of selecting candidates. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="font-style:normal;letter-spacing:0.2pt;">We were founded in 2011 and incorporated as a </font><font style="letter-spacing:0.2pt;">soci&#233;t&#233; anonyme</font><font style="font-style:normal;letter-spacing:0.2pt;"> in 2016. We are registered at the Dijon Trade and Companies Register (</font><font style="letter-spacing:0.2pt;">Registre du commerce et des soci&#233;t&#233;s</font><font style="font-style:normal;letter-spacing:0.2pt;">) under the number 537 530 255. In January&#160;2021, we incorporated our wholly-owned U.S. subsidiary, Inventiva Inc. in the state of New Jersey. Our ordinary shares are listed on Euronext Paris under the symbol &#8220;IVA&#8221; and our ADSs are listed on the Nasdaq Global Market under the symbol &#8220;IVA.&#8221; </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our principal executive offices are located at 50 rue de Dijon, 21121 Daix, France. Our telephone number at our principal executive offices is +33 3 80 44 75 00. Our agent for service of process in the United States is Cogency Global Inc., 122 East 42nd Street, 18th Floor, New York, New York 10168. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The SEC maintains a website that contains reports, proxy information statements and other information regarding issuers that file electronically with the SEC. The address of that site is www.sec.gov. Our website address is </font><font style="font-style:italic;letter-spacing:0.2pt;">www.inventivapharma.com</font><font style="letter-spacing:0.2pt;">. The reference to our website is an inactive textual reference only and </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">information contained in, or that can be accessed through, our website or any other website cited in this prospectus is not part of this prospectus. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Implications of Being an Emerging Growth Company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We qualify as an &#8220;emerging growth company&#8221; as defined in the U.S. Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">exemption from the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">to the extent that we no longer qualify as a foreign private issuer, (1)&#160;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (2)&#160;exemptions from the requirements of holding a non-binding advisory vote on executive compensation, including golden parachute compensation. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We may take advantage of these provisions until December&#160;31, 2025 or such earlier time that we no longer qualify as an emerging growth company. We would cease to be an emerging growth company if we have more than $1.235&#160;billion in total annual gross revenue, have more than $700&#160;million in market value of our capital stock held by non-affiliates or issue more than $1.0&#160;billion of non-convertible debt over a three-year period. We may choose to take advantage of some but not all of these reduced burdens. To the extent that we take advantage of these reduced burdens, the information that we provide stockholders may be different than you might obtain from other public companies in which you hold equity interests. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. Since International Financial Reporting Standards make no distinction between public and private companies for purposes of compliance with new or revised accounting standards, the requirements for our compliance as a private company and as a public company are the same. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Implications of Being a Foreign Private Issuer</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are also considered a &#8220;foreign private issuer&#8221; under U.S. securities laws. In our capacity as a foreign private issuer, we are exempt from certain rules under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, that impose certain disclosure obligations and procedural requirements for proxy solicitations under Section&#160;14 of the Exchange Act. In addition, our officers, directors and principal shareholders are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions of Section&#160;16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our securities. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. In addition, we are not required to comply with Regulation&#160;FD, which restricts the selective disclosure of material information. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We will remain a foreign private issuer until such time that more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (1)&#160;the majority of our executive officers or directors are U.S. citizens or residents; (2)&#160;more than 50% of our assets are located in the United States; or (3)&#160;our business is administered principally in the United States. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTHOF">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-bottom:29.61pt; margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">THE OFFERING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Securities offered by us </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">ADSs representing our ordinary shares, having an aggregate offering price of up to $58.0 million and representing, together with all the other shares which have been admitted to trading on Euronext Paris, on a 12-month rolling basis less than 20% of the total number of the Company&#8217;s securities admitted to trading on Euronext Paris. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Plan of distribution </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8220;At the market offering&#8221; that may be made from time to time through our sales agent, TD Cowen. See &#8220;Plan of Distribution&#8221; on page S-27 of this prospectus supplement. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Purchaser restrictions </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Under the authority granted by our shareholders, the ADSs may only be purchased initially by (i) persons, legal entities (including companies), trusts or investment funds, or other investment vehicles, regardless of their form, under French or foreign law, investing on a regular basis in the pharmaceutical, biotechnology or medical technology sectors; and/or (ii) French or foreign companies, institutions or entities, regardless of their form, carrying out a significant part of their activities in the pharmaceutical, cosmetic or chemical sectors or in medical devices and/or technologies or in research in these fields. In order to purchase ADSs in the offering, you will be required to execute and provide to TD Cowen an investor letter representing that you satisfy the foregoing investor criteria. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">The ADSs </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Each ADS represents one ordinary share, nominal value &euro;0.01 per share. The offered ADSs may be evidenced by American Depositary Receipts, or ADRs. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Depositary </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The Bank of New York Mellon </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Use of proceeds </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We currently intend to use the net proceeds from this offering primarily to fund the research and development of our product candidates, for working capital and for general corporate purposes. We may also use a portion of the net proceeds to acquire or invest in businesses, products or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus. See &#8220;Use of Proceeds&#8221; on page S-15 of this prospectus supplement. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Risk factors </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Investing in our securities involves significant risks. See &#8220;Risk Factors&#8221; on page S-6 of this prospectus, and in documents incorporated by reference into this prospectus supplement. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Euronext Paris trading symbol for our ordinary shares </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8220;IVA&#8221; </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Nasdaq Global Market symbol for our ADSs </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8220;IVA&#8221;</font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">All information in this prospectus supplement related to the number of ordinary shares (including ordinary shares represented by ADSs) that will be outstanding after this offering is based on 42,044,796 ordinary shares outstanding as of June&#160;30, 2023, and excludes: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">9,618,638 ordinary shares issued to investors in August&#160;2023 in a transaction exempt from registration under the Securities Act of 1933, as amended; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">816,800 ordinary shares issuable upon the exercise of founder share warrants (</font><font style="font-style:italic;letter-spacing:0.2pt;">bons de souscription de parts de cr&#233;ateur d&#8217;entreprise</font><font style="letter-spacing:0.2pt;">) and share warrants (</font><font style="font-style:italic;letter-spacing:0.2pt;">bons de souscription d&#8217;actions</font><font style="letter-spacing:0.2pt;">) outstanding as of June&#160;30, 2023; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">2,266,023 ordinary shares issuable upon the exercise of warrants issued to the European Investment Bank in November&#160;2022, at a weighted average exercise price of &euro;4.0152 per ordinary share </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">1,079,100 ordinary shares issuable upon the vesting of free shares (</font><font style="font-style:italic;letter-spacing:0.2pt;">actions gratuites</font><font style="letter-spacing:0.2pt;">) outstanding as of June&#160;30, 2023; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">300,000 ordinary shares issuable upon the vesting of performance&#160;units granted to Fr&#233;d&#233;ric Cren, our Chief Executive Officer, subject to Mr.&#160;Cren&#8217;s eligibility to receive free shares (</font><font style="font-style:italic;letter-spacing:0.2pt;">actions gratuites</font><font style="letter-spacing:0.2pt;">) and the subsequent determination of the board of directors to allocate to Mr.&#160;Cren an equivalent number of free shares (</font><font style="font-style:italic;letter-spacing:0.2pt;">actions gratuites</font><font style="letter-spacing:0.2pt;">) in substitution for such performance&#160;units; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">89,771,362 ordinary shares reserved for future issuance under our share-based compensation plans and other delegations of authority from our shareholders.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described below and under the heading &#8220;Risk Factors&#8221; in our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1756594/000110465923038571/iva-20221231x20f.htm">Annual Report on Form 20-F for the year ended December&#160;31, 2022</a>, as updated by our subsequent filings, which are incorporated by reference into this prospectus supplement, before deciding whether to purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors could adversely affect our business, results of operations, financial condition and cash flows, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. Please also read carefully the section below titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to This Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">You may experience immediate and substantial dilution in the net tangible book value per ADS of your investment.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The offering price per ADS in this offering may exceed the net tangible book value per ADS outstanding prior to this offering. After giving effect to the sale of ADSs in the aggregate amount of $58.0 million at an assumed offering price of $4.16 per ADS, the last reported sale price of our ADSs on September&#160;27, 2023 on the Nasdaq Global Market, and after deducting commissions and estimated offering expenses, our as adjusted net tangible book value as of June&#160;30, 2023 would have been $46.7 million, or $0.83 per ADS. You will experience additional dilution at the end of the vesting period for our free shares that we have granted, and upon exercise of any outstanding warrants or options to purchase ordinary shares, or if we otherwise issue additional ordinary shares or ADSs below the offering price. See the section titled &#8220;Dilution&#8221; below for a more detailed illustration of the dilution you would incur if you participate in this offering. Because the sales of the securities offered hereby will be made directly into the market or in negotiated transactions, the prices at which we sell these securities will vary and these variations may be significant. Purchasers of the securities we sell, as well as our existing shareholders, will experience significant dilution if we sell the securities at prices significantly below the price at which they invested. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The ADSs offered hereby will be sold at other than fixed prices, and investors who buy ADSs at different times will likely pay different prices.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because the sales of ADSs offered hereby will be made at other than fixed prices from time to time, the prices at which we sell these ADSs will vary and these variations may be significant. Investors who participate in this offering at different times will likely pay different prices. We will have discretion, subject to investor demand, to vary the timing, prices, and numbers of ADSs sold, and there is no minimum or maximum sale price. Investors may experience a decline in the value of their investment as a result of sales made at prices lower than the prices they paid </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Raising additional capital, including as a result of this offering, may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Until such time, if ever, as we can generate substantial revenue from the sale of our product candidates, we expect to finance our cash needs through a combination of equity offerings, debt financing, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity securities, including from this offering, or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a shareholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements with third parties when </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have broad discretion in the use of the net proceeds from this offering and may use them in ways with which you do not agree and in ways that may not increase the value of your investment.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our management will have broad discretion in the application of the net proceeds that we receive from this offering. We may spend or invest these proceeds in a way with which our shareholders and ADS holders disagree. The failure by our management to apply these funds effectively could harm our business and financial condition. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. These investments may not yield a favorable return to our investors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The actual number of ADSs we will issue under the Sales Agreement at any one time or in total is uncertain.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have not committed to sell, and TD Cowen has not committed to purchase or underwrite, any specific number of ADSs under the Sales Agreement. The number of ADSs that are sold in this offering will be determined by us throughout the duration of the Sales Agreement based on, among other things, market conditions and the market price of our ADSs and ordinary shares. Accordingly, it is not possible to predict the number of ADSs that will ultimately be issued under the Sales Agreement, if any ADSs are issued thereunder </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">You may not be able to exercise your right to vote the ordinary shares underlying your ADSs.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Holders of ADSs may exercise voting rights with respect to the ordinary shares represented by the ADSs only in accordance with the provisions of the deposit agreement. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the determination of ADS holders who shall be entitled to give instructions for the exercise of voting rights. Upon timely receipt of notice from us, if we so request, the depositary shall distribute to the holders as of the record date (1)&#160;the notice of the meeting or solicitation of consent or proxy sent by us and (2)&#160;a statement as to the manner in which instructions may be given by the holders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Purchasers of ADSs in the offering may instruct the depositary of their ADSs to vote the ordinary shares underlying their ADSs. Otherwise, purchasers of ADSs in the offering will not be able to exercise voting rights unless they withdraw the ordinary shares underlying the ADSs they hold. However, a holder of ADSs may not know about the meeting far enough in advance to withdraw those ordinary shares. If we ask for a holder of ADSs&#8217; instructions, the depositary, upon timely notice from us, will notify him or her of the upcoming vote and arrange to deliver our voting materials to him or her. We cannot guarantee to any holder of ADSs that he or she will receive the voting materials in time to ensure that he or she can instruct the depositary to vote his or her ordinary shares or to withdraw his or her ordinary shares so that he or she can vote them. If the depositary does not receive timely voting instructions from a holder of ADSs, it may give a proxy to a person designated by us to vote the ordinary shares underlying his or her ADSs. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that a holder of ADSs may not be able to exercise his or her right to vote, and there may be nothing he or she can do if the ordinary shares underlying his or her ADSs are not voted as he or she requested. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Purchasers of ADSs in the offering may not be directly holding our ordinary shares.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A holder of ADSs will not be treated as one of our shareholders and will not have direct shareholder rights. French law governs our shareholder rights. The depositary will be the holder of the ordinary shares underlying ADSs held by purchasers of ADSs in the offering. Purchasers of ADSs in the offering will have ADS holder rights. The deposit agreement among us, the depositary and purchasers of ADSs in the offering, as an ADS holder, and all other persons directly and indirectly holding ADSs, sets out ADS holder rights, as well as the rights and obligations of the depositary. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The right as a holder of ADSs to participate in any future preferential subscription rights or to elect to receive dividends in shares may be limited, which may cause dilution to the holdings of purchasers of ADSs in the offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">According to French law, if we issue additional securities for cash, current shareholders will have preferential subscription rights for these securities on a pro&#160;rata basis unless they waive those rights at an extraordinary meeting of our shareholders (by a two-thirds majority vote) or individually by each shareholder. However, our ADS holders in the United States will not be entitled to exercise or sell such rights unless we register the rights and the securities to which the rights relate under the Securities Act or an exemption from the registration requirements is available. In addition, the deposit agreement provides that the depositary will not make rights available to purchasers of ADSs in the offering unless the distribution to ADS holders of both the rights and any related securities are either registered under the Securities Act or exempted from registration under the Securities Act. Further, if we offer holders of our ordinary shares the option to receive dividends in either cash or shares, under the deposit agreement the depositary may require satisfactory assurances from us that extending the offer to holders of ADSs does not require registration of any securities under the Securities Act before making the option available to holders of ADSs. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to participate in our rights offerings or to elect to receive dividends in shares and may experience dilution in their holdings. In addition, if the depositary is unable to sell rights that are not exercised or not distributed or if the sale is not lawful or reasonably practicable, it will allow the rights to lapse, in which case you will receive no value for these rights. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Purchasers of ADSs in the offering may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ADSs, which may be evidenced by ADRs, are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for any other reason subject to a holder of ADSs&#8217; right to cancel his or her ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders&#8217; meeting or we are paying a dividend on our ordinary shares. In addition, a holder of ADSs may not be able to cancel his or her ADSs and withdraw the underlying ordinary shares when he or she owes money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities. See the section of this prospectus titled &#8220;Description of American Depositary Shares.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">U.S. holders of ADSs may suffer adverse tax consequences if we are characterized as a passive foreign investment company.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the U.S. Internal Revenue Code of 1986, as amended, or the Code, we will be a passive foreign investment company, or PFIC, for any taxable year in which, after the application of certain &#8220;look-through&#8221; rules with respect to subsidiaries, at least 75% of our gross income is passive income, or at least 50% of the value of our assets is attributable to assets that produce passive income or are held for the production of passive income. For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and rents and royalties other than rents and royalties which are received from unrelated parties in connection with the active conduct of a trade or business. Assets that produce or are held for the production of passive income may include cash, even if held as working capital or raised in a public offering, marketable securities, and other assets that may produce passive income. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our PFIC analysis for any taxable year depends on our financial results for all of that year. While we cannot express a definitive view about our PFIC status for 2023, based on our current estimates of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">composition of our income and the valuation of our assets for the taxable year ending December&#160;31, 2023, we do not anticipate being classified as a PFIC with respect to the 2023 taxable year. However, no assurances can be provided that we will not be a PFIC for the current year or any future taxable year. Our status as a PFIC is a fact-intensive determination made on an annual basis and we cannot provide any assurances regarding our PFIC status for the past, current or future taxable&#160;years. In addition, whether we are a PFIC for any taxable year depends on the composition of our income (including whether we receive certain non-refundable grants or subsidies and whether such amounts and reimbursements of certain refundable research tax credits will constitute gross income for purposes of the PFIC test) and the composition and value of our assets (which, may be determined in large part by reference to our market capitalization, which is likely to continue to fluctuate, and on how quickly we use the cash proceeds from this offering in our business) in each year. Therefore, we cannot provide any assurances regarding our PFIC status for the past, current or future taxable&#160;years and our U.S. counsel expresses no opinion regarding our past, current or future PFIC status. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are characterized as a PFIC, U.S. holders (as defined below under the section of this prospectus titled &#8220;&#8212; Material U.S. Federal Income and French Tax Considerations&#8221;) of the ADSs may suffer adverse tax consequences, including having gains realized on the sale of the ADSs treated as ordinary income, rather than capital gain, the loss of the preferential rate applicable to dividends received on the ADSs by individuals who are U.S. holders, and having interest charges apply to distributions by us and the proceeds of sales of the ADSs, and additional reporting requirements under U.S. federal income tax laws and regulations. A U.S. shareholder of a PFIC generally may mitigate these adverse U.S. federal income tax consequences by making a &#8220;qualified electing fund,&#8221; or QEF, election, or a &#8220;mark to market&#8221; election. If we determine that we are a PFIC for any taxable year, we will use commercially reasonable efforts to, and currently expect to, provide the necessary information for U.S. holders to make a QEF election. For further discussion of the PFIC rules and the adverse U.S. federal income tax consequences in the event we are classified as a PFIC, see the section of this prospectus titled &#8220;&#8212; Material U.S. Federal Income and French Tax Considerations&#160;&#8212; Material U.S. Federal Income Tax Considerations For U.S. Holders&#8201;&#8212;&#8201;Passive Foreign Investment Company Considerations.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If a United States person is treated as owning at least 10% of the value or voting power of our ADSs, such United States person may be subject to adverse U.S. federal income tax consequences.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If a U.S. holder (as defined below under &#8220;Material U.S. Federal Income and French Tax Considerations&#8221;) is treated as owning (directly, indirectly or constructively) at least 10% of the value or voting power of our ordinary shares, such U.S. holder may be treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign corporation&#8221; in our group (if any), which may subject such person to adverse U.S. federal income tax consequences. Because our group includes a U.S. subsidiary (Inventiva Inc.), if we were to form or acquire any non-U.S. subsidiaries in the future, such non-U.S. subsidiaries generally will be treated as controlled foreign corporations. A United States shareholder of a controlled foreign corporation will be required to annually report and include in its U.S. taxable income its pro&#160;rata share of &#8220;subpart F income&#8221; and investments in U.S. property by the controlled foreign corporations and its &#8220;global intangible low-taxed income,&#8221; regardless of whether we make any distributions. An individual that is a United States shareholder with respect to a controlled foreign corporation generally will not be allowed certain tax deductions or foreign tax credits that are available to a United States shareholder that is a U.S. corporation. We cannot provide any assurance that we will assist investors in determining whether we or any of our future non-U.S. subsidiaries are treated as controlled foreign corporations or furnish to any United States shareholder the information required to comply with the reporting and tax-paying obligations discussed above. Failure to comply with such reporting obligations may subject a U.S. holder that is a United States shareholder to significant monetary penalties and may prevent the statute of limitations with respect to your U.S. federal income tax return for the year for which reporting was due from starting. U.S. holders should consult their tax advisors regarding the potential application of these rules to their investment in our ADSs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Future changes to tax laws could materially adversely affect our company and reduce net returns to our shareholders.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our tax treatment is subject to the enactment of, or changes in, tax laws, regulations and treaties, or the interpretation thereof, tax policy initiatives and reforms under consideration and the practices of tax </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">authorities in jurisdictions in which we operate, including those related to the Organization for Economic Co-operation and Development&#8217;s, Base Erosion and Profit Shifting Project (including &#8220;BEPS 2.0&#8221;), the European Commission&#8217;s state aid investigations and other initiatives. Such changes may include (but are not limited to) the taxation of operating income, investment income, dividends received or (in the specific context of withholding tax) dividends paid. We are unable to predict what tax reform may be proposed or enacted in the future or what effect such changes would have on our business, but such changes, to the extent they are brought into tax legislation, regulations, policies or practices, could affect our financial position and overall or effective tax rates in the future in countries where we have operations, reduce post-tax returns to our shareholders, and increase the complexity, burden and cost of tax compliance. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Tax authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or non-realization of expected benefits.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, the U.S. Internal Revenue Service or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#8220;permanent establishment&#8221; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. A tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, in which case, we expect that we might contest such assessment. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The foreign investment control regime in France may limit the ability to certain non-French investors to participate in this or any other offering of our securities.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any investment (i)&#160;by (a)&#160;an individual of foreign nationality, (b)&#160;any individual of French nationality not domiciled in France within the meaning of article 4B of the French General Tax Code (</font><font style="font-style:italic;letter-spacing:0.2pt;">Code G&#233;n&#233;ral des Imp&#244;ts</font><font style="letter-spacing:0.2pt;">), (c)&#160;any entity governed by foreign law, and (d)&#160;any entity governed by French law controlled by one or more of the entities referred to in (a)&#160;to (c), (ii)&#160;which would result in (a)&#160;the acquisition of control&#8201;&#8212;&#8201;within the meaning of article L. 233-3 of the French Commercial Code (Code de Commerce)&#8201;&#8212;&#8201;of a French company, (b)&#160;the acquisition of all or part of a branch of activity of a French company, or (c)&#160;for individuals who are not nationals of a Member State of the European Union or of a State party to the agreement on the European Economic Area that has entered into an administrative assistance agreement with France and/or are not domiciled in one of these States, or for legal entities of which at least one of the members of the control chain is not governed by the law of one of these States or is not a national and/or is not domiciled there, to cross the threshold of 25% of the voting rights of a French company and (iii)&#160;whose activities concern, even occasionally, the research and development of so-called critical technologies, such as biotechnologies, and considered essential to the protection of public health, is subject to prior authorization by the French Minister of the Economy (</font><font style="font-style:italic;letter-spacing:0.2pt;">Minist&#232;re de l&#8217;Economie</font><font style="letter-spacing:0.2pt;">). On July&#160;2, 2020, the Ministry of the Economy and Finance confirmed to us that our activities fell within the scope of this regime. Consequently, all investment projects in our share capital corresponding to the above-mentioned criteria will have to be authorized by the Minister of the Economy prior to their final realization, by referral of the investor concerned. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, French Decree (</font><font style="font-style:italic;letter-spacing:0.2pt;">D&#233;cret</font><font style="letter-spacing:0.2pt;">) No. 2020-892 of July&#160;22, 2020 as amended by French Decree No.&#160;2020-1729 of December&#160;28, 2020, French Decree No. 2021-1758 of December&#160;22, 2021 and French Decree No. 2022-1622 of December&#160;23, 2022 (i)&#160;lowers the scope of application of the foreign investment regime until December&#160;31, 2023 to the crossing of the threshold of 10% of the voting rights of French companies whose shares are admitted to trading on a regulated market and (ii)&#160;subjects this new threshold to a fast track review procedure (filing of a simplified form, delay for the Minister to respond limited to 10&#160;days, transaction deemed authorized in the absence of a response at the end of the delay). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If an investment in our securities requiring the prior authorization of the Minister of the Economy is made without such authorization having been granted, the Minister of the Economy may cancel the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">transaction or order (possibly under financial penalty) the investor concerned (i)&#160;to submit an application for authorization, (ii)&#160;to have the previous situation restored at its own expense or (iii)&#160;to modify the investment. In addition, the Minister may impose undertakings and conditions on the investor (including regular reporting commitments). The investor concerned could also be declared criminally liable and be sanctioned, in particular, by five&#160;years of imprisonment, by exclusion from any public contract or by a fine which may not exceed the highest of the following three amounts: (i)&#160;twice the amount of the investment concerned, (ii)&#160;10% of our annual pre-tax revenues and (iii)&#160;&euro;5&#160;million (for a company) or &euro;1&#160;million (for an individual). The application of these regulations is likely to constitute a potential barrier to investments made by investors located outside the European Economic Area and could therefore limit our access to sources of financing. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our bylaws and French corporate law contain provisions that may delay or discourage a takeover attempt.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Provisions contained in our bylaws and French corporate law could make it more difficult for a third-party to acquire us, even if doing so might be beneficial to our shareholders. In addition, provisions of our bylaws impose various procedural and other requirements, which could make it more difficult for shareholders to effect certain corporate actions. These provisions include the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">under French law, the owner of 90% of the share capital and voting rights of a public company with registered seat in France and whose shares are listed on a regulated market in a Member State of the European Union or in a state party to the European Economic Area Agreement, including France, has the right to force out minority shareholders following a tender offer made to all shareholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">under French law, a non-French resident must file a declaration for statistical purposes with the Bank of France (</font><font style="font-style:italic;letter-spacing:0.2pt;">Banque de France</font><font style="letter-spacing:0.2pt;">) within twenty working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In particular, such filings are required in connection with investments exceeding &euro;15&#160;million that lead to the acquisition of at least 10% of our share capital or voting rights or cross such 10% threshold; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">under French law, certain investments in a French company relating to certain strategic industries that are considered essential for the protection of public health, such as biotechnologies, by individuals or entities are subject to prior authorization of the Ministry of Economy pursuant to&#160;Law n&#176;2019-486 (and as from April&#160;1, 2020 pursuant to the decree n&#176;2019-1590); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a merger (i.e., in a French law context, a stock for stock exchange following which our company would be dissolved into the acquiring entity and our shareholders would become shareholders of the acquiring entity) of our company into a company incorporated in the European Union would require the approval of our board of directors as well as a two-thirds majority of the votes cast by the shareholders present, represented by proxy or voting by mail at the relevant meeting; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a merger of our company into a company incorporated outside of the European Union would require 100% of our shareholders to approve it; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">under French law, a cash merger is treated as a share purchase and would require the consent of each participating shareholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our shareholders have granted and may grant in the future our board of directors broad authorizations to increase our share capital or to issue additional ordinary shares or other securities, such as warrants, to our shareholders, the public or qualified investors, including as a possible defense following the launching of a tender offer for our shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our shareholders have preferential subscription rights on a pro&#160;rata basis on the issuance by us of any additional securities for cash or a set-off of cash debts, which rights may only be waived by the extraordinary general meeting (by a two-thirds majority vote) of our shareholders or on an individual basis by each shareholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our Chief Executive Officer and Deputy Chief Executive Officer have double voting rights with respect to ordinary shares held by them, and their interests may not be aligned with those of our shareholders more generally with respect to a takeover attempt; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our board of directors has the right to appoint directors to fill a vacancy created by the resignation or death of a director, for the remaining duration of such director&#8217;s term of office and subject to the </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:214pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">approval by the shareholders of such appointment at the next shareholders&#8217; meeting, which prevents shareholders from having the sole right to fill vacancies on our board of directors; </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our board of directors can be convened by our chairman, or in the event of his temporary inability, death or incapacity, at the request of at least one-third of the directors. If the board of directors has not met for more than two&#160;months, at least one third of the directors may ask the chairman, who is bound by this request, to convene a meeting of the board of directors on a specific agenda. The Chief Executive Officer may also ask the chairman to convene a meeting of the board of directors on a specific agenda; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our board of directors meetings can only be regularly held if at least half of the directors attend either physically or by way of videoconference or teleconference enabling the directors&#8217; identification and ensuring their effective participation in the board&#8217;s decisions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our shares are nominative or bearer, if the legislation so permits, according to the shareholder&#8217;s choice; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">approval of at least a majority of the votes cast by shareholders present, represented by a proxy, or voting by mail at the relevant ordinary shareholders&#8217; general meeting is required to remove directors with or without cause; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">advance notice is required for nominations to the board of directors or for proposing matters to be acted upon at a shareholders&#8217; meeting, except that a vote to remove and replace a director can be proposed at any shareholders&#8217; meeting without notice; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our bylaws can be amended in accordance with applicable laws; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the crossing of certain thresholds has to be disclosed and can impose certain obligations; see the documents referenced in the section of this annual report titled &#8220;Item&#160;10. Additional Information-Memorandum and Articles of Association;&#8221; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">transfers of shares shall comply with applicable insider trading laws and regulations and, in particular, with the Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16&#160;April&#160;2014 on market abuse, or Market Abuse Regulation; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">pursuant to French law, our bylaws, including the sections relating to the number of directors and election and removal of a director from office, may only be modified by a resolution adopted by at least a two-third majority of the votes cast by our shareholders present, represented by a proxy or voting by mail at the meeting. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein contain forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, that are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. Discussions containing these forward-looking statements may be found, among other places, in the sections titled &#8220;Information on the Company,&#8221; &#8220;Risk Factors&#8221; and &#8220;Operating and Financial Review and Prospects&#8221; incorporated by reference from our most recent Annual Report on Form 20-F, as well as any amendments thereto, filed with the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All statements other than present and historical facts and conditions contained in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein, including statements regarding our future results of operations and financial positions, business strategy, plans and our objectives for future operations, are forward-looking statements. Words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;is designed to,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;objective,&#8221; &#8220;should,&#8221; or the negative of these and similar expressions identify forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our plans to develop and commercialize our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing of initiation of our planned clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing of the availability of data from our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing of any planned investigational new drug application or new drug application; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our plans to research, develop and commercialize our current and future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to successfully cooperate with existing partners or enter into new partnerships, and to fulfill our obligations under any such partnership agreements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to potentially enter into a partnership with a third party for the development and commercialization of odiparcil; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the clinical utility, potential benefits and market acceptance of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our commercialization, marketing and manufacturing capabilities and strategy; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to identify additional products or product candidates with significant commercial potential; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations related to the sufficiency of our capital resources; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">developments and projections relating to our competitors and our industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the impact of government laws and regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the effects of the COVID-19 pandemic on our business and, operations and clinical development timelines and plans; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our intellectual property position; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our estimates regarding future revenue, expenses, capital requirements and need for additional financing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">unfavorable conditions in our industry, the global economy or global supply chain, including financial and credit market fluctuations, international trade relations, political turmoil, natural catastrophes, warfare (such as the conflict involving Russia and Ukraine), and terrorist attacks; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expected use of proceeds from this offering; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">other risks and uncertainties, including those listed in this prospectus under the caption &#8220;Risk Factors.&#8221; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:360pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should refer to the &#8220;Risk Factors&#8221; section contained in this prospectus supplement, and under similar headings in the other documents that are incorporated by reference into this prospectus supplement, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements contained or incorporated by reference in this prospectus supplement or the accompanying prospectus will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should read this prospectus supplement, the accompanying prospectus and the documents and the documents incorporated by reference herein and therein completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The information incorporated by reference in prospectus supplement contains market data and industry forecasts that were obtained from industry publications. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified any third-party information. While we believe the market position, market opportunity and market size information incorporated by reference in this prospectus supplement is generally reliable, such information is inherently imprecise. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:456pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may issue and sell our ADSs representing our ordinary shares, having aggregate sales proceeds of up to $58.0 million from time to time. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares under or fully utilize the sales agreement with TD Cowen as a source of financing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We currently intend to use the net proceeds from this offering primarily to fund the research and development of our product candidates, for working capital and for general corporate purposes. We may also use a portion of the net proceeds to acquire or invest in businesses, products or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus supplement. Pending the use of net proceeds, we intend to invest the net proceeds in short-term, investment-grade, interest bearing obligations, certificates of deposit or direct or guaranteed obligations of the United States government. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIL">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DILUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our net tangible book value as of June&#160;30, 2023 was &euro;(8.3) million ($(9.1) million), with this and all other convenience translations presented in this section, &#8220;Dilution,&#8221; based on the noon buying rate of the Federal Reserve Bank of New York in effect as of June&#160;30, 2023, of &euro;1.00 = $1.0920), or &euro;(0.20) per ordinary share (equivalent to $(0.22) per ADS). Net tangible book value per ordinary share is determined by dividing (1)&#160;our total assets less our intangible assets and our total liabilities by (2)&#160;42,044,796 ordinary shares outstanding as of June&#160;30, 2023. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">After giving effect to the sale of our ADSs in the aggregate amount of $58.0 million at an assumed offering price of $4.16 per ADS, the last reported sale price of our ADSs on the Nasdaq Global Market on September&#160;27, 2023, and after deducting estimated commissions and offering expenses payable by us, our as adjusted net tangible book value as of June&#160;30, 2023 would have been &euro;42.7 million, or &euro;0.76 per ordinary share, equivalent to $46.7 million, or $0.83 per ordinary share and per ADS. This represents an immediate increase in net tangible book value of $0.62 per ordinary share and ADS to existing shareholders and an immediate decrease in net tangible book value of $3.33 per ordinary share and ADSs to investors purchasing in this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table illustrates this calculation on a per ADS basis. The information is illustrative only and will adjust based on the actual prices at which ADSs are sold, the actual number of ADSs sold and other terms of the offering determined at the time our ADSs are sold pursuant to this prospectus supplement. </font>
        </div>
        <table style="width:416pt;height:95pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:343.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Assumed public offering price per ADS </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">4.16 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:343.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net tangible book value per ADS as of June&#160;30, 2023 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">(0.22<font style="position:absolute;">) </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:343.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Increase in net tangible book value per ADS attributable to this offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">0.62 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:343.26pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">As adjusted net tangible book value per ADS as of June&#160;30, 2023, after giving effect to this offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">0.83 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.583pt 0pt; width:343.26pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Decrease in net tangible book value per ADSs to investors purchasing in this </font>
                <br >
                <font style="letter-spacing:0.2pt;">offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">3.33</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All information in this prospectus supplement related to the number of ordinary shares (including ordinary shares represented by ADSs) that will be outstanding after this offering is based on 42,044,796 ordinary shares outstanding as of June&#160;30, 2023, and excludes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">9,618,638 ordinary shares issued to investors in August&#160;2023 in a transaction exempt from registration under the Securities Act of 1933, as amended; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">816,800 ordinary shares issuable upon the exercise of founder share warrants (</font><font style="font-style:italic;letter-spacing:0.2pt;">bons de souscription de parts de cr&#233;ateur d&#8217;entreprise</font><font style="letter-spacing:0.2pt;">) and share warrants (</font><font style="font-style:italic;letter-spacing:0.2pt;">bons de souscription d&#8217;actions</font><font style="letter-spacing:0.2pt;">) outstanding as of June&#160;30, 2023; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">2,266,023 ordinary shares issuable upon the exercise of warrants issued to the European Investment Bank in November&#160;2022, at a weighted average exercise price of &euro;4.0152 per ordinary share </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">1,079,100 ordinary shares issuable upon the vesting of free shares (</font><font style="font-style:italic;letter-spacing:0.2pt;">actions gratuites</font><font style="letter-spacing:0.2pt;">) outstanding as of June&#160;30, 2023; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">300,000 ordinary shares issuable upon the vesting of performance&#160;units granted to Fr&#233;d&#233;ric Cren, our Chief Executive Officer, subject to Mr.&#160;Cren&#8217;s eligibility to receive free shares (</font><font style="font-style:italic;letter-spacing:0.2pt;">actions gratuites</font><font style="letter-spacing:0.2pt;">) and the subsequent determination of the board of directors to allocate to Mr.&#160;Cren an equivalent number of free shares (</font><font style="font-style:italic;letter-spacing:0.2pt;">actions gratuites</font><font style="letter-spacing:0.2pt;">) in substitution for such performance&#160;units; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">89,771,362 ordinary shares reserved for future issuance under our share-based compensation plans and other delegations of authority from our shareholders. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The ADSs subject to the sales agreement with TD Cowen will be sold from time to time at various prices. An increase of $1.00 per ADS in the price at which the ADSs are sold from the assumed offering price of $4.16 per ADS shown in the table above, assuming all of our securities in the aggregate amount of $58.0 million during the term of the sales agreement with TD Cowen are sold at that price, would increase our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:520pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">as adjusted net tangible book value per ADS after the offering to $0.88 per ADS, which would represent a decrease in net tangible book value per ADS to new investors in this offering of $4.28 per ADS, after deducting commissions and estimated offering expenses payable by us. A decrease of $1.00 per ADS in the price at which the ADSs are sold from the assumed offering price of $4.16 per ADS shown in the table above, assuming all of our securities in the aggregate amount of $58.0 million during the term of the sales agreement with TD Cowen are sold at that price, would decrease our as adjusted net tangible book value per ADS after the offering to $0.77 per ADS, which would represent a decrease in net tangible book value per ADS to new investors in this offering of $2.39 per ADS, after deducting commissions and estimated offering expenses payable by us. This information is supplied for illustrative purposes only.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMUFI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MATERIAL U.S. FEDERAL INCOME AND FRENCH TAX CONSIDERATIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following is a summary of certain material U.S. federal income tax and French tax considerations relating to the acquisition, ownership and disposition of ADSs by a U.S. holder (as defined below). This summary addresses these tax considerations only for U.S. holders that purchase the ADSs pursuant to this offering and that will hold such ADSs as capital assets for U.S. federal income tax purposes (generally, property held for investment). This discussion does not address all U.S. federal income tax and French tax matters that may be relevant to a particular U.S. holder. This summary does not address tax considerations applicable to a holder of ADSs that may be subject to special tax rules including, without limitation, the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">banks, financial institutions or insurance companies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">brokers, dealers or traders in securities, currencies, commodities, or notional principal contracts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">tax-exempt or governmental organizations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">persons who hold ADSs through tax-qualified retirement accounts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">real estate investment trusts, regulated investment companies or grantor trusts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">persons that hold the ADSs as part of a &#8220;hedging,&#8221; &#8220;integrated,&#8221; &#8220;wash sale&#8221; or &#8220;conversion&#8221; transaction or as a position in a &#8220;straddle&#8221; for U.S. federal income tax purposes; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">S corporations, partnerships, or other entities or arrangements classified as partnerships for U.S. federal income tax purposes (and investors therein); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">persons acquiring ADSs in connection with a trade or business conducted outside of the United States, including a permanent establishment in France; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">persons that received ADSs as compensation for the performance of services; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">certain former U.S. citizens or long-term residents of the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">holders that own directly, indirectly, or through attribution 10% or more of the voting power or value of our ADSs or, in the case of the discussion of French tax consequences, 5% or more of the voting stock or our share capital; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">holders that have a &#8220;functional currency&#8221; other than the U.S. dollar. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For the purposes of this description, a &#8220;U.S. holder&#8221; is a beneficial owner of ADSs that is (or is treated as), for U.S. federal income tax purposes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an individual who is a citizen or resident of the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a trust, if (1)&#160;a court within the United States is able to exercise primary supervision over its administration and one or more U.S. persons have the authority to control all of the substantial decisions of such trust, or (2)&#160;such trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If a partnership (or any other entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds ADSs, the U.S. federal income tax consequences relating to an investment in the ADSs will depend in part upon the status of the partner and the activities of the partnership. Such a partner or partnership should consult its tax advisor regarding the U.S. federal income tax considerations of acquiring, owning and disposing of the ADSs in its particular circumstances. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The discussion in this section is based in part upon the representations of the depositary and the assumption that each obligation in the deposit agreement and any related agreement will be performed in accordance with its terms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">References in this discussion to ADSs mean ADSs and ordinary shares represented by ADSs, as the case may be. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Persons considering an investment in the ADSs should consult their own tax advisors as to the particular tax consequences applicable to them relating to the acquisition, ownership and disposition of the ADSs, including the applicability of U.S. federal, state and local tax laws, French tax laws and other non-U.S. tax laws.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Material French Tax Considerations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following describes the material French income tax consequences to U.S. holders of purchasing, owning and disposing of our ADSs and, unless otherwise noted, this discussion is the opinion of Gide Loyrette Nouel A.A.R.P.I., our French tax counsel, insofar as it relates to matters of French tax law and legal conclusions with respect to those matters. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This discussion does not purport to be a complete analysis or listing of all potential tax effects of the acquisition, ownership or disposition of our ADSs to any particular investor, and does not discuss tax considerations that arise from rules of general application or that are generally assumed to be known by investors. All of the following is subject to change. Such changes could apply retroactively and could affect the consequences described below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The description of the French income tax and wealth tax consequences set forth below is based on the Convention Between the Government of the United States of America and the Government of the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital of August&#160;31, 1994, or the Treaty, which came into force on December&#160;30, 1995 (as amended by any subsequent protocols, including the protocol of January&#160;13, 2009), and the tax guidelines issued by the French tax authorities in force as of the date of this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This discussion applies only to investors that are entitled to Treaty benefits under the &#8220;Limitation on Benefits&#8221; provision contained in the Treaty. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2011, France introduced a comprehensive set of new tax rules applicable to French assets that are held by or in foreign trusts. These rules provide inter alia for the inclusion of trust assets in the settlor&#8217;s net assets for the purpose of applying the French real estate wealth tax, for the application of French gift and death duties to French assets held in trust, for a specific tax on capital on the French assets of foreign trusts not already subject to the French real estate wealth tax and for a number of French tax reporting and disclosure obligations. The following discussion does not address the French tax consequences applicable to securities (including ADSs) held in trusts. If ADSs are held in trust, the grantor, trustee and beneficiary are urged to consult their own tax advisor regarding the specific tax consequences of acquiring, owning and disposing of securities (including ADSs). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">U.S. holders are urged to consult their own tax advisors regarding the tax consequences of the purchase, ownership and disposition of securities in light of their particular circumstances, especially with regard to the &#8220;Limitations on Benefits&#8221; provision. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Estate and Gift Taxes and Transfer Taxes</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In general, a transfer of securities by gift or by reason of death of a U.S. holder that would otherwise be subject to French gift or inheritance tax, respectively, will not be subject to such French tax by reason of the Convention between the Government of the United States of America and the Government of the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Estates, Inheritances and Gifts, dated November&#160;24, 1978 (as amended by the protocol of December&#160;8, 2004), unless (i)&#160;the donor or the transferor has French nationality or is domiciled in France at the time of making the gift or at the time of his or her death, or (ii)&#160;the securities were used in, or held for use in, the conduct of a business through a permanent establishment or a fixed base in France. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Financial Transaction Tax</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="font-style:normal;letter-spacing:0.2pt;">Pursuant to Article&#160;235 ter ZD of the </font><font style="letter-spacing:0.2pt;">Code g&#233;n&#233;ral des imp&#244;ts</font><font style="font-style:normal;letter-spacing:0.2pt;"> (French Tax Code, or FTC), purchases of shares or ADSs of a French company listed on a regulated market of the European Union or on a foreign regulated market formally acknowledged by the French Financial Market Authority (AMF) are subject to a 0.3% </font><font style="font-style:normal;letter-spacing:-0.35pt;letter-spacing:0.186pt;">French tax on financial transactions provided that the issuer&#8217;s market capitalization exceeds 1&#160;billion euros as of December&#160;1 of the year preceding the taxation year pursuant to Regulations&#160;BOI-ANNX-000467-21/12/2022</font><font style="font-style:normal;letter-spacing:-0.35pt;">&#8203;<font style="letter-spacing:0.186pt;"> </font></font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-size:9.3pt;">
          <font style="letter-spacing:-0.35pt;font-size:10pt;letter-spacing:0.186pt;">issued on December 21, 2022. The Nasdaq Global Market is not currently acknowledged by the French AMF but this may change in the future. A list of French relevant companies whose market capitalization exceeds 1&#160;billion euros as of December&#160;1 of the year preceding the taxation year is published annually and at least once a year, by the French State. As at December&#160;1, 2022, our market capitalization did not exceed 1&#160;billion euros. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Purchases of our securities may be subject to such tax provided that (i)&#160;its market capitalization exceeds 1&#160;billion euros and (ii)&#160;that the Nasdaq Global Market becomes a foreign regulated market formally acknowledged by the AMF. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the case where Article&#160;235 ter ZD of the FTC is not applicable, transfers of shares issued by a French company, which is listed on a regulated or organized market within the meaning of the French Financial and Monetary Code, are subject to uncapped registration duties at the rate of 0.1% if the transfer is evidenced by a written statement (&#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">acte</font><font style="letter-spacing:0.2pt;">&#8221;) executed either in France or outside France. Although there is no case law or official guidelines published by the French tax authorities on this point, transfers of ADSs should remain outside of the scope of the aforementioned 0.1% registration duties. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Tax on Sale or Other Disposition</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a matter of principle, under French tax law, a U.S. holder should not be subject to any French tax on any capital gain from the sale, exchange, repurchase or redemption by us of ordinary shares or ADSs, provided such U.S. holder is not a French tax resident for French tax purposes and has not held more than 25% of our dividend rights, known as </font><font style="font-style:italic;letter-spacing:0.2pt;">&#8220;droits aux benefices sociaux,&#8221;</font><font style="letter-spacing:0.2pt;"> at any time during the preceding five&#160;years, either directly or indirectly, and, as relates to individuals, alone or with relatives (as an exception, a U.S holder resident, established or incorporated in a non-cooperative State or territory as defined in Article&#160;238-0 A of the FTC other than those States or territories mentioned in 2&#176; of 2 bis of the same Article&#160;238-0 A should be subject to a 75% withholding tax in France on any such capital gain, regardless of the fraction of the dividend rights it holds). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under application of the Treaty, a U.S. holder who is a U.S. resident for purposes of the Treaty and entitled to Treaty benefit will not be subject to French tax on any such capital gain unless the ordinary shares or the ADSs form part of the business property of a permanent establishment or fixed base that the U.S. holder has in France. U.S. holders who own ordinary shares or ADSs through U.S. partnerships that are not resident for Treaty purposes are advised to consult their own tax advisors regarding their French tax treatment and their eligibility for Treaty benefits in light of their own particular circumstances. A U.S. holder that is not a U.S. resident for Treaty purposes or is not entitled to Treaty benefit (and in both cases is not resident, established or incorporated in a non-cooperative State or territory as defined in Article&#160;238-0 A of the FTC other than those States or territories mentioned in 2&#176; of 2 bis of the same Article&#160;238-0 A) and has held more than 25% of our dividend rights, known as</font><font style="font-style:italic;letter-spacing:0.2pt;">&#8220;droits aux benefices sociaux,&#8221;</font><font style="letter-spacing:0.2pt;"> at any time during the preceding five&#160;years, either directly or indirectly, and, as relates to individuals, alone or with relatives will be subject to a levy in France at the rate of 12.8% if such U.S. holder is an individual and not a French tax resident or 25% for corporate bodies or other legal entities. Special rules apply to U.S. holders who are residents of more than one country. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Taxation of Dividends</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Dividends paid by a French corporation to non-residents of France are generally subject to French withholding tax at a rate of 12.8% for individuals who are not French tax residents and 25% for corporate bodies. Dividends paid by a French corporation in a non-cooperative State or territory, as defined in Article&#160;238-0 A of the FTC other than those States or territories mentioned in 2&#176; of 2 bis of the same Article&#160;238-0 A, may be subject to French withholding tax at a rate of 75%. However, eligible U.S. holders, other than individuals subject to the French withholding tax at a rate of 12.8%, entitled to Treaty benefits under the &#8220;Limitation on Benefits&#8221; provision contained in the Treaty who are U.S. residents, as defined pursuant to the provisions of the Treaty, will not be subject to this 25% or 75% withholding tax rate, but may be subject to the withholding tax at a reduced rate (as described below). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Treaty, the rate of French withholding tax on dividends paid to an eligible U.S. holder who is a U.S. resident as defined pursuant to the provisions of the Treaty and whose ownership of the ordinary shares or ADSs is not effectively connected with a permanent establishment or fixed base that such U.S. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">holder has in France, may be reduced to 15%, or to 5% if such U.S. holder is a corporation and owns directly or indirectly at least 10% of the share capital of the issuer; such U.S. holder may claim a refund from the French tax authorities of the amount withheld in excess of the Treaty rates of 15% or 5%, if any. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For U.S. holders that are not individuals but are U.S. residents, as defined pursuant to the provisions of the Treaty, the requirements for eligibility for Treaty benefits, including the reduced 5% or 15% withholding tax rates contained in the &#8220;Limitation on Benefits&#8221; provision of the Treaty, are complex, and certain technical changes were made to these requirements by the protocol of January&#160;13, 2009. U.S. holders are advised to consult their own tax advisors regarding their eligibility for Treaty benefits in light of their own particular circumstances. Dividends paid to an eligible U.S. holder may immediately be subject to the reduced rates of 5% or 15% provided that: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">such holder establishes before the date of payment that it is a U.S. resident under the Treaty by completing and providing the depositary with a treaty form (Form 5000) in accordance with the French guidelines (BOI-INT-DG-20-20-20-20-12/09/2012); or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the depositary or other financial institution managing the securities account in the United States of such holder provides the French paying agent with a document listing certain information about the U.S. holder and its ordinary shares or ADSs and a certificate whereby the financial institution managing the U.S. holder&#8217;s securities account in the United States takes full responsibility for the accuracy of the information provided in the document. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Otherwise, dividends paid to a U.S. holder, other than individuals subject to the French withholding tax at a rate of 12.8%, will be subject to French withholding tax at the rate of 25%, or 75% for any U.S. holder if paid in a non-cooperative State or territory (as defined in Article&#160;238-0 A of the FTC, other than those States or territories mentioned in 2&#176; of 2 bis of the same Article&#160;238-0 A), and then reduced at a later date to 5% or 15%, provided that such holder duly completes and provides the French tax authorities with the treaty forms Form 5000 and Form 5001 before December&#160;31 of the calendar year following the year during which the dividend is paid (due to recent case law regarding statute of limitations for filing a withholding tax claim, U.S. holders are advised to consult their own tax advisors in this respect). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain qualifying pension funds and certain other tax-exempt entities are subject to the same general filing requirements as other U.S. holders except that they may have to supply additional documentation evidencing their entitlement to these benefits. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Since the withholding tax rate applicable under French domestic law to U.S. holders who are individuals does not exceed the cap provided in the Treaty (i.e. 15%), the 12.8% rate shall apply, without any reduction provided under the Treaty</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Besides, pursuant to Article&#160;235 quater of the FTC and under certain conditions (in particular reporting obligations), a corporate U.S. Holder which is in a tax loss position for the fiscal year during which the dividend is received may be entitled to a deferral regime, and obtain a withholding tax refund. The tax deferral ends in respect of the first financial year during which this U.S. Holder is in a profit making position, as well as in the cases set out in Article&#160;235 quater of the FTC. Also, pursuant to Article&#160;235 quinquies of the FTC and under certain conditions, a corporate U.S. Holder may be entitled to a refund of a fraction of the withholding tax, up to the difference between the withholding tax paid (on a gross basis) and the withholding tax based on the dividend net of the expenses incurred for the acquisition and conservation directly related to the income, provided broadly (i)&#160;that these expenses would have been tax deductible had the U.S. Holder been established in France, and (ii)&#160;that the tax rules in the United States do not allow the U.S. Holder to offset the withholding tax. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Real Estate Wealth Tax</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;1, 2018, the French wealth tax (</font><font style="font-style:italic;letter-spacing:0.2pt;">imp&#244;t de solidarit&#233; sur la fortune</font><font style="letter-spacing:0.2pt;">) was replaced with a French real estate wealth tax (</font><font style="font-style:italic;letter-spacing:0.2pt;">imp&#244;t sur la fortune immobili&#232;re</font><font style="letter-spacing:0.2pt;">) which applies only to individuals owning French real estate assets or rights, directly or indirectly through one or more legal entities and whose net taxable assets amount to at least 1,300,000 euros to the extent such individials are not French tax residents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">French real estate wealth tax may only apply to U.S. holders to the extent the company holds real estate assets that are not allocated to its operational activity, for the fraction of the value of the financial rights </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">representing such assets. French real estate wealth tax does not generally apply to securities held by an eligible U.S. holder who is a U.S. resident, as defined pursuant to the provisions of the Treaty, provided that such U.S. holder does not own directly or indirectly more than 25% of the issuer&#8217;s financial rights.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Material U.S. Federal Income Tax Considerations for U.S. Holders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This section is a summary of certain material U.S. federal income tax considerations relating to the acquisition, ownership and disposition of ADSs by a U.S. holder. This summary does not address the estate tax considerations, alternative minimum tax considerations, the potential application of the Medicare contribution tax on net investment income, the special tax accounting rules under Section&#160;451(b) of the Internal Revenue Code of 1986, as amended, or the Code, or any U.S. state, local, or non-U.S. tax considerations of the acquisition, ownership and disposition of the ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This summary is based on the Code, existing, proposed and temporary U.S. Treasury Regulations promulgated thereunder and administrative and judicial interpretations thereof and the income tax treaty between France and the United States, in each case as in effect and available on the date hereof. All the foregoing is subject to change, which change could apply retroactively, and to differing interpretations, all of which could affect the tax considerations described below. There can be no assurances that the U.S. Internal Revenue Service, or the IRS, will not take a position different from what is described below concerning the tax consequences of the acquisition, ownership and disposition of the ADSs or that such a position would not be sustained by a court. U.S. holders should consult their own tax advisers concerning the U.S. federal, state, local and non-U.S. tax consequences of acquiring, owning and disposing of the ADSs in their particular circumstances. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In general, and taking into account the earlier assumptions, for U.S. federal income tax purposes, a U.S. holder of an ADS should be treated as holding the ordinary shares represented by such ADS. Accordingly, no gain or loss will be recognized upon an exchange of ADSs for ordinary shares. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Passive Foreign Investment Company Considerations</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In general, a non-U.S. corporation generally will be classified as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes in any taxable year in which, after applying certain look-through rules with respect to the income and assets of its subsidiaries, either: (i)&#160;at least 75% of its gross income is &#8220;passive income&#8221; or (ii)&#160;at least 50% of the average quarterly value of its total gross assets (which would generally be measured by fair market value of its assets, and for which purpose the total value of its assets may be determined in part by the market value of the ADSs, which are subject to change) is attributable to assets that produce &#8220;passive income&#8221; or are held for the production of &#8220;passive income.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Passive income for this purpose generally includes dividends, interest, royalties and rents (other than royalties and rents which are received from unrelated parties in connection with the active conduct of a trade or business), gains from commodities and securities transactions, the excess of gains over losses from the disposition of assets which produce passive income, and includes amounts derived by reason of the temporary investment of funds raised in offerings of the ADSs. If a non-U.S. corporation owns directly or indirectly at least 25% (by value) of the stock of another corporation, the non-U.S. corporation is treated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation and as receiving directly its proportionate share of the other corporation&#8217;s income. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our PFIC analysis for any year depends on our financial results for all of that year. While we cannot express a definitive view about our PFIC status for 2023, based on our current estimates of the composition of our gross income, the valuation of our assets, the nature of our business and our market capitalization, we do not anticipate being classified as a PFIC with respect to the 2023 taxable year. Whether we are a PFIC for any taxable year will depend on our assets and income (including whether we receive certain non-refundable grants or subsidies and whether such amounts and reimbursements of certain refundable research tax credits will constitute gross income for purposes of the PFIC income test) in each year, and because this is a factual determination made annually after the end of each taxable year, there can be no assurance that we will not be considered a PFIC in any taxable year. The composition of our income and assets will be affected by how, and how quickly, we use the cash proceeds from this offering in our business, and the value of our assets may be determined in large part by reference to the market price of the ADSs and our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">ordinary shares, which is likely to fluctuate. As a result, our PFIC status may change from year to year, we cannot provide any assurances regarding our PFIC status for the past, current or future taxable&#160;years and we have not yet made any determination as to our expected PFIC status for the current year. Our U.S. counsel expresses no opinion regarding our past, current or future PFIC status. If we are classified as a PFIC, a U.S. holder will be subject to special rules discussed below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under attribution rules, if we are a PFIC, U.S. holders will be deemed to own their proportionate shares of the stock of any non-U.S. corporations that we own and which are PFICs, or lower-tier PFICs, and will be subject to U.S. federal income tax according to the rules described in the following paragraphs on (1)&#160;certain distributions by a lower-tier PFIC and (2)&#160;a direct or indirect disposition of shares of a lower-tier PFIC, in each case as if the U.S. holder held such shares directly, even though such holders have not received the proceeds of those distributions or dispositions directly. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are a PFIC for any year during which a U.S. holder holds ADSs, and such U.S. holder does not make a timely &#8220;qualified electing fund&#8221; election, as described below, for all taxable&#160;years in such U.S. holder&#8217;s holding period during which we are a PFIC, we generally will continue to be treated as a PFIC with respect to such U.S. holder for all succeeding&#160;years during which the U.S. holder holds ADSs, unless we cease to meet the requirements for PFIC status and the U.S. holder makes a &#8220;deemed sale&#8221; election with respect to the ADSs. If the deemed sale election is made, the U.S. holder will be deemed to sell the ADSs it holds at their fair market value on the last day of the last taxable year in which we qualified as a PFIC which may result in recognition of gain (but not loss) taxable under the PFIC excess distribution regime without the receipt of any corresponding cash. After the deemed sale election, the U.S. holder&#8217;s ADSs would not be treated as shares of a PFIC unless we subsequently again become a PFIC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are a PFIC, and you are a U.S. holder that does not make one of the elections described below, a special tax regime will apply to both (a)&#160;any &#8220;excess distribution&#8221; by us to you (generally, your ratable portion of distributions in any year which are greater than 125% of the average annual distribution received by you in the shorter of the three preceding&#160;years or your holding period for the ADSs) and (b)&#160;any gain realized on the sale or other disposition of the ADSs. Under this regime, any excess distribution and realized gain will be treated as ordinary income and will be subject to tax as if (i)&#160;the excess distribution or gain had been realized ratably over your holding period, (ii)&#160;the amount deemed realized in each year had been subject to tax in each year of that holding period at the highest marginal rate for such year (other than income allocated to the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. holder&#8217;s regular ordinary income rate for the current year and would not be subject to the interest charge discussed below), and (iii)&#160;the interest charge generally applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those&#160;years. In addition, distributions treated as dividends made to you will not qualify for reduced tax rates applicable to long-term capital gains on dividends discussed below under &#8220;Distributions.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain elections may alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment of the ADSs. If a U.S. holder makes a mark-to-market election, the U.S. holder generally will recognize as ordinary income any excess of the fair market value of the ADSs at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ADSs over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. holder makes the election, the U.S. holder&#8217;s tax basis in the ADSs will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of ADSs in a year when we are a PFIC will be treated as ordinary income and any recognized loss will be treated as an ordinary loss. The mark-to-market election is available only if we are a PFIC and the ADSs are &#8220;regularly traded&#8221; on a &#8220;qualified exchange.&#8221; The ADSs will be treated as &#8220;regularly traded&#8221; in any calendar year in which more than a de minimis quantity of the ADSs are traded on a qualified exchange on at least 15&#160;days during each calendar quarter (subject to the rule that trades that have as one of their principal purposes the meeting of the trading requirement as disregarded). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Nasdaq Global Market on which we currently list our ADSs is a qualified exchange for this purpose and, consequently, if the ADSs remain listed on the Nasdaq Global Market and are regularly traded, the mark-to-market election will be available to a U.S. holder. Once made, the election cannot be revoked without the consent of the IRS, unless the ADSs cease to be marketable. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Alternatively, if we provide the necessary information, a U.S. holder can make a &#8220;qualified electing fund election&#8221; or QEF Election, for any taxable year in which we are treated as a PFIC with respect to the U.S. holder. If a U.S. holder makes a QEF Election with respect to a PFIC, in lieu of the tax consequences described above, the U.S. holder will be subject to current taxation on its pro&#160;rata share of the PFIC&#8217;s ordinary earnings and net capital gain for each taxable year that the entity is classified as a PFIC. If a U.S. holder makes a QEF Election with respect to us, any distributions paid by us out of our earnings and profits that were previously included in the U.S. holder&#8217;s income under the QEF Election will not be taxable to the holder. A U.S. holder will increase its tax basis in its ADSs by an amount equal to any income included under the QEF Election and will decrease its tax basis by any amount distributed on the ADSs that is not included in the holder&#8217;s income. In addition, if a U.S. holder has made a QEF election with respect to ADSs, any gain or loss recognized by the U.S. holder on a sale or other disposition of such ADSs will constitute capital gains or losses. If we are a PFIC, we will use commercially reasonable efforts to, and currently expect to, provide the necessary information for U.S. holders to make a QEF Election for United States federal income tax purposes. Generally, a U.S. holder must make the QEF Election by attaching a separate properly completed IRS Form 8621 to the U.S. holder&#8217;s timely filed U.S. federal income tax return for the first taxable year in which the U.S. holder held our ADSs that includes the close of our taxable year for which we are a PFIC. If a U.S. holder does not make and maintain a QEF election for the U.S. holder&#8217;s entire holding period for our ADSs by making the election for the first year in which the U.S. holder owns our ADSs pursuant to this offering, the U.S. holder will be subject to the adverse PFIC rules discussed above unless the U.S. holder can properly make a &#8220;purging election&#8221; with respect to our ADSs in connection with the U.S. Shareholder&#8217;s QEF Election. A purging election may require the U.S. holder to recognize taxable gain on the U.S. holder&#8217;s ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">U.S. holders should consult their tax advisors to determine whether any of these elections would be available and if so, what the consequences of the alternative treatments would be in their particular circumstances. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are determined to be a PFIC, the general tax treatment for U.S. holders described in this section will apply to indirect distributions and gains deemed to be realized by U.S. holders in respect of any of our future subsidiaries that are also determined to be PFICs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If a U.S. holder owns ADSs during any taxable year in which we are a PFIC, the U.S. holder generally will be required to file an IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund) with respect to the company, generally with the U.S. holder&#8217;s federal income tax return for that year. If our company is a PFIC for a given taxable year, then you should consult your tax advisor concerning your annual filing requirements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The U.S. federal income tax rules relating to PFICs are complex. Prospective U.S. investors are urged to consult their own tax advisers with respect to the acquisition, ownership and disposition of the ADSs, the consequences to them of an investment in a PFIC, any elections available with respect to the ADSs and the IRS information reporting obligations with respect to the acquisition, ownership and disposition of the ADSs.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">U.S. Federal Income Tax Consequences If We Are Not a PFIC</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The description of the U.S. federal income tax consequences of the receipt of distributions and the sale or other taxable exchange of our ADSs, described in the following two sections &#8220;&#8212; Distributions&#8221; and &#8220;&#8212; Sale, Exchange or Other Taxable Disposition of the ADSs,&#8221; apply only if we are not a PFIC in the relevant year and our stock is not subject to the rules described above under &#8220;&#8212; Passive Foreign Investment Company Considerations&#8221; because we were a PFIC with respect to a U.S. holder and its ADSs in a prior year. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Distributions</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We do not expect to make any distribution in respect of our ADSs. However, if we do make any such distribution, the gross amount of the distribution (including any amount of non-U.S. tax withheld in respect of such distribution) actually or constructively received by a U.S. holder with respect to ADSs will be taxable to the U.S. holder as a dividend to the extent of the U.S. holder&#8217;s pro&#160;rata share of our current and accumulated earnings and profits as determined under U.S. federal income tax principles. Distributions in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">excess of earnings and profits will be non-taxable to the U.S. holder to the extent of, and will be applied against and reduce (but not below zero), the U.S. holder&#8217;s adjusted tax basis in the ADSs. Distributions in excess of earnings and profits and such adjusted tax basis will generally be taxable to the U.S. holder as described below under &#8220;&#8212; Sale, exchange or other taxable disposition of the ADSs.&#8221; However, since we do not calculate our earnings and profits under U.S. federal income tax principles, it is expected that any distribution will be reported as a dividend, even if that distribution would otherwise be treated as a non-taxable return of capital or as capital gain under the rules described above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Distributions treated as dividends that are received by non-corporate U.S. holders may qualify for reduced tax rates applicable to long-term capital gains on dividends received from a &#8220;qualified foreign corporation&#8221; provided certain holding period and other requirements are met. A non-U.S. corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation (a)&#160;if it is eligible for the benefits of a comprehensive tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange of information provision, or (b)&#160;with respect to any dividend it pays on ADSs which are readily tradable on an established securities market in the United States. Our ADSs are currently listed on the Nasdaq Global Market, which is an established securities market in the United States, and we expect the ADSs to be readily tradable on the Nasdaq Global Market. However, there can be no assurance that the ADSs will be considered readily tradable on an established securities market in the United States in later&#160;years. The Company, which is incorporated under the laws of France, believes that it qualifies as a resident of France for purposes of, and is eligible for the benefits of, the Convention between the Government of the United States of America and the Government of the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital, signed on August&#160;31, 1994, as amended and currently in force, or the U.S.-France Tax Treaty, although there can be no assurance in this regard. Further, the IRS has determined that the U.S.-France Tax Treaty is satisfactory for purposes of the qualified dividend rules and that it includes an exchange-of-information program. Therefore, such dividends will generally qualify for reduced tax rates applicable to long-term capital gains on dividends received from a &#8220;qualified foreign corporation&#8221; provided certain holding period and other requirements are met. The dividends will not be eligible for the dividends-received deduction generally allowed to corporate U.S. holders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A U.S. holder generally may claim the amount of any French withholding tax as either a deduction from gross income or a credit against its U.S. federal income tax liability, subject to generally applicable limitations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">However, the foreign tax credit is subject to numerous complex limitations that must be determined and applied on an individual basis. Each U.S. holder should consult its own tax advisors regarding the foreign tax credit rules. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In general, the amount of a distribution paid to a U.S. holder in a foreign currency will be the dollar value of the foreign currency calculated by reference to the spot exchange rate on the day the Depositary receives the distribution, regardless of whether the foreign currency is converted into U.S. dollars at that time. Any foreign currency gain or loss a U.S. holder realizes on a subsequent conversion of foreign currency into U.S. dollars will be U.S. source ordinary income or loss. If dividends received in a foreign currency are converted into U.S. dollars on the day they are received, a U.S. holder should not be required to recognize foreign currency gain or loss in respect of the dividend. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sale, Exchange or Other Taxable Disposition of the ADSs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A U.S. holder will generally recognize gain or loss for U.S. federal income tax purposes upon the sale, exchange or other taxable disposition of ADSs in an amount equal to the difference between the U.S. dollar value of the amount realized from such sale or exchange and the U.S. holder&#8217;s adjusted tax basis in those ADSs, determined in U.S. dollars. This gain or loss will generally be a capital gain or loss. The adjusted tax basis in the ADSs generally will be equal to the cost of such ADSs. Under current law, capital gain from the sale, exchange or other taxable disposition of ADSs of a non- corporate U.S. holder is generally eligible for a preferential rate of taxation applicable to capital gains, if the non-corporate U.S. holder&#8217;s holding period determined at the time of such sale, exchange or other taxable disposition for such ADSs exceeds one year </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:268pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(i.e., such gain is long-term taxable gain). The deductibility of capital losses for U.S. federal income tax purposes is subject to limitations. Any such gain or loss that a U.S. holder recognizes generally will be treated as U.S. source gain or loss for foreign tax credit limitation purposes. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Backup Withholding and Information Reporting</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">U.S. holders generally will be subject to information reporting requirements with respect to dividends on ADSs and on the proceeds from the sale, exchange or disposition of ADSs that are paid within the United States or through U.S.-related financial intermediaries, unless the U.S. holder is an &#8220;exempt recipient.&#8221; In addition, U.S. holders may be subject to backup withholding on such payments, unless the U.S. holder provides a taxpayer identification number and a duly executed IRS Form W-9 or otherwise establishes an exemption. Backup withholding is not an additional tax, and the amount of any backup withholding will be allowed as a credit against a U.S. holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Foreign Asset Reporting</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain individual U.S. holders are required to report information relating to an interest in the ADSs, subject to certain exceptions (including an exception for shares held in accounts maintained by U.S. financial institutions) by filing IRS Form 8938 (Statement of Specified Foreign Financial Assets) with their federal income tax return. U.S. holders are urged to consult their tax advisors regarding their information reporting obligations, if any, with respect to their ownership and disposition of the ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE DISCUSSION ABOVE IS A SUMMARY OF THE MATERIAL FRENCH AND U.S. FEDERAL INCOME TAX CONSEQUENCES OF AN INVESTMENT IN OUR ADSs OR ORDINARY SHARES AND IS BASED UPON LAWS AND RELEVANT INTERPRETATIONS THEREOF IN EFFECT AS OF THE DATE OF THIS PROSPECTUS, ALL OF WHICH ARE SUBJECT TO CHANGE, POSSIBLY WITH RETROACTIVE EFFECT. EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN ADSs OR ORDINARY SHARES IN LIGHT OF THE INVESTOR&#8217;S OWN CIRCUMSTANCES. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have entered into a sales agreement, or the Sales Agreement, with TD Cowen, under which we may issue and sell from time to time up to $58,000,000 of American Depositary Shares, or ADSs, each ADS representing one ordinary share, through TD Cowen as our sales agent. Sales of the ADSs, if any, will be made at market prices by any method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415 under the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">TD Cowen will offer the ADSs subject to the terms and conditions of the Sales Agreement on a daily basis or as otherwise agreed upon by us and TD Cowen. We will designate the maximum amount of ADSs to be sold through TD Cowen on a daily basis or otherwise determine such maximum amount together with TD Cowen. Subject to the terms and conditions of the Sales Agreement, TD Cowen will use its commercially reasonable efforts to sell on our behalf all of the ADSs requested to be sold by us. We may instruct TD Cowen not to sell the ADSs if the sales cannot be effected at or above the price designated by us in any such instruction. TD Cowen or we may suspend the offering of the ADSs being made through TD Cowen under the Sales Agreement upon proper notice to the other party. TD Cowen and we each have the right, by giving written notice as specified in the Sales Agreement, to terminate the Sales Agreement in each party&#8217;s sole discretion at any time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the authority granted by our shareholders, the ADSs may only be purchased initially by (i)&#160;persons, legal entities (including companies), trusts or investment funds, or other investment vehicles, regardless of their form, under French or foreign law, investing on a regular basis in the pharmaceutical, biotechnology or medical technology sectors; and/or (ii)&#160;French or foreign companies, institutions or entities, regardless of their form, carrying out a significant part of their activities in the pharmaceutical, cosmetic or chemical sectors or in medical devices and/or technologies or in research in these fields. In order to purchase ADSs in the offering, you will be required to execute and provide to TD Cowen an investor letter representing that you satisfy the foregoing investor criteria. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The aggregate compensation payable to TD Cowen as sales agent equals up to 3.0% of the gross sales price of the shares sold through it pursuant to the Sales Agreement. We have also agreed to reimburse TD Cowen up to $200,000 of TD Cowen&#8217;s actual outside legal expenses incurred by TD Cowen in connection with this offering. We estimate that the total expenses of the offering payable by us, excluding commissions payable to TD Cowen under the Sales Agreement, will be approximately $500,000. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory, or self-regulatory organization in connection with the sales, will equal our net proceeds for the sale of such ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">TD Cowen will provide written confirmation to us before the open on Euronext Paris on the day following each day on which the ADSs are sold through it as sales agent under the Sales Agreement. Each confirmation will include the number of ADSs sold through it as sales agent on that day, the volume weighted average price of the shares sold, the&#160;percentage of the daily trading volume and the net proceeds to us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will report at least quarterly the number of ADSs sold through TD Cowen under the Sales Agreement, the net proceeds to us and the compensation paid by us to TD Cowen in connection with the sales of the ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Settlement for sales of the ADSs will occur, unless the parties agree otherwise, on the second business day that is also a trading day following the date on which any sales were made in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the sales of our common stock on our behalf, TD Cowen will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act, and the compensation paid to TD Cowen will be deemed to be underwriting commissions or discounts. We have agreed in the Sales Agreement to provide indemnification and contribution to TD Cowen against certain liabilities, including liabilities under the Securities Act. As sales agent, TD Cowen will not engage in any transactions that stabilizes our common stock. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:548pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The ADSs are listed on The Nasdaq Global Market and trades under the symbol &#8220;IVA.&#8221; Our ordinary shares are listed on Euronext Paris and trades under the symbol &#8220;IVA.&#8221; The depositary for the ADSs is The Bank of New York Mellon. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">TD Cowen and/or its affiliates have provided, and may in the future provide, various investment banking and other financial services for us for which services they have received and, may in the future receive, customary fees. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMACH">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:572pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">MATERIAL CHANGES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Except as described above or otherwise described in our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1756594/000110465923038571/iva-20221231x20f.htm">Annual Report on Form 20-F for the fiscal year ended December&#160;31, 2022</a> and in our Reports on Form 6-K incorporated by reference into this prospectus supplement, no reportable material changes have occurred since December&#160;31, 2022. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">S-29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tEOJ">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:120pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ENFORCEMENT OF JUDGMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are a corporation organized under the laws of France. Half of our directors are citizens and residents of countries other than the United States, and the majority of our assets are located outside of the United States. We have appointed an agent for service of process in the United States; however, it may be difficult for investors: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to obtain jurisdiction over us or our non-U.S. resident officers and directors in U.S. courts in actions predicated on the civil liability provisions of the U.S. federal securities laws; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to enforce in U.S. courts judgments obtained in such actions against us or our non-U.S. resident officers and directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to bring an original action in a French court to enforce liabilities based upon the U.S. federal securities laws against us or our non-U.S. resident officers or directors; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to enforce against us or our directors in non-U.S. courts, including French courts, judgments of U.S. courts predicated upon the civil liability provisions of the U.S. federal securities laws. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Nevertheless, a final judgment for the payment of money rendered by any federal or state court in the United States based on civil liability, whether or not predicated solely upon the U.S. federal securities laws, would be recognized and enforced in France provided that a French judge considers that this judgment meets the French legal requirements concerning the recognition and the enforcement of foreign judgments and is capable of being immediately enforced in the United States. In the absence of any applicable international convention, a French court is therefore likely to grant the enforcement of a foreign judgment without a review of the merits of the underlying claim, only if (1)&#160;that judgment is enforceable in the jurisdiction of the U.S. court which rendered it, (2)&#160;that judgement was rendered by a court having jurisdiction over the dispute (the condition will be met if the dispute is clearly connected to the jurisdiction of the U.S. court and French courts did not have exclusive jurisdiction over the matter), (3)&#160;that judgment does not contravene French international public order and public policy, including the right to due process and (4)&#160;the U.S. judgment is not tainted with fraud and is not incompatible with a judgment rendered by a French court in the same matter, or with an earlier judgment rendered by a foreign court in the same matter. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, French law guarantees full compensation for the harm suffered but is limited to the actual damages, so that the victim does not suffer or benefit from the situation. Such system excludes damages such as, but not limited to, punitive and exemplary damages. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a result, the enforcement, by U.S. investors, of any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities law against us or members of our board of directors, officers or certain experts named herein who are residents of France or countries other than the United States would be subject to the above conditions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Finally, there may be doubt as to whether a French court would impose civil liability on us, the members of our board of directors, our officers or certain experts named herein in an original action predicated solely upon the U.S. federal securities laws brought in a court of competent jurisdiction in France against us or such members, officers or experts, respectively. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA1">&#8203;</a><a name="tEXP">&#8203;</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:16pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The validity of our ordinary shares, including ordinary shares represented by ADSs offered by this prospectus supplement and certain other matters governed by French law will be passed on for us by Gide Loyrette Nouel A.A.R.P.I. Cooley LLP, New York, New York, will be representing us in regards to certain matters governed by U.S. law in connection with this offering. French and U.S. legal counsel to the placement agent in connection with this offering is Davis Polk &amp; Wardwell LLP and Linklaters LLP, Paris, France. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The consolidated financial statements of Inventiva S.A. as of and for the&#160;years ended December&#160;31, 2022, 2021 and 2020 appearing in our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1756594/000110465923038571/iva-20221231x20f.htm">Annual Report on Form 20-F for the year ended December&#160;31, 2022</a>, have been audited by KPMG S.A., independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. KPMG S.A.&#8217;s audit report contains an explanatory paragraph that states that as discussed in Note 3.26 to the consolidated financial statements, the Company has incurred operating losses and negative cash flows from operations since inception and current cash and cash equivalents are not expected to be sufficient for at least the next twelve&#160;months. These matters raise substantial doubt about the ability of the Company to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 3.26. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The offices of KPMG S.A. are located at Tour Eqho, 2 avenue Gambetta, CS 60055, 92066 Paris la D&#233;fense Cedex. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement is part of a registration statement we filed with the SEC. This prospectus supplement does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus supplement, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus supplement or incorporated by reference herein. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus supplement is accurate as of any date other than the date on the front page of this prospectus supplement, regardless of the time of delivery of this prospectus supplement or any sale of the securities offered by this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are subject to the reporting requirements of the Exchange Act that are applicable to a foreign private issuer. Under the Exchange Act, we file annual reports on Form 20-F and other information with the SEC. We also furnish to the SEC under cover of Form 6-K material information required to be made public in France, filed with and made public by any stock exchange on which we are listed or distributed by us to our shareholders. As a foreign private issuer, we are exempt from, among other things, the rules under the Exchange Act prescribing the furnishing and content of proxy statements and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&#160;16 of the Exchange Act. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers, such as us, that file electronically with the SEC. The address of the SEC website is </font><font style="font-style:italic;letter-spacing:0.2pt;">www.sec.gov</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We maintain a website at </font><font style="font-style:italic;letter-spacing:0.2pt;">www.inventivapharma.com</font><font style="letter-spacing:0.2pt;">. Information contained in or accessible through our website does not constitute a part of this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIOCI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:162pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus supplement is considered to be part of this prospectus supplement. Any statement contained in this prospectus supplement or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement or a subsequently filed document incorporated by reference modifies or replaces that statement. The SEC file number for the documents incorporated by reference in this prospectus supplement is 001-39374. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following documents are incorporated by reference into this document: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1756594/000110465923038571/iva-20221231x20f.htm">Annual Report on Form 20-F for the year ended December&#160;31, 2022, filed with the SEC on March&#160;30, 2023; </a></font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our reports on Form 6-K furnished to the SEC on <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1756594/000117184323000048/f6k_010423.htm">January&#160;4, 2023</a> (including Exhibit&#160;99.1 thereto), <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1756594/000117184323000492/f6k_012623.htm">January&#160;26, 2023</a> (including Exhibit&#160;99.1 thereto), <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1756594/000110465923049610/tm2313521d1_6k.htm">April&#160;25, 2023</a>, <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1756594/000117184323003560/f6k_052523.htm">May&#160;25, 2023</a> (including Exhibit&#160;99.1 thereto), <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1756594/000117184323003576/f6k_052523.htm">May&#160;25, 2023</a> (including Exhibit&#160;99.1 thereto), <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1756594/000117184323003599/f6k_052623.htm">May&#160;26, 2023</a> (including Exhibit&#160;99.1 thereto), <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1756594/000117184323003904/f6k_061323.htm">June&#160;14, 2023</a> (including Exhibit&#160;99.1 thereto), <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1756594/000110465923097094/tm2325230d1_6k.htm">August&#160;31, 2023</a> (including Exhibits&#160;99.1, 99.2 and 99.3 thereto), and <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1756594/000117184323005807/f6k_092023.htm">September&#160;20, 2023</a> (including Exhibit&#160;99.1 thereto); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the description of ADSs representing our ordinary shares contained in our <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1756594/000110465920081719/tm2024125-1_8a12b.htm">Registration Statement on Form 8-A filed with the SEC on July&#160;7, 2020</a>, including any amendments or reports filed for the purpose of updating such description. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are also incorporating by reference all subsequent Annual Reports on Form 20-F that we file with the SEC and certain reports on Form 6-K that we furnish to the SEC after the date of this prospectus supplement (if they state that they are incorporated by reference into this prospectus supplement) prior to the termination of this offering. In all cases, you should rely on the later information over different information included in this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the statements in the preceding paragraphs, no document, report or exhibit (or portion of any of the foregoing) or any other information that we have &#8220;furnished&#8221; to the SEC pursuant to the Exchange Act shall be incorporated by reference into this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You should direct any requests for documents to Inventiva S.A., 50 rue de Dijon 21121 Daix France; telephone: +33 3 80 44 75 00.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">
        <div style="width:541.31pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;text-align:center; width:541.31pt;">
          <img src="lg_inventiva-4c.jpg" alt="[MISSING IMAGE: lg_inventiva-4c.jpg]" height="74" width="196" >
        </div>
        <div style="margin-top:17pt; text-align:center; width:541.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">$300,000,000</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:541.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Ordinary Shares </font>
          <br >
          <font style="letter-spacing:-0.28pt;">American Depositary Shares representing Ordinary Shares </font>
          <br >
          <font style="letter-spacing:-0.28pt;">Warrants to Purchase Ordinary Shares or American Depositary Shares</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus will allow us to issue, from time to time at prices and on terms to be determined at or prior to the time of the offering, up to $300,000,000 of our ordinary shares, including ordinary shares represented by American Depositary Shares, or ADSs, as well as warrants to purchase ordinary shares or ADSs. These securities may be offered individually or in any combination. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We will provide you with the specific terms of any offering in one or more supplements to this prospectus. The prospectus supplements will also describe the specific manner in which these securities will be offered and may also supplement, update or amend information contained in this document. You should read this prospectus and any prospectus supplement, as well as any documents incorporated by reference into this prospectus or any prospectus supplement, carefully before you invest. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our securities may be sold directly by us to you, through agents designated from time to time or to or through underwriters or dealers. For additional information on the methods of sale, you should refer to the section titled &#8220;Plan of Distribution&#8221; in this prospectus and in the applicable prospectus supplement. If any underwriters or agents are involved in the sale of our securities with respect to which this prospectus is being delivered, the names of such underwriters or agents and any applicable fees or commissions and over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds that we expect to receive from such sale will also be set forth in a prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ADSs representing our ordinary shares are listed on the Nasdaq Global Market under the symbol &#8220;IVA.&#8221; On July&#160;29, 2021, the last reported sale price of the ADSs on the Nasdaq Global Market was $13.17 per ADS. Our ordinary shares are listed on Euronext Paris under the symbol &#8220;IVA.&#8221; On July&#160;29, 2021, the closing price of our ordinary shares on Euronext Paris was &euro;11.36 per ordinary share. The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on the Nasdaq&#160;Global Market or any securities market or other securities exchange of the securities covered by the prospectus supplement. There is currently no market through which warrants may be sold and purchasers may not be able to resell warrants purchased under this prospectus. This may affect the pricing of any warrants in the secondary market, the transparency and availability of trading prices, the liquidity of the warrants and&#160;the extent of issuer regulation. Prospective purchasers of our securities are urged to obtain current information as to the market prices of our securities, where applicable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks that we have described on page <a href="#tRIFA1">6</a> of this prospectus under the caption &#8220;Risk Factors&#8221; and under the caption &#8220;Risk Factors&#8221; in our most recent Annual Report on Form 20-F incorporated by reference in this prospectus. We may also include specific risk factors in supplements to this prospectus under the caption &#8220;Risk Factors.&#8221; This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Owning our securities may subject you to tax consequences both in France and in the United States. This prospectus and any applicable prospectus supplement may not describe these tax consequences fully. You should read the tax discussion in this prospectus and any applicable prospectus supplement. In addition, your ability to enforce civil liabilities under U.S. federal securities laws may be affected adversely by the fact that we are incorporated under the laws of France, many of our officers and directors and experts named in this prospectus are residents of France or elsewhere outside of the United States, and a substantial portion of our assets and the assets of such persons are located outside the United States. See &#8220;Enforcement of Civil Liabilities.&#8221;</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541.31pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:541.31pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The date of this prospectus is August 6, 2021.</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC3">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:282.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:308.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATP">ii</a></font> <a href="#tATP"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRSU1"><font style="letter-spacing:0.2pt;">PROSPECTUS SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPRSU1">1</a></font> <a href="#tPRSU1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA1"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA1">6</a></font> <a href="#tRIFA1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF1"><font style="letter-spacing:0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSNRF1">7</a></font> <a href="#tSNRF1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tOSAE1"><font style="letter-spacing:0.2pt;">OFFER STATISTICS AND EXPECTED TIMETABLE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tOSAE1">9</a></font> <a href="#tOSAE1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCAP1"><font style="letter-spacing:0.2pt;">CAPITALIZATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCAP1">10</a></font> <a href="#tCAP1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tOALD1"><font style="letter-spacing:0.2pt;">OFFER AND LISTING DETAILS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tOALD1">11</a></font> <a href="#tOALD1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP1"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP1">12</a></font> <a href="#tUOP1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD1"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD1">13</a></font> <a href="#tPOD1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOSC1"><font style="letter-spacing:0.2pt;">DESCRIPTION OF SHARE CAPITAL </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOSC1">14</a></font> <a href="#tDOSC1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLASO1"><font style="letter-spacing:0.2pt;">LIMITATIONS AFFECTING SHAREHOLDERS OF A FRENCH COMPANY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLASO1">35</a></font> <a href="#tLASO1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOAD1"><font style="letter-spacing:0.2pt;">DESCRIPTION OF AMERICAN DEPOSITARY SHARES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOAD1">37</a></font> <a href="#tDOAD1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOW1"><font style="letter-spacing:0.2pt;">DESCRIPTION OF WARRANTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOW1">45</a></font> <a href="#tDOW1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tTAX1"><font style="letter-spacing:0.2pt;">TAXATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tTAX1">46</a></font> <a href="#tTAX1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">47</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP1"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP1">47</a></font> <a href="#tEXP1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEOCL1"><font style="letter-spacing:0.2pt;">ENFORCEMENT OF CIVIL LIABILITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEOCL1">48</a></font> <a href="#tEOCL1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF1"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF1">49</a></font> <a href="#tWYCF1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIODB1"><font style="letter-spacing:0.2pt;">INCORPORATION OF DOCUMENTS BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIODB1">50</a></font> <a href="#tIODB1"></a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEAWR1"><font style="letter-spacing:0.2pt;">EXPENSES ASSOCIATED WITH REGISTRATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEAWR1">51</a></font>
            </td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tATP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:20pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is part of a registration statement on Form F-3 that we filed with the Securities and Exchange Commission, or SEC, utilizing a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may offer ordinary shares, including ordinary shares represented by ADSs, and warrants to purchase ordinary shares or ADSs, either individually or in combination, in one or more offerings, with a total aggregate offering price of up to $300,000,000. This prospectus provides you with a general description of the securities we may offer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each time we sell securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the heading &#8220;Incorporation of Certain Information by Reference,&#8221; before investing in any of the securities offered. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we, nor any agent, underwriter or dealer has authorized any person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on behalf of us or to which we have referred you. This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus and the information incorporated herein by reference contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#8220;Where You Can Find More Information.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise indicated in this prospectus, &#8220;Inventiva,&#8221; &#8220;the company,&#8221; &#8220;our company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Inventiva S.A. and its consolidated subsidiary. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In this prospectus, references to &#8220;euro&#8221; or &#8220;&euro;&#8221; are to the legal currency of the countries of the European Union, including the Republic of France, and references to &#8220;dollars,&#8221; &#8220;U.S. dollars&#8221; or &#8220;$&#8221; are to the legal currency of the United States of America.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tPRSU1">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">The following summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you need to consider in making your investment decision. We urge you to read this entire prospectus, including the more detailed consolidated financial statements, notes to the consolidated financial statements and other information incorporated by reference from our other filings with the SEC or included in any applicable prospectus supplement. Investing in our securities involves risks. Therefore, carefully consider the risk factors set forth in any prospectus supplements and in our most recent filings with the SEC including our Annual Reports on Form 20-F and reports on Form 6-K, as well as other information in this prospectus and any prospectus supplements and the documents incorporated by reference herein or therein, before purchasing our securities. Each of the risk factors could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our securities.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Company Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH and other diseases with significant unmet medical need. We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, we are advancing lanifibranor for the treatment of NASH, as well as a pipeline of earlier stage programs in oncology and other diseases with significant unmet medical need. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Lanifibranor for the Treatment of NASH</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;We are developing our lead product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a progressive, chronic liver disease for which there are currently no approved therapies. NASH is believed to affect 12% of the United States adult population and is a leading cause of cirrhosis, liver transplantation and liver cancer. Compared to the general population, patients with NASH have a ten-fold greater risk of liver-related mortality. NASH is characterized by a metabolic process known as steatosis, or the excessive accumulation of fat in the liver, inflammation and ballooning of liver cells and progressive liver fibrosis that can ultimately lead to cirrhosis. Lanifibranor is an orally-available small molecule in development for the treatment of NASH that acts to induce anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor, or PPAR, isoforms. PPARs are well-characterized nuclear receptor proteins that regulate gene expression, and their relevance for the fibrotic, inflammatory, vascular and metabolic processes that characterize NASH is well-established. While there are other PPAR agonists that target only one or two PPAR isoforms, lanifibranor is the only pan-PPAR agonist, meaning that it targets the three isoforms, in clinical development. We believe that this pan-PPAR approach provides for a combination of anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic effects that cannot be obtained with single and dual PPAR agonists. In June&#160;2020, we announced positive topline results from our NATIVE Phase&#160;IIb clinical trial of lanifibranor in patients with NASH. In this trial, treatment with lanifibranor at a dose of 1,200 mg met the primary endpoint of a reduction in inflammation and ballooning with no worsening of fibrosis after 24 weeks of treatment, while continuing to show the favorable tolerability profile observed in prior clinical trials of lanifibranor. Treatment with lanifibranor at doses of 800 mg and 1,200 mg also met the key secondary endpoints of resolution of NASH with no worsening of fibrosis and, at the 1,200 mg dose, improvement in liver fibrosis without worsening NASH, which are the primary endpoints relevant for seeking accelerated approval from the U.S. Food and Drug Administration, or FDA, and the European Medical Agency, or EMA, after future Phase&#160;III development. On October&#160;12, 2020, the FDA granted Breakthrough Therapy designation to lanifibranor for the treatment of NASH based on Phase&#160;IIb data, in addition to Fast Track designation which was previously granted to lanifibranor in this indication. We believe that lanifibranor is the first oral drug candidate to be granted this status for the treatment of NASH since January&#160;2015. The Breakthrough Therapy designation by the FDA is intended to expedite the development and review of drug candidates for serious or life-threatening conditions. To qualify for this designation, drug candidates must show preliminary clinical evidence that they may demonstrate a substantial improvement on at least one clinically significant endpoint over available therapies or over placebo if there are no approved therapies. In light of the Phase&#160;IIb results, we plan to advance lanifibranor, either alone or together with a collaborator. Following the end-of-phase II meeting with the </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">FDA and the receipt of the Scientific Advice letter from the EMA during the fourth quarter of 2020, the Phase&#160;III trial design and clinical strategy have been discussed with both regulatory authorities and are summarized as follows: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Submission for U.S. accelerated approval and EU conditional approval of lanifibranor will be based on a 72-week histology analysis&#8201;&#8212;&#8201;We will seek to obtain accelerated approval in the U.S. and conditional approval in the EU for lanifibranor based on a pre-specified histology analysis in approximately 900 patients if we are able to establish a positive benefit-risk ratio after 72 weeks of treatment. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Primary composite endpoint expected to be a combination of NASH resolution and fibrosis improvement&#8201;&#8212;&#8201;The primary composite endpoint of patients having both NASH resolution and fibrosis improvement of at least one stage will be used for the 72-week histology analysis. The endpoint is designed to predict a significant improvement of prognostic risk and, if met, may support a label for the treatment of NASH and the improvement in liver fibrosis in adult non-cirrhotic NASH patients. During our NATIVE Phase&#160;IIb clinical trial, this endpoint was met with statistical significance by both doses of 800 mg and 1,200 mg, including in NASH patients with F2/F3 fibrosis, the patient population that will be included in the Phase&#160;III trial, as well as in NASH patients with type two diabetes. Endpoints of NASH resolution and no worsening of fibrosis, and improvement of fibrosis with no worsening of NASH will be included as key secondary endpoints. Additional supportive histologic endpoints, non-invasive markers of liver fibrosis and steatohepatitis as well as effects on lipids and insulin resistance will also be evaluated. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Long-term use to be established after 72 weeks&#8201;&#8212;&#8201;The duration of 72 weeks was considered adequate by both the FDA and EMA to establish long-term use as well as dose and cumulative drug exposure. With this trial, the proposed size of the safety database required for marketing application would be consistent with regulatory guidelines. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Named NATIV3 (NASH lanifibranor Phase&#160;III trial), the planned trial has been designed as a double-blind, placebo-controlled global pivotal Phase&#160;III clinical trial to assess the potential benefit of lanifibranor treatment on liver-related clinical outcomes. Patients will be randomized 1:1:1 to receive lanifibranor (800mg once daily or 1200mg once daily) or placebo. The trial will remain blinded after the pre-specified histological analysis and continue in a total of approximately 2,000 patients until the occurrence of a pre-specified number of adverse liver-related clinical events, including progression to cirrhosis. The trial would be completed on a post-marketing basis in the event that U.S. accelerated approval or EU conditional approval is received. Statistical powering of 90% was considered for the sample size calculations of the Phase&#160;III clinical trial. The trial preparations are progressing and we plan to initiate Part&#160;1 of the trial in the first half of 2021, with Part&#160;1 referring to a 72-week treatment in approximately 900 patients allowing to seek accelerated approval in the U.S. and conditional approval in the EU for lanifibranor based on a pre-specified histology analysis; this part of the study is followed by an extension period (Part&#160;2), the end date of which depends on a pre-defined number of clinical events. Part&#160;1 of the study has the following timelines: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">First Patient First Visit&#8201;&#8212;&#8201;expected in the third quarter of 2021. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Last Patient First Visit&#8201;&#8212;&#8201;expected in the second half of 2022. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Last Patient Last Visit&#8201;&#8212;&#8201;expected in the first half of 2024. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Publication of headline results&#8201;&#8212;&#8201;expected in the second half of 2024. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Odiparcil for the Treatment of MPS</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Our second clinical-stage asset is odiparcil, which we developed for the treatment of patients with mucopolysaccharidoses, or MPS, a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells. Odiparcil is an orally-available small molecule designed to modify how GAGs are synthesized. Odiparcil acts to facilitate the production of soluble GAGs that can be excreted in the urine, rather than accumulating in cells. As announced in November&#160;2020, we have decided to focus our clinical efforts on the development of lanifibranor for the treatment of NASH and as part of this decision, we are reviewing all available options to optimize the development of odiparcil for the treatment of MPS VI. During this time, we will suspend all MPS-related research and development activities. As a consequence, the Phase&#160;I/II SAFE-KIDDS (SAFEty, pharmacoKInetics and pharmacoDynamics, Dose escalating Study) clinical trial evaluating </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">odiparcil in MPS VI children and the Phase&#160;IIa extension clinical trial with odiparcil in MPS VI patients who completed the prior iMProveS Phase&#160;IIa clinical trial was not initiated in the first half of 2021 as initially planned. Odiparcil has received orphan drug designation from the FDA and EMA and Rare Pediatric Disease Designation from the FDA for the treatment of MPS VI. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Discovery Engine</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;We have a scientific team of approximately 70 people with deep biology, medicinal and computational chemistry, pharmacokinetics and pharmacology expertise, more than 75% of whom have worked together for more than 15&#160;years. We also own a library of approximately 240,000 pharmacologically relevant molecules, 60% of which are proprietary, as well as a wholly-owned research and development facility. Using these assets and this expertise, we have built a discovery engine focused on small molecule compounds that target nuclear receptors, transcription factors and epigenetic modulation. We are leveraging this discovery engine to identify and develop compounds addressing a wide range of indications. Our Hippo signaling pathway program aims to disrupt the interaction between yes-associated protein, or YAP, and transcription enhancer associated domain transcription factors, or TEAD, an interaction that plays a key role in oncogenic and fibrotic processes. In xenograft and orthotopic models of malignant pleural mesothelioma, or MPM, we observed that YAP-TEAD inhibition was associated with reduced tumor growth and we are in the process of selecting development candidate for our Hippo program, which we anticipate entering pre-clinical development in 2021 for the treatment of non-small cell lung cancer and mesothelioma. We are also advancing a pre-clinical program for the treatment of idiopathic pulmonary fibrosis, or IPF, and have validated a new target within the transforming growth factor beta, or TGF-&beta;, signaling pathway. We have also entered into a collaboration with AbbVie Inc., or AbbVie, for the treatment of some autoimmune diseases. The collaboration led to the discovery of cedirogant (formerly ABBV-157), a selective and orally-available ROR-y inverse agonist. After achieving clinical proof of concept in a phase I trial in patients with psoriasis, AbbVie is planning to initiate a phase 2b trial during the second half of 2021. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Pipeline</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
            <img src="tm2123561d2-tbl_indica4clr.jpg" alt="[MISSING IMAGE: tm2123561d2-tbl_indica4clr.jpg]" height="379" width="608" >
          </div>
          <div style="margin-top:16.4pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Recent Developments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">As of June&#160;30, 2021, we had approximately &euro;93.6&#160;million in cash and cash equivalents, compared to &euro;107.8&#160;million as of March&#160;31, 2021 and &euro;113.0&#160;million as of December&#160;31, 2020. Net cash used in operating </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">activities amounted to &euro;19.0&#160;million in the first half of 2021 compared to &euro;7.2&#160;million for the same period in 2020. The Company&#8217;s revenues for the first half of 2021&#160;amounted to &euro;0.2&#160;million, as compared to &euro;0.1&#160;million for the same period in 2020. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We were founded in 2011 and incorporated as a soci&#233;t&#233; anonyme, or S.A., in 2016. We are registered at the Dijon Trade and Companies Register (Registre du commerce et des soci&#233;t&#233;s) under the number 537 530 255. In January&#160;2021, we incorporated our wholly-owned U.S. subsidiary, Inventiva Inc. in the state of New&#160;Jersey. Our ordinary shares are listed on Euronext Paris under the symbol &#8220;IVA&#8221; and our ADSs are listed on the Nasdaq Global Market under the symbol &#8220;IVA.&#8221; </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our principal executive offices are located at 50 rue de Dijon, 21121 Daix, France. Our telephone number at our principal executive offices is +33 3 80 44 75 00. Our agent for service of process in the United States is Cogency Global Inc., 122 E 42nd Street, 18</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> Floor, New York, New York 10168. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The SEC maintains a website that contains reports, proxy information statements and other information regarding issuers that file electronically with the SEC. The address of that site is www.sec.gov. Our website address is www.inventivapharma.com. The reference to our website is an inactive textual reference only and information contained in, or that can be accessed through, our website or any other website cited in this prospectus is not part of this prospectus. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Implications of Being an Emerging Growth Company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We qualify as an &#8220;emerging growth company&#8221; as defined in the U.S. Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">exemption from the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">to the extent that we no longer qualify as a foreign private issuer, (1)&#160;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (2)&#160;exemptions from the requirements of holding a non-binding advisory vote on executive compensation, including golden parachute compensation. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We may take advantage of these provisions until December&#160;31, 2025 or such earlier time that we no longer qualify as an emerging growth company. We would cease to be an emerging growth company if we have more than $1.07&#160;billion in total annual gross revenue, have more than $700&#160;million in market value of our capital stock held by non-affiliates or issue more than $1.0&#160;billion of non-convertible debt over a three-year period. We may choose to take advantage of some but not all of these reduced burdens. To the extent that we take advantage of these reduced burdens, the information that we provide stockholders may be different than you might obtain from other public companies in which you hold equity interests. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. Since International Financial Reporting Standards make no distinction between public and private companies for purposes of compliance with new or revised accounting standards, the requirements for our compliance as a private company and as a public company are the same. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Implications of Being a Foreign Private Issuer</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are also considered a &#8220;foreign private issuer&#8221; under U.S. securities laws. In our capacity as a foreign private issuer, we are exempt from certain rules under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, that impose certain disclosure obligations and procedural requirements for proxy solicitations under Section&#160;14 of the Exchange Act. In addition, our officers, directors and principal shareholders are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions of Section&#160;16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">securities. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. In addition, we are not required to comply with Regulation&#160;FD, which restricts the selective disclosure of material information. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We will remain a foreign private issuer until such time that more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (1)&#160;the majority of our executive officers or directors are U.S. citizens or residents; (2)&#160;more than 50% of our assets are located in the United States; or (3)&#160;our business is administered principally in the United States. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The Securities We May Offer</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Under this prospectus, we may offer ordinary shares, including ADSs representing our ordinary shares, and warrants to purchase ordinary shares or ADSs, either individually or in any combination, with a total aggregate offering price of up to $300,000,000, from time to time at prices and on terms to be determined by market conditions at the time of the offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">designation or classification; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">aggregate principal amount or aggregate offering price; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">maturity, if applicable; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">rates and times of payment of interest or dividends, if any; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">redemption, conversion or sinking fund terms, if any; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">voting or other rights, if any; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">conversion or exercise prices, if any. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The prospectus supplement also may add, update or change information contained in this prospectus or in documents we have incorporated by reference into this prospectus. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We may sell the securities directly to investors or to or through agents, underwriters or dealers. We, and our agents or underwriters, reserve the right to accept or reject all or part of any proposed purchase of securities. If we offer securities through agents or underwriters, we will include in the applicable prospectus supplement: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the names of those agents or underwriters; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">applicable fees and commissions to be paid to them; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">details regarding over-allotment options, if any; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the net proceeds to us. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">This prospectus may not be used to consummate a sale of any securities unless it is accompanied by a prospectus supplement.</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tRIFA1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:488pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in our <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1756594/000117184321001782/f20f_031521.htm">Annual Report on Form 20-F for the year ended December&#160;31, 2020</a> as updated by our subsequent filings, which are incorporated by reference into this prospectus, before deciding whether to purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors could adversely affect our business, results of operations, financial condition and cash flows, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSNRF1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus and the documents incorporated by reference contain forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, that are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. Discussions containing these forward-looking statements may be found, among other places, in the sections titled &#8220;Information on the Company,&#8221; &#8220;Risk Factors&#8221; and &#8220;Operating and Financial Review and Prospects&#8221; incorporated by reference from our most recent Annual Report on Form 20-F, as well as any amendments thereto, filed with the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All statements other than present and historical facts and conditions contained in this prospectus, including statements regarding our future results of operations and financial positions, business strategy, plans and our objectives for future operations, are forward-looking statements. When used in this prospectus, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;is designed to,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;objective,&#8221; &#8220;should,&#8221; or the negative of these and similar expressions identify forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our plans to develop and commercialize our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing of initiation of our planned clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing of the availability of data from our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing of any planned investigational new drug application or new drug application; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our plans to research, develop and commercialize our current and future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to successfully collaborate with existing collaborators or enter into new collaborations, and to fulfill our obligations under any such collaboration agreements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the clinical utility, potential benefits and market acceptance of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our commercialization, marketing and manufacturing capabilities and strategy; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to identify additional products or product candidates with significant commercial potential; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations related to the sufficiency of our capital resources; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">developments and projections relating to our competitors and our industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the impact of government laws and regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the potential effects of the recent COVID-19 pandemic on our business and, operations and clinical development timelines and plans; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our intellectual property position; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our estimate regarding future revenue, expenses, capital requirements and need for additional financing; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">other risks and uncertainties, including those listed in this prospectus under the caption &#8220;Risk Factors&#8221;. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should refer to the &#8220;Risk Factors&#8221; section contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:480pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to this prospectus completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains market data and industry forecasts that were obtained from industry publications. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified any third-party information. While we believe the market position, market opportunity and market size information included in this prospectus is generally reliable, such information is inherently imprecise. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tOSAE1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:536pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">OFFER STATISTICS AND EXPECTED TIMETABLE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">We may sell from time to time pursuant to this prospectus (as may be detailed in a prospectus supplement) an indeterminate number of ordinary shares, including ADSs representing our ordinary shares, and warrants to purchase ordinary shares or ADSs, either individually or in combination, as shall have a maximum aggregate offering price of up to $300,000,000. The actual price per share or per security of the securities that we will offer pursuant hereto will depend on a number of factors that may be relevant as of the time of offer. See &#8220;Plan of Distribution.&#8221; </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCAP1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:214.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAPITALIZATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table presents our total capitalization and cash and cash equivalents as of March&#160;31, 2021. You should read the financial data in the following table in conjunction with our financial statements and related notes incorporated by reference into this prospectus. </font>
        </div>
        <table style="width:456pt;height:208.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:397.69pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">March&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:397.69pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:397.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">&euro;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">107,806</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:397.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other financial liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:397.69pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total debt </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&euro;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">10,086</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:397.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Shareholders&#8217; equity </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:397.69pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Ordinary shares, nominal value &euro;0.01 per share, 38,630,261 shares issued and outstanding </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&euro;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">386</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:397.69pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Premiums related to share capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&euro;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">139,668</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:397.69pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Reserves </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">(&euro;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">28,958<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:397.69pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Translation reserve </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6pt; text-align:right; ">&euro;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">0</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:397.69pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss for the period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">(&euro;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">8,840<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:397.69pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total shareholders&#8217; equity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; ">&euro;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">102,256</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:397.69pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total capitalization </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; ">&euro;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">112,342</td>
            <td style="padding:0pt;padding-left:4.3pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The number of ordinary shares (including ordinary shares represented by ADSs) outstanding as of March&#160;31, 2021 was 38,630,261, which excludes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">29,100 ordinary shares issued after March&#160;31, 2021 in connection with the vesting of free shares under the AGA 2019-1 bonus share award plan that have no exercise price; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">1,396,800 ordinary shares issuable upon the exercise of founder&#8217;s share warrants (bons de souscription de parts de cr&#233;ateur d&#8217;entreprise) and share warrants (bons de souscription d&#8217;actions) and the vesting of free shares outstanding as of April&#160;16, 2021; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">18,521,739 ordinary shares reserved for future issuance under our share-based compensation plans and other delegations of authority from our shareholders as of March&#160;31, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tOALD1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:472pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">OFFER AND LISTING DETAILS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may sell from time to time pursuant to this prospectus (as may be detailed in a prospectus supplement) an indeterminate number of ordinary shares, including ADSs representing our ordinary shares, and warrants to purchase ordinary shares or ADSs, either individually or in combination, as shall have a maximum aggregate offering price of up to $300,000,000. The actual price per share or per security of the securities that we will offer pursuant hereto will depend on a number of factors that may be relevant as of the time of offer. See &#8220;Plan of Distribution.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our ADSs have been listed on the Nasdaq Global Market under the symbol &#8220;IVA&#8221; since July&#160;2020. Our ordinary shares have been listed on Euronext Paris under the symbol &#8220;IVA&#8221; since November&#160;2017. Prior to that date, there was no public trading market for our ADSs or our ordinary shares. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There is currently no public trading market for our warrants. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tUOP1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:476pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Except as described in any applicable prospectus supplement or in any free writing prospectuses that we may authorize to be provided to you in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered hereby to fund the research and development of our product candidates, for working capital and for general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus. We will set forth in the applicable prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement or free writing prospectus. Pending these uses, we intend to invest the net proceeds in investment-grade, interest-bearing securities. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tPOD1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may offer securities under this prospectus from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities (1)&#160;through underwriters or dealers, (2)&#160;through agents and/or (3)&#160;directly to one or more purchasers. We may distribute the securities from time to time in one or more transactions, in accordance with applicable law and regulations and existing shareholders delegations of authority, at: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a fixed price or prices, which may be changed from time to time; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">market prices prevailing at the time of sale; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">prices related to such prevailing market prices; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">negotiated prices. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each time that we sell securities covered by this prospectus, we will provide a prospectus supplement or supplements that will describe the method of distribution and set forth the terms and conditions of the offering of such securities, including the offering price of the securities and the proceeds to us, if applicable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may directly solicit offers to purchase the securities being offered by this prospectus. We may also designate agents to solicit offers to purchase the securities from time to time. We will name in a prospectus supplement any underwriter or agent involved in the offer or sale of the securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we utilize a dealer in the sale of the securities being offered by this prospectus, we will sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we utilize an underwriter in the sale of the securities being offered by this prospectus, we will execute an underwriting agreement with the underwriter at the time of sale, and we will provide the name of any underwriter in the prospectus supplement which the underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we, or the purchasers of the securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting commissions. The underwriter may sell the securities to or through dealers, and the underwriter may compensate those dealers in the form of concessions or commissions from the underwriters and/or commissions from the purchasers for which they may act as agent. Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best efforts basis and a dealer will purchase securities as a principal, and may then resell the securities at varying prices to be determined by the dealer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will provide in the applicable prospectus supplement information regarding any compensation we pay to underwriters, dealers or agents in connection with the offering of the securities, and any concessions or commissions allowed by underwriters to participating dealers. Underwriters, dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of the Securities Act of 1933, as amended, and any commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting commissions. We may enter into agreements to indemnify underwriters, dealers and agents against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof. </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In order to facilitate the offering of the securities, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. This may include over-allotments or short sales of the securities, which involve the sale by persons participating in the offering of more securities than were sold to them. In these circumstances, these persons would cover such over-allotments or short positions by making purchases in the open market or by exercising their over-allotment option. In addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing the applicable security in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if the securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The underwriters, dealers and agents may engage in other transactions with us, or perform other services for us, in the ordinary course of their business.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDOSC1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF SHARE CAPITAL</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following description of our share capital summarizes certain provisions of our bylaws. Such summaries do not purport to be complete and are subject to, and are qualified in their entirety by reference to, all of the provisions of our bylaws, a copy of which has been filed as an exhibit to the registration statement of which this prospectus forms a part.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of June&#160;30, 2021, our outstanding share capital consisted of a total of 38,659,361 ordinary shares, with nominal value &euro;0.01 per share. In general, each shareholder is entitled to one vote per share at any general shareholders&#8217; meeting. Pursuant to our bylaws, however, a double voting right is attached to each registered share which is held in the name of the same shareholder for at least two&#160;years. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under French law, our bylaws set forth only our issued and outstanding share capital as of the date of the bylaws. Our fully diluted share capital represents all issued and outstanding shares, as well as all potential shares which may be issued upon exercise of outstanding founder&#8217;s share warrants and share warrants, as approved by our shareholders and granted by our board of directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Reconciliation of the Number of Ordinary Shares Outstanding through June&#160;30, 2021</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:418pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:398.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ordinary shares outstanding at December&#160;31, 2016 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">10,030,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:398.59pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued in connection with the exercise of founder&#8217;s share warrants </font>
                <br >
                <font style="letter-spacing:0.2pt;">and share warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">707,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:398.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued on February&#160;16, 2017 in connection with the share capital increase authorized on February&#160;14, 2017 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,651,240</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:398.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued on March&#160;20, 2017 (greenshoe) in connection with the share capital increase authorized on March&#160;16, 2017 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">55,337</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:398.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ordinary shares outstanding at December&#160;31, 2017 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">16,444,477</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:398.59pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued in connection with the exercise of founder&#8217;s share warrants </font>
                <br >
                <font style="letter-spacing:0.2pt;">and share warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">180,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:398.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued in connection with the vesting of free shares that have no exercise price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">60,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:398.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued on April&#160;17, 2018 in connection with the share capital increase authorized on April&#160;12, 2017 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,572,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:398.59pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued in connection with the exercise of founder&#8217;s share warrants </font>
                <br >
                <font style="letter-spacing:0.2pt;">and share warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">27,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:398.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued in connection with the vesting of free shares that have no exercise price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">10,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:398.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued in connection with the vesting of free shares that have no exercise price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">77,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:398.59pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued on September&#160;20, 2019 in connection with the share capital </font>
                <br >
                <font style="letter-spacing:0.2pt;">increase authorized on September&#160;18, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,159,999</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:398.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued on October&#160;2, 2019 in connection with the share capital increase authorized on September&#160;30, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">313,936</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:398.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued in connection with the vesting of free shares that have no exercise price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">63,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:398.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued on February&#160;11, 2020 in connection with the share capital increase authorized on February&#160;6, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3,778,338</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:398.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ordinary shares outstanding at February&#160;11, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">30,687,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:398.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued in connection with the vesting of free shares that have no exercise price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">227,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:178pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:398.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ordinary shares outstanding at June&#160;30, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">30,914,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:398.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued on July&#160;15, 2020 in connection with the share capital increase authorized on July&#160;5, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7,478,261</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:398.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ordinary shares outstanding at July&#160;15, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">38,393,011</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:398.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued in connection with the vesting of free shares that have no exercise price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">227,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:398.59pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued in connection with the exercise of founder&#8217;s share warrants </font>
                <br >
                <font style="letter-spacing:0.2pt;">and share warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">10,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:398.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ordinary shares outstanding at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">38,630,261</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:398.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ordinary shares outstanding at March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">38,630,261</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:398.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Number of ordinary shares issued in connection with the vesting of free shares that have no exercise price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">29,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:398.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ordinary shares outstanding at June&#160;30, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">38,659,361</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:19.9pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Shareholder Authorizations Regarding Share Capital</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At a combined general meeting of shareholders held on April&#160;16, 2021, our board of directors received the following authorizations from shareholders: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">delegation of authority to implement a share buyback program within certain agreed-upon financial limits, whereby the Company can buy back up to 10% of the total number of shares comprising the share capital at any time; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">delegation of authority to reduce our share capital by canceling certain treasury shares held by the Company up to a limit of 10% of the Company&#8217;s share capital per 24-month period; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">delegations of authority to increase our share capital by issuing ordinary shares for the maximum duration permitted under French law (18 to 26&#160;months depending of the delegations) within a maximum aggregate potential dilution of 26,000,000 ordinary shares for which delegations our shareholders waived their preferential subscription rights with respect to all such issuances (except when conducted through rights issues); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">delegations of authority to grant free shares (</font><font style="font-style:italic;letter-spacing:0.2pt;">actions gratuites</font><font style="letter-spacing:0.2pt;">) and/or stock options (</font><font style="font-style:italic;letter-spacing:0.2pt;">options de souscription et/ou d&#8217;achat d&#8217;actions</font><font style="letter-spacing:0.2pt;">), to our employees, executive officers and directors, for the maximum duration permitted under French law (38&#160;months) within a maximum aggregate potential dilution of 26,000,000 ordinary shares to free shares and stock options issued shall grant, for which delegations our shareholders waived their preferential subscription rights with respect to all such grants; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">delegations of authority to grant warrants (</font><font style="font-style:italic;letter-spacing:0.2pt;">bons de souscription d&#8217;actions</font><font style="letter-spacing:0.2pt;">, or BSAs) to our employees, executive officers and directors for the maximum duration permitted under French law (18&#160;months) within a maximum aggregate potential dilution of 600,000 ordinary shares to which the BSAs issued shall grant, for which delegations our shareholders waived their preferential subscription rights with respect to all such grants. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">History of Securities Issuances</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From January&#160;1, 2018 through June&#160;30, 2021, the following events have changed the number and classes of our issued and outstanding shares: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">On April&#160;17, 2018, we issued an aggregate of 5,572,500 ordinary shares in connection with a private placement at a purchase price of &euro;6.37 per share. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">On September&#160;20, 2019 and October&#160;2, 2019, we issued an aggregate of 4,473,935 ordinary shares in connection with a private placement at a purchase price of &euro;1.99 per share. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">On February&#160;11, 2020, we issued an aggregate of 3,778,338 ordinary shares in connection with a private placement at a purchase price of &euro;3.97 per share. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">On July&#160;15, 2020, we issued an aggregate of 7,478,261 ordinary shares in connection with our initial public offering on the Nasdaq Global Market, at a purchase price of &euro;12.70 per share and $14.40 per ADS. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Key Provisions of Our Bylaws and French Law Affecting Our Ordinary Shares</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The description below reflects the terms of our bylaws and summarizes the material rights of holders of our ordinary shares under French law. Please note that this is only a summary and is not intended to be exhaustive. For further information, please refer to the full text of our bylaws, a copy of which has been filed as an exhibit to the registration statement of which this prospectus forms a part.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Key Provisions of Our Bylaws and French Law Affecting our Ordinary Shares</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The description below reflects the terms of our bylaws and summarizes the material rights of holders of our ordinary shares under French law. Please note that this is only a summary and is not intended to be exhaustive. For further information, please refer to the full text of our bylaws and French law. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Corporate Purpose (Article&#160;3 of the Bylaws)</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our corporate purpose in France and abroad includes the research and development, production, distribution and marketing, at different stages of development, with respect to all products, principally pharmaceutical, cosmetic and chemical products, including in the area of animal health. Our company is also engaged in the provision of study, advisory or commercial services and, more generally, any ancillary services, similar or connected to the activities described hereof, including the leasing of laboratories or offices. Our company may participate, by any means, directly or indirectly in any operations that may be related to its purpose through the creation of new companies, contribution, subscription or purchase of company securities or rights, merger or otherwise, creation, acquisition, leasing, management lease of any businesses or establishments. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">More generally, we are authorized to engage in any financial, commercial, industrial, civil immovable or movable operations related directly or indirectly to the company&#8217;s purpose or any similar or related purpose which may facilitate its expansion or growth. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Directors (Articles 15 to 22 of the Bylaws)</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Duties of the Board (Article&#160;18 of the Bylaws).</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Except for powers given to our shareholders by law and within the limit of the corporate purpose, our board of directors is responsible for all matters relating to the successful operations of our company and, through its resolutions, governs matters involving the company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Appointment and Term (Article&#160;15 and 16 of the Bylaws).</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our board of directors must be composed of at least three members, but may not exceed eighteen members, subject to the dispensation established by law in the event of merger. Directors are appointed, renewed or dismissed by the ordinary general meeting. The term of a director is three&#160;years, and directors may be re-elected at our annual ordinary share meetings; however, a director over the age of 70 may not be appointed if such appointment would result in the number of directors over the age of 70 constituting more than one-third of the board. An employee can only be appointed as a director if his or her employment contract corresponds to an actual job. The number of directors who are also our employees cannot exceed one-third of the board. Directors need not to be shareholders of our company and may be natural persons or legal entities except for the Chairman of the board who must be a natural person. Legal entities appointed to the board must designate a permanent representative. If a director dies or resigns between annual meetings, the board may appoint a temporary director to fill the vacancy, subject to ratification at the next ordinary general meeting, or, if such vacancy results in a number of directors below three, the board must call an ordinary general meeting to fill the vacancy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Organization (Article&#160;16 of the Bylaws).</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The board must elect a Chairman from among the board members. The Chairman must be a natural person, age 65 or younger, and may be removed by the board at </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">any time. The board may also elect a natural person as vice Chairman to preside in the Chairman&#8217;s absence and may designate up to two non-voting board observers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Deliberations (Article&#160;17 of the Bylaws).</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;At least half of the number of directors in office must be present to constitute a quorum. Decisions are made by a majority of the directors present or represented and, if there is a tie, the vote of the chair of the meeting will carry the decision. Meetings may be held as often as required; however, the Chairman is required to call a meeting with a determined agenda upon the request of at least one-third of the directors if the board has not met for more than two&#160;months. French law and our charter and bylaws allow directors to attend meetings in person or, to the extent permitted by applicable law and with specified exceptions in our bylaws, by videoconference or other telecommunications arrangements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Directors&#8217; Voting Powers on Proposal, Arrangement or Contract in Which Any Director is Materially Interested (Article&#160;22 of the Bylaws).</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Under French law, any agreement entered into, directly or through an intermediary, between us and any director that is not entered into in the ordinary course of our business and upon standard market terms is subject to the prior authorization of the board of directors (it being specified that the interested director cannot vote on such decision). The same provision applies to agreements between us and another company, except where such company is one of our wholly owned subsidiaries, if one of our directors is the owner or a general partner, manager, director, general manager or member of the executive or supervisory board of the other company, as well as to agreements in which one of our directors has an indirect interest. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Directors&#8217; Compensation (Article&#160;20 of the Bylaws).</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Directors&#8217; compensation for their functions is determined at the annual ordinary general meeting. The board of directors may also grant special compensation for missions or offices conferred upon directors subject to the circumstances and conditions provided for by law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Board of Directors&#8217; Borrowing Powers (Article&#160;18 of the Bylaws).</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;There are currently no limits imposed by our bylaws on the amounts of loans or borrowings that the board of directors may approve. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rights, Preferences and Restrictions Attaching to Ordinary Shares (Articles 11, 14, 28, 31 and 32 of the Bylaws) </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Dividends.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We may only distribute dividends out of our distributable profits, plus any amounts held in our reserves that the shareholders decide to make available for distribution, other than those reserves that are specifically required by law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">&#8220;Distributable Profits&#8221;</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;consist of our statutory net profit in each fiscal year, calculated in accordance with accounting standards applicable in France, as increased or reduced by any profit or loss carried forward from prior&#160;years, less any contributions to the reserve accounts pursuant to French law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Legal Reserve.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Pursuant to French law, we must allocate at least 5% of our statutory net profit for each year to our legal reserve fund before dividends may be paid with respect to that year. Funds must be allocated until the amount in the legal reserve is equal to 10% of the aggregate par value of our issued and outstanding share capital. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Approval of Dividends.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Pursuant to French law, our board of directors may propose a dividend for approval by the shareholders at the annual ordinary general meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon recommendation of our board of directors, our shareholders may decide to allocate all or part of any distributable profits to special or general reserves, to carry them forward to the next fiscal year as retained earnings or to allocate them to the shareholders as dividends. However, dividends may not be distributed when our net assets are or would become as a result of such distribution lower than the amount of the share capital plus the amount of any reserve that the law or the bylaws do not allow to be distributed to shareholders. The amount of our share capital plus the amount of our legal reserves which may not be distributed was equal to &euro;425,322.61 at March&#160;31, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors may distribute interim dividends after the end of the fiscal year but before the approval of the financial statements for the relevant fiscal year when the interim statement of financial position, established during such year and certified by an auditor, reflects that we have earned distributable </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">profits since the close of the last financial year, after recognizing the necessary depreciation and provisions and after deducting prior losses, if any, and the sums to be allocated to reserves, as required by law or the bylaws, and including any retained earnings. The amount of such interim dividends may not exceed the amount of the profit so defined. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Distribution of Dividends.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Dividends are distributed to shareholders pro&#160;rata according to their respective holdings of shares. In the case of interim dividends, distributions are made to shareholders on the date set by our board of directors during the meeting in which the distribution of interim dividends is approved. The actual dividend payment date is decided by the shareholders at an ordinary general shareholders&#8217; meeting or by our board of directors in the absence of such a decision by the shareholders. Shareholders that own shares on the actual payment date are entitled to the dividend. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Shareholders may be granted an option to receive dividends in cash or in shares, in accordance with legal conditions. The conditions for payment of dividends in cash shall be set at the shareholders&#8217; meeting or, failing this, by the board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Timing of Payment.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Pursuant to French law, dividends must be paid within a maximum of nine&#160;months after the close of the relevant fiscal year, unless extended by court order. Dividends not claimed within five&#160;years after the payment date shall be deemed to expire and revert to the French state. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Voting Rights.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We will only have ordinary shares outstanding. Each share shall entitle its holder to vote and be represented in the shareholders&#8217; meetings in accordance with the provisions of French law and of our bylaws. Ownership of one share implies, ipso jure, adherence to our bylaws and the decisions of the shareholders&#8217; meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In general, each shareholder is entitled to one vote per share at any general shareholders&#8217; meeting. Pursuant to our bylaws, however, a double voting right is attached to each fully paid-up registered ordinary share which is held in the name of the same shareholder for at least two&#160;years. However, under French law, ordinary bearer shares represented by ADSs are not eligible for double voting rights. Purchasers of ADSs or ordinary shares, in the open market will be unlikely to meet the requirements to have double voting rights attach to any ordinary shares held by them. To our knowledge, double voting rights only attach to the 5,612,224 ordinary shares held by the Cren Family (composed of Fr&#233;d&#233;ric Cren, our Chief Executive Officer and Roberta Becherucci, married name Cren and their minor child), and to the 3,882,500 ordinary shares held by Pierre Broqua, our Deputy Chief Executive Officer and Chief Scientific Officer, as of March&#160;31, 2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under French law, treasury shares or shares held by entities controlled by us are not entitled to voting rights and do not count for quorum purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Rights to Share in Our Profit.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Each share entitles its holder to a portion of the corporate profits and assets proportional to the amount of share capital represented thereby. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Rights to Share in the Surplus in the Event of Liquidation.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If we are liquidated, any assets remaining after payment of the debts, liquidation expenses and all of the remaining obligations will first be used to repay in full the par value of our shares. Any surplus will be distributed pro&#160;rata among shareholders in proportion to the number of shares respectively held by them, taking into account, where applicable, of the rights attached to shares of different classes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Repurchase and Redemption of Shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Under French law, we may acquire our own shares. Such acquisition may be challenged on the ground of market abuse regulations. However, Market Abuse Regulation (EU) No. 596/2014 of April&#160;16, 2014, or MAR, provides for safe harbor exemptions when the acquisition is made for one of the following purposes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to decrease our share capital, provided that such a decision is not driven by losses and that a purchase offer is made to all shareholders on a pro&#160;rata basis, with the approval of the shareholders at an extraordinary general meeting; in this case, the shares repurchased must be cancelled within one month from the expiry of the purchase offer; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to meet obligations arising from debt securities that are exchangeable into equity instruments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to provide shares for distribution to employees or managers under a profit-sharing, free share or share option plan; in this case the shares repurchased must be distributed within 12&#160;months from their repurchase failing which they must be cancelled; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;font-style:italic;">
          <font style="font-style:normal;letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;font-style:italic;">
          <!--blacklining:none;-->
          <font style="font-style:normal;letter-spacing:0.2pt;">we benefit from a simple exemption when the acquisition is made under a liquidity contract complying with the General Regulations (</font><font style="letter-spacing:0.2pt;">r&#233;glement g&#233;n&#233;ral</font><font style="font-style:normal;letter-spacing:0.2pt;">) of, and market practices accepted by the French Financial Markets Authority, or the AMF. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All other purposes, and especially share buy-backs made for external growth operations in pursuance of Article&#160;L. 225-209 of the French Commercial Code, while not forbidden, must be pursued in strict compliance of market manipulation and insider dealing rules. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under MAR and in accordance with the General Regulations (</font><font style="font-style:italic;letter-spacing:0.2pt;">r&#233;glement g&#233;n&#233;ral</font><font style="letter-spacing:0.2pt;">) of the AMF, or the General Regulations, a corporation shall report to the competent authority of the trading value on which the shares have been admitted to trading or are traded, no later than by the end of the seventh daily market session following the date of the execution of the transaction, all the transactions relating to the buy-back program, in a detailed form and in an aggregated form. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">No such repurchase of ordinary shares may result in us holding, directly or through a person acting on our behalf, more than 10% of our issued share capital. Ordinary shares repurchased by us continue to be deemed &#8220;issued&#8221; under French law but are not entitled to dividends or voting rights so long as we hold them directly or indirectly, and we may not exercise the pre-emptive rights attached to them. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Sinking Fund&#160;Provisions.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our bylaws do not provide for any sinking fund provisions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Liability to Further Capital Calls.</font><font style="letter-spacing:0.2pt;"> Shareholders are liable for corporate liabilities only up to the par value of the shares they hold; they are not liable to further capital calls. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Requirements for Holdings Exceeding certain&#160;percentages.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;None, except as described below under the section of this prospectus titled &#8220;Form, holding and transfer of shares (Articles 10 and 13 of the bylaws)&#8201;&#8212;&#8201;ownership of ordinary shares and ADSs by non-French persons.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Actions Necessary to Modify Shareholders&#8217; Rights.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Shareholders&#8217; rights may be modified as allowed by French law. Only the extraordinary shareholders&#8217; meeting is authorized to amend any and all provisions of our bylaws. It may not, however, increase shareholder commitments without the prior approval of each shareholder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Special Voting Rights of Warrant Holders.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Under French law, the holders of warrants of the same class (i.e., warrants that were issued at the same time and with the same rights), including founder&#8217;s share warrants (</font><font style="font-style:italic;letter-spacing:0.2pt;">bons de souscription de parts de cr&#233;ateur d&#8217;entreprise</font><font style="letter-spacing:0.2pt;">) and share warrants (</font><font style="font-style:italic;letter-spacing:0.2pt;">bons de souscription d&#8217;actions</font><font style="letter-spacing:0.2pt;">), are entitled to vote as a separate class at a general meeting of that class of warrant holders under certain circumstances, principally in connection with any proposed modification of the terms and conditions of the class of warrants or any proposed issuance of preferred shares or any modification of the rights of any outstanding class or series of preferred shares. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rules for Admission to and Calling Annual Shareholders&#8217; Meetings and Extraordinary Shareholders&#8217; Meetings (Section&#160;IV of the Bylaws)</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Access to, participation in and voting rights at shareholders&#8217; meetings.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Shareholders&#8217; meetings are composed of all shareholders, regardless of the number of shares they hold. Each shareholder has the right to attend the meetings and participate in the discussions (1)&#160;personally; (2)&#160;by granting proxy to any individual or legal entity of his choosing; (3)&#160;by sending a proxy to the company without indication of the mandate; (4)&#160;by voting by correspondence; or (5)&#160;at the option of the board of directors at the time the meeting is called, by videoconference or another means of telecommunication, including internet, in accordance with applicable laws that allow identification. The board of directors organizes, in accordance with legal and regulatory requirements, the participation and vote of these shareholders at the meeting, assuring, in particular, the effectiveness of the means of identification. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Participation in shareholders&#8217; general meetings, in any form whatsoever, is subject to registration or registration of shares two trading days prior to the date of the relevant general meeting under the conditions provided by applicable laws. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The final date for returning voting ballots by correspondence is set by the board of directors and disclosed in the notice of meeting published in the French Journal of Mandatory Statutory Notices, or BALO </font><font style="font-style:italic;letter-spacing:0.2pt;">(Bulletin des Annonces L&#233;gales Obligatoires)</font><font style="letter-spacing:0.2pt;">. This date cannot be earlier than three days prior to the meeting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A shareholder who has voted by correspondence will no longer be able to participate directly in the meeting or to be represented. In the case of returning the proxy form and the voting by correspondence form, the proxy form is taken into account, subject to the votes cast in the voting by correspondence form. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A shareholder may be represented at meetings by any individual or legal entity by means of a proxy form which we send to such shareholder either at the shareholder&#8217;s request or at our initiative. A shareholder&#8217;s request for a proxy form must be received at the registered office at least five days before the date of the meeting. The proxy is only valid for a single meeting or for successive meetings convened with the same agenda. It can also be granted for two meetings, one ordinary, and the other extraordinary, held on the same day or within a period of 15&#160;days. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A shareholder may vote by correspondence by means of a voting form, which we send to such shareholder either at the shareholder&#8217;s request or at our initiative, or which we include in an appendix to a proxy voting form under the conditions provided for by current laws and requirements. A shareholder&#8217;s request for a voting form must be received at the registered office at least six days before the date of the meeting. The voting form is also available on our website at least 21&#160;days before the date of the meeting. The voting form must be recorded by us three days prior to the shareholders&#8217; meeting, in order to be taken into consideration. The voting by correspondence form addressed by a shareholder is only valid for a single meeting or for successive meetings convened with the same agenda. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To better understand the voting rights of the ADSs, you should carefully read the section in this prospectus titled &#8220;Description of American Depositary Shares&#8201;&#8212;&#8201;Voting rights.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Notice of Annual Shareholders&#8217; Meetings.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Shareholders&#8217; meetings are convened by our board of directors, or, failing that, by the statutory auditors, or by a court appointed agent or liquidator in certain circumstances. Meetings are held at our registered offices or at any other location indicated in the meeting announcement (</font><font style="font-style:italic;letter-spacing:0.2pt;">avis de r&#233;union</font><font style="letter-spacing:0.2pt;">). A meeting announcement is published in the BALO at least 35&#160;days prior to a meeting, as well as on our website at least 21&#160;days prior to the meeting. In addition to the particulars relative to the company, it indicates, notably, the meeting&#8217;s agenda and the draft resolutions that will be presented. The requests for recording of issues or draft resolutions on the agenda must be addressed to the company under the conditions provided for in the current legislation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to special legal provisions, the convening notice (</font><font style="font-style:italic;letter-spacing:0.2pt;">avis de convocation</font><font style="letter-spacing:0.2pt;">) is sent out at least 15&#160;days prior to the date of the meeting, by means of a notice inserted both in a legal announcement bulletin of the registered office department and in the BALO. Further, the holders of registered shares for at least a month at the time of the latest of the insertions of the convening notice shall be summoned individually, by regular letter (or by registered letter if they request it and include an advance of expenses) sent to their last known address. This notice may also be transmitted by electronic means of telecommunication, in lieu of any such mailing, to any shareholder requesting it beforehand by registered letter with acknowledgment of receipt in accordance with legal and regulatory requirements, specifying his e-mail address. The latter may at any time expressly request by registered letter to the company with acknowledgment of receipt that the aforementioned means of telecommunication should be replaced in the future by a mailing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The convening notice must also indicate the conditions under which the shareholders may vote by correspondence and the places and conditions in which they can obtain voting forms by mail. The convening notice may be addressed, where appropriate, with a proxy form and a voting by correspondence form, under the conditions specified in our bylaws, or with a voting by correspondence form alone, under the conditions specified in our bylaws. When the shareholders&#8217; meeting cannot deliberate due to the lack of the required quorum, the second meeting must be called at least ten days in advance in the same manner as used for the first notice. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Agenda and Conduct of Annual Shareholders&#8217; Meetings.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The agenda of the shareholders&#8217; meeting shall appear in the convening notice of the meeting and is set by the author of the notice. The shareholders&#8217; meeting may only deliberate on the items on the agenda except for the removal of directors and the appointment of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">their successors which may be put to vote by any shareholder during any shareholders&#8217; meeting. Pursuant to French law and our current share capital, one or more shareholders representing 5% of our share capital, acting in accordance with legal requirements and within applicable time limits, may request the inclusion of items or proposed resolutions on the agenda. Such request must be received at the latest on the 25</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> day preceding the date of the shareholders&#8217; meeting, and in any event no later than the 20</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> day following the date of the shareholders&#8217; meeting announcement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Shareholders&#8217; meetings shall be chaired by the Chairman of the board of directors or, in his or her absence, by a Deputy Chairman or by a director elected for this purpose. Failing that, the meeting itself shall elect a Chairman. Vote counting shall be performed by the two members of the meeting who are present and accept such duties, who represent, either on their own behalf or as proxies, the greatest number of votes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Ordinary Shareholders&#8217; Meeting.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Ordinary shareholders&#8217; meetings are those meetings called to make any and all decisions that do not amend our bylaws. An ordinary meeting shall be convened at least once a year within six&#160;months of the end of each fiscal year in order to approve the annual accounts for the relevant fiscal year or, in case of postponement, within the period established by court order. Upon first notice, the meeting may validly deliberate only if the shareholders present or represented by proxy or voting by mail represent at least one-fifth of the shares entitled to vote. Upon second notice, no quorum is required. Decisions are made by a majority of the votes cast by the shareholders present, or represented by proxy, or voting by mail. The votes cast do not include those attached to shares for which the shareholder did not participate in the vote, abstained, voted blank or for which the vote is otherwise void. In addition, pursuant to an AMF recommendation dated 15 June&#160;2015, French listed companies may be required to conduct a consultation of the ordinary shareholders meeting prior to the disposal of the majority of their assets, under certain circumstances. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Extraordinary shareholders&#8217; meeting.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our bylaws may only be amended by approval at an extraordinary shareholders&#8217; meeting. Our bylaws may not, however, be amended to increase shareholder commitments without the approval of each shareholder. Subject to the legal provisions governing share capital increases from reserves, profits or share premiums, the resolutions of the extraordinary meeting shall be valid only if the shareholders present, represented by proxy or voting by mail represent at least one-fourth of all shares entitled to vote upon first notice, or one-fifth upon second notice. If the latter quorum is not reached, the second meeting may be postponed to a date no later than two&#160;months after the date for which it was initially called. Decisions are made by a two-thirds majority of the votes cast by the shareholders present, represented by proxy, or voting by mail. The votes cast do not include those attached to shares for which the shareholder did not participate in the vote, abstained, voted blank or for which the vote is otherwise void. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Temporary measures for shareholders meetings and Board of Directors meetings due to COVID-19 crisis</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;25, 2020, the French government adopted the ordinance No. 2020-321, adapting the rules governing meetings and deliberations of assemblies and governing bodies of legal entities held until September&#160;30, 2021 due to the COVID-19 pandemic. The ordinance provides the possibility of convening board of directors remotely for all decisions, including the closing of accounts, which previously required a physical meeting. In addition, the ordinance provides two options for holding general meetings of shareholders: behind closed doors or by means of a teleconference or audio-visual conference call. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">By decision of the board of directors, the general meeting of shareholders may be held behind closed doors ie., without the shareholders or their proxies (and any other person having the right to attend the meeting such as the statutory auditors and the employee representatives) being physically present. The possibility of holding a meeting behind closed doors requires that the meeting be convened in a place that, on the date of the meeting announcement, the convening notice or on the date of the meeting, is subject to an administrative measure restricting or prohibiting collective gatherings for health reasons, even if this measure is ultimately no longer in effect on the date of the meeting. As of the day of this filing, measures restricting gatherings (decree No. 2021-699 of June&#160;1, 2021, as amended, provides that, as general rule, any gathering, meeting or activity in public or in a place open to the public shall be organized to respect hygienic measures) are applicable until September&#160;30, 2021. Shareholders will only be able to vote remotely and prior to the general meeting of shareholders by the usual means available to date, i.e., vote by correspondence, blank proxy or Internet voting. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The ordinance provides that shareholders (and all the persons who may attend the general meeting of shareholders) may participate in the meeting by means of a teleconference or audio-visual conference call if this conference allows for the identification of the participants, transmits at least the voice of the participants and allows the continuous and simultaneous retransmission of the debates. On May&#160;31 and June&#160;1, 2021, the French government adopted several laws and decrees relating to the management of the sanitary crisis exit. Law No. 2021-689 of May&#160;31, 2021 on the health crisis management (i)&#160;notably provided rules for the gathering of people, meetings, and activities on public streets and in places open to the public (</font><font style="font-style:italic;letter-spacing:0.2pt;">L. No. 2021-689, art. 1, I, 3&#176;</font><font style="letter-spacing:0.2pt;">) and (ii)&#160;extended the measures resulting from Ordinance No. 2020-321 of March&#160;25, 2020 for Annual Shareholders Meetings and Board of Directors held until September&#160;31, 2021 (</font><font style="font-style:italic;letter-spacing:0.2pt;">L. No. 2021-689, art. 8, VI</font><font style="letter-spacing:0.2pt;">). Decree No.2021-699 of June&#160;1, 2021 providing general measures necessary for the management of the exit from the sanitary crisis, as amended by Decree No. 2021-850 of June&#160;29, 2021, authorized physical meetings provided that place of gatherings be arranged so as to ensure strict compliance with hygiene and social distancing measures (</font><font style="font-style:italic;letter-spacing:0.2pt;">D. No.2021-699, June&#160;1, 2021, art. 1 and 45, II</font><font style="letter-spacing:0.2pt;">). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Provisions having the effect of delaying, deferring or preventing a change in control of our company</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Provisions contained in our bylaws and French corporate law, could make it more difficult for a third party to acquire us, even if doing so might be beneficial to our shareholders. These provisions include the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">under French law, the owner of 90% of the share capital and voting rights of a public company listed on a regulated market in a Member State of the European Union or in a state party to the EEA Agreement, including from the main French Stock Exchange, has the right to force out minority shareholders following a tender offer made to all shareholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">under French law, a non-French resident must file a declaration for statistical purposes with the Bank of France (</font><font style="font-style:italic;letter-spacing:0.2pt;">Banque de France</font><font style="letter-spacing:0.2pt;">) within twenty working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In particular, such filings are required in connection with investments exceeding &euro;15,000,000 that lead to the acquisition of at least 10% of our company&#8217;s share capital or voting rights or cross such 10% threshold; see &#8220;Limitations affecting shareholders of a French company&#8221;; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">under French law, certain investments in a French company relating to certain strategic industries by individuals or entities are subject to prior authorization of the French Minister of Economy pursuant to Law No. 2019-486; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">under French law, certain investments in a French company relating to certain strategic industries by individuals or entities are subject to prior authorization of the French Minister of Economy pursuant to the decree No. 2019-1590; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a merger (i.e., in a French law context, a share for share exchange following which our company would be dissolved into the acquiring entity and our shareholders would become shareholders of the acquiring entity) of our company into a company incorporated in the European Union would require the approval of our board of directors as well as a two-thirds majority of the votes cast by the shareholders present, represented by proxy or voting by mail at the relevant meeting (unless the merger will result in an increase of the shareholders&#8217; commitments, in which case the approval of each shareholder is required); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a merger of our company into a company incorporated outside of the European Union would require 100% of our shareholders to approve it; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">under French law, a cash merger is treated as a share purchase and would require the consent of each participating shareholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our shareholders have granted and may grant in the future our board of directors broad authorizations to increase our share capital or to issue additional ordinary shares or other securities, such as warrants, to our shareholders, the public or qualified investors, including as a possible defense following the launching of a tender offer for our shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our shareholders have preferential subscription rights on a pro&#160;rata basis on the issuance by us of any additional securities for cash or a set-off of cash debts, which rights may only be waived by the </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">extraordinary general meeting (by a two-thirds majority vote) of our shareholders or on an individual basis by each shareholder; </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our board of directors has the right to appoint new directors to fill a vacancy created by the resignation or death of a director, subject to the approval by the shareholders of such appointment at the next shareholders&#8217; meeting, which prevents shareholders from having the sole right to fill vacancies on our board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our board of directors can be convened by our Chairman or our managing director, if any, or, when no board meeting has been held for more than two consecutive&#160;months, by directors representing at least one third of the total number of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our board of directors meetings can only be regularly held if at least half of the directors attend either physically or by way of videoconference or teleconference enabling the directors&#8217; identification and ensuring their effective participation in the board&#8217;s decisions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our shares are nominative or bearer, if the legislation so permits, according to the shareholder&#8217;s choice; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">approval of at least a majority of the votes cast by shareholders present, represented by a proxy, or voting by mail at the relevant ordinary shareholders&#8217; general meeting is required to remove directors with or without cause; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">advance notice is required for nominations to the board of directors or for proposing matters to be acted upon at a shareholders&#8217; meeting, except that a vote to remove and replace a director can be proposed at any shareholders&#8217; meeting without notice; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our bylaws can be amended in accordance with applicable laws; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the crossing of certain thresholds has to be disclosed and can impose certain obligations; see &#8220;Declaration of crossing of ownership thresholds (Article&#160;11 of the bylaws)&#8221;; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">transfers of shares shall comply with applicable insider trading rules and regulations, and in particular with MAR; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">pursuant to French law, the sections of the bylaws relating to the number of directors and election and removal of a director from office may only be modified by a resolution adopted by at least a two-third majority vote of our shareholders present, represented by a proxy or voting by mail at the meeting. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Declaration of Crossing of Ownership Thresholds (Article&#160;11 of the Bylaws)</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Set forth below is a summary of certain provisions of the French Commercial Code applicable to us. This summary is not intended to be a complete description of applicable rules under French law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any individual or legal entity referred to in Articles L. 233-7, L. 233-9 and L. 233-10 of the French Commercial Code coming to directly or indirectly own, or cease to own, alone or in concert, a number of shares representing a fraction of the company&#8217;s capital or voting rights greater or equal to 5%, 10%, 15%, 20%, 25%, 30%, 33.33%, 50%, 66.66%, 90% and 95% shall inform the company as well as the AMF of the total number of shares and voting rights and of securities giving access to the capital or voting rights that it owns immediately or over time within a period of four trading days from the crossing of the said holding thresholds. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This obligation applies when crossing each of the above-mentioned thresholds in a downward direction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In case of failure to declare shares or voting rights exceeding the fraction that should have been declared, such shares shall be deprived of voting rights at General Meetings of Shareholders for any meeting that would be held until the expiry of a period of two&#160;years from the date of regularization of the notification in accordance with Article&#160;L. 233-14 of the French Commercial Code. Additional sanctions may apply in particular pursuant to Article&#160;L.621-15 of the French Monetary and Financial Code. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, any shareholder crossing, alone or acting in concert, the 10%, 15%, 20% or 25% threshold shall file a declaration with the AMF pursuant to which it shall expose its intention over the following </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">six&#160;months, including notably whether it intends to continue acquiring shares of the company, it intends to acquire control over the company, its intended strategy for the company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, and subject to certain exemptions, any shareholder crossing, alone or acting in concert, the 30% threshold shall file a mandatory public tender offer with the AMF. Also, any shareholder holding directly or indirectly a number between 30% and 50% of the capital or voting rights and who, in less than 12 consecutive&#160;months, increases his/her/its holding of capital or voting rights by at least 1% of a company&#8217;s capital or voting rights, shall file a mandatory public tender offer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to the thresholds provided for by applicable laws and regulations, any person who comes to hold or ceases to hold, acting alone or in concert within the meaning of Article&#160;L.233-10 of the French Commercial Code, directly or indirectly, a number of shares representing at least 2% of the share capital or voting rights, including beyond the reporting thresholds provided for by laws and regulations, must inform the company of the total number of shares and voting rights of the company that such person holds, by registered letter with return receipt requested sent to the company&#8217;s registered office within four trading days after crossing such threshold(s). Such person shall also indicate the number of securities giving access to the capital and the voting right potentially attached thereto, as well as any other information provided for by law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The notification shall be repeated in the conditions stated above each time an additional fraction of 2% of the share capital or voting rights is crossed upward or downward. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event of failure to comply with the notification requirements described above, shares exceeding the fraction that should have been notified will be deprived of voting rights at shareholders&#8217; meetings if, at such meetings, the notification failure has been recorded and if one or more shareholders jointly holding at least 5% of the share capital so request. Loss of voting rights shall be applicable in all shareholders&#8217; meetings that would be held up until two&#160;years following proper notification. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Changes in Share Capital (Article&#160;7 of the Bylaws)</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Increases in share capital.</font><font style="font-style:normal;letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;As the bylaws do not provide any specific stipulations, the share capital may be increased, decreased or amortized by any methods or means authorized by law. Pursuant to French law, our share capital may be increased only with shareholders&#8217; approval at an extraordinary general shareholders&#8217; meeting following the recommendation of our board of directors. The shareholders may delegate to our board of directors either the authority (</font><font style="letter-spacing:0.2pt;">d&#233;l&#233;gation de comp&#233;tence</font><font style="font-style:normal;letter-spacing:0.2pt;">) or the power (</font><font style="letter-spacing:0.2pt;">d&#233;l&#233;gation de pouvoir</font><font style="font-style:normal;letter-spacing:0.2pt;">) to carry out any increase in share capital. If shareholders delegate authority to the board of directors at an extraordinary general meeting to decide a capital increase (</font><font style="letter-spacing:0.2pt;">d&#233;l&#233;gation de comp&#233;tence</font><font style="font-style:normal;letter-spacing:0.2pt;">), the delegation determines the period (26&#160;months maximum) during which the board of directors may decide to carry out the capital increase and the overall threshold of the capital increase. If shareholders delegate power to the board of directors at an extraordinary general meeting to carry out a capital increase (</font><font style="letter-spacing:0.2pt;">d&#233;l&#233;gation de pouvoir</font><font style="font-style:normal;letter-spacing:0.2pt;">) already decided by the extraordinary general meeting, the board of directors is granted the power to determine the terms and conditions of the capital increase within the limits set forth by the extraordinary general meeting. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Increases in our share capital may be effected by: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">issuing additional shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">increasing the par value of existing shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">creating a new class of equity securities; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">exercising the rights attached to securities giving access to the share capital. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Increases in share capital by issuing additional securities may be effected through one or a combination of the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in consideration for cash; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in consideration for assets contributed in kind; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">through an exchange offer; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">by conversion of previously issued debt instruments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">by capitalization of profits, reserves or share premium; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">subject to certain conditions, by way of offset against debt incurred by us. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Decisions to increase the share capital through the capitalization of reserves, profits and/or share premium require shareholders&#8217; approval at an extraordinary general shareholders&#8217; meeting, acting under the quorum and majority requirements applicable to ordinary shareholders&#8217; meetings. Increases effected by an increase in the par value of shares require unanimous approval of the shareholders, unless effected by capitalization of reserves, profits or share premium. All other capital increases require shareholders&#8217; approval at an extraordinary general shareholders&#8217; meeting acting under the regular quorum and majority requirements for such meetings. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Reduction in Share Capital.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Pursuant to French law, any reduction in our share capital requires shareholders&#8217; approval at an extraordinary general shareholders&#8217; meeting following the recommendation of our board of directors. The share capital may be reduced either by decreasing the par value of the outstanding shares or by reducing the number of outstanding shares. The number of outstanding shares may be reduced by the repurchase and cancellation of shares. Holders of each class of shares must be treated equally unless each affected shareholder agrees otherwise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Preferential Subscription Right.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;According to French law, if we issue additional securities for cash, current shareholders will have preferential subscription rights to these securities on a pro&#160;rata basis. Preferential subscription rights entitle the individual or entity that holds them to subscribe pro&#160;rata based on the number of shares held by them to the issuance of any securities increasing, or that may result in an increase of, our share capital by means of a cash payment or a set-off of cash debts. The preferential subscription rights are transferable during the subscription period relating to a particular offering, such period starting two days prior to the opening of the subscription period and ending two days prior to the closing of the subscription period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The preferential subscription rights with respect to any particular offering may be waived at an extraordinary general meeting by a two-thirds vote of our shareholders or individually by each shareholder. Our board of directors and our independent auditors are required by French law to present reports to the shareholders&#8217; meeting that specifically address any proposal to waive the preferential subscription rights. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our current shareholders have waived their preferential subscription rights with respect to this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the future, to the extent permitted under French law, we may seek shareholder approval to waive preferential subscription rights at an extraordinary general shareholders&#8217; meeting in order to authorize the board of directors to issue additional shares and/or other securities convertible or exchangeable into shares. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Form, Holding and Transfer of Shares (Articles 10 and 13 of the Bylaws)</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Form of shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The shares are held in registered form, until their full payment. When they are fully paid up, they may be in registered form or bearer, at the option of the shareholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Further, in accordance with applicable laws, we may request at any time from the central depository responsible for holding our shares, or directly to one or several intermediaries listed in Article&#160;L. 211-3 of the French Monetary and Financial Code, information regarding the owners of our ordinary shares in accordance with Article&#160;L. 228-2 of the French Commercial Code. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Holding of shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In accordance with French law concerning the &#8220;dematerialization&#8221; of securities, the ownership rights of shareholders are represented by book entries instead of share certificates. Shares issued are registered in individual accounts opened and maintained by us or any authorized intermediary, in the name of each shareholder and kept according to the terms and conditions laid down by the legal and regulatory provisions. Each shareholder&#8217;s account shows the name of the relevant shareholder and number of shares held. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Ownership of ordinary shares and ADSs by non-French persons.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Neither French law nor our bylaws limit the right of non-residents of France or non-French persons to own or, where applicable, to vote our securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">However, under French law, certain investments in any entity governed by a French law relating to certain strategic industries (such as research and development in biotechnologies and activities relating to public health) and activities by individuals or entities not French, not resident in France or controlled by entities not French or not resident in France are subject to prior authorization of the French Minister of Economy (See &#8220;Limitations Affecting Shareholders of a French Company.&#8221;) If an investment requiring the prior authorization of the French Minister of Economy is completed without such authorization having been granted, the French Minister of Economy might direct the relevant investor to nonetheless (i)&#160;submit a request for authorization, (ii)&#160;have the previous situation restored at its own expense or (iii)&#160;amend the investment. The relevant investor might also be found criminally liable and might be sanctioned with a fine which cannot exceed the greater of: (i)&#160;twice the amount of the relevant investment, (ii)&#160;10% of the annual turnover before tax of the target company and (iii)&#160;&euro;5&#160;million (for an entity) or &euro;1&#160;million (for an individual). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, (a)&#160;any non-French citizen, (b)&#160;any French citizen not residing in France, (c)&#160;any non-French entity or (d)&#160;any French entity controlled by one of the aforementioned persons or entities must file a declaration for statistical purposes with the Bank of France (</font><font style="font-style:italic;letter-spacing:0.2pt;">Banque de France</font><font style="letter-spacing:0.2pt;">) within twenty working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In particular, such filings are required in connection with investments exceeding &euro;15,000,000 that lead to the acquisition of at least 10% of our share capital or voting rights or cross such 10% threshold. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any violation of one of these requirements may be criminally sanctioned by five&#160;years of imprisonment and a fine of up to twice the amount of the relevant investment. This amount may be increased fivefold if the violation is made by a legal entity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Assignment and transfer of shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Shares are freely negotiable, subject to applicable legal and regulatory provisions. French law notably provides for standstill obligations and prohibition of insider trading. They are registered in a share account and transferred by means of a transfer order from account to account. We must receive notice of any transfer for it to be validly registered in our accounts. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Differences in Corporate Law</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are a </font><font style="font-style:italic;letter-spacing:0.2pt;">soci&#233;t&#233; anonyme</font><font style="letter-spacing:0.2pt;">, or S.A., incorporated under the laws of France. The laws applicable to French </font><font style="font-style:italic;letter-spacing:0.2pt;">soci&#233;t&#233;s anonymes</font><font style="letter-spacing:0.2pt;"> differ from laws applicable to U.S. corporations and their shareholders. The following discussion summarizes material differences between the provisions of the rights of holders of our ordinary shares and the rights of holders of the common shares of a typical corporation incorporated under the laws of the state of Delaware, which result from differences in governing documents and the laws of France and Delaware. For a more complete discussion, please refer to the Delaware General Corporation Law, French law (including the French Commercial Code) and our bylaws. </font>
        </div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">France </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Delaware </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Number of Directors </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under French law, a </font><font style="font-style:italic;letter-spacing:0.2pt;">soci&#233;t&#233; anonyme</font><font style="letter-spacing:0.2pt;"> must have at least three (3)&#160;and may have up to eighteen (18) directors. The number of directors is fixed by or in the manner provided in the bylaws. The number of directors of each gender may not be less than 40%. Any appointment made in violation of this limit that is not remedied will be null and void. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the bylaws. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Director Qualifications </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under French law, a corporation may prescribe qualifications for directors under its bylaws. In addition, under French law, members of a board of directors of a corporation may be legal </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under Delaware law, a corporation may prescribe qualifications for directors under its certificate of incorporation or bylaws. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">France </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Delaware </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:84pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:174pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">entities, and such legal entities may designate an individual to represent them and to act on their behalf at meetings of the board of directors. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:174pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Removal of Directors </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under French law, directors may be removed from office, with or without cause, at any shareholders&#8217; meeting without notice or justification, by a simple majority vote. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under Delaware law, unless otherwise provided in the certificate of incorporation, directors may be removed from office, with or without cause, by a majority stockholder vote, though in the case of a corporation whose board is classified, stockholders may effect such removal only for cause. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Vacancies on the Board of Directors </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under French law, vacancies on the board of directors resulting from death or a resignation, provided that at least three directors remain in office, may be filled by a majority of the remaining directors pending ratification by the shareholders by the next shareholders&#8217; meeting. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under Delaware law, vacancies on a corporation&#8217;s board of directors, including those caused by newly created directorships, may be filled by a majority of the remaining directors (even though less than a quorum). </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Annual General Meeting </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under French law, the annual general meeting of shareholders shall be held at such place, on such date and at such time as decided each year by the board of directors and notified to the shareholders in the convening notice of the annual meeting, within six&#160;months after the close of the relevant fiscal year unless such period is extended by court order. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or by the bylaws.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:84pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">General Meetings </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under French law, general meetings of the shareholders may be called by the board of directors or, failing that, by the statutory auditors, or by a court appointed agent or liquidator in certain circumstances, or by the majority shareholder in capital or voting rights following a public tender offer or exchange offer or the transfer of a controlling block on the date decided by the board of directors or the relevant person. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the bylaws. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Notice of General Meetings </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under French law, a meeting announcement is published in the Bulletin des Annonces L&#233;gales Obligatoires (BALO) at least 35&#160;days prior to a meeting and made available on the website of the company at least 21&#160;days prior to the meeting. Subject to limited exceptions provided by French law an additional convening notice is sent out at least 15&#160;days prior to the date </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than ten nor more than 60&#160;days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">France </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Delaware </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:84pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.833pt 0pt; width:174pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">of the meeting, by means of a notice inserted both in a legal announcement bulletin of the registered office department and in the BALO. Further, shareholders holding registered shares for at least a month at the time of the notices shall be summoned individually, by regular letter (or by registered letter if they request it and include an advance of expenses) sent to their last known address. This notice to registered shareholders may also be transmitted by electronic means of telecommunication, in lieu of any such mailing, to any shareholder requesting it beforehand by registered letter with acknowledgment of receipt in accordance with legal and regulatory requirements, specifying his email address. When the shareholders&#8217; meeting cannot deliberate due to lack of required quorum, the second meeting must be called at least 10 calendar days in advance in the same manner as used for the first notice.</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">The convening notice shall specify the name of the company, its acronym, legal form, share capital, registered office address, registration number with the French Trade and Companies Register (</font><font style="font-style:italic;letter-spacing:0.2pt;">Registre du commerce et des soci&#233;t&#233;s</font><font style="letter-spacing:0.2pt;">), the place, date, hour and agenda of the meeting and its nature (ordinary or extraordinary meeting). This notice must also indicate the conditions under which the shareholders may vote by correspondence and the places and conditions in which they can obtain voting forms by mail and, as the case may be, the e-mail address to which they may send written questions. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:174pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:84pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Proxy </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Each shareholder has the right to attend the meetings and participate in the discussions (1)&#160;personally, or (2)&#160;by granting proxy to his/her spouse, his/her partner with whom he/she has entered into a civil union or to another shareholder or to any individual or legal entity of his choosing; or (3)&#160;by sending a proxy to the company without indication of the mandate, or (4)&#160;by voting by correspondence, or (5)&#160;by videoconference or another means of </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three&#160;years from its date, unless the proxy provides for a longer period. A director of a Delaware corporation may not issue a proxy representing the director&#8217;s voting rights as a director. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">France </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Delaware </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:84pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:174pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">telecommunication in accordance with applicable laws that allow identification. The proxy is only valid for a single meeting or for successive meetings convened with the same agenda. It can also be granted for two meetings, one ordinary, and the other extraordinary, held on the same day or within a period of 15&#160;days. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:174pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Shareholder action by written consent </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <div style="font-style:italic;">
                <font style="font-style:normal;letter-spacing:0.2pt;">Under French law, shareholders&#8217; action by written consent is not permitted in a </font><font style="letter-spacing:0.2pt;">soci&#233;t&#233; anonyme.</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under Delaware law, a corporation&#8217;s certificate of incorporation (1)&#160;may permit stockholders to act by written consent if such action is signed by all stockholders, (2)&#160;may permit stockholders to act by written consent signed by stockholders having the minimum number of votes that would be necessary to take such action at a meeting or (3)&#160;may prohibit actions by written consent. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:84pt;white-space:nowrap;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Preemptive Rights </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under French law, in case of issuance of additional shares or other securities for cash or set-off against cash debts, the existing shareholders have preferential subscription rights to these securities on a pro&#160;rata basis unless such rights are waived by a two-thirds majority of the votes cast by the shareholders present at the extraordinary general meeting deciding or authorizing the capital increase, voting in person or represented by proxy or voting by mail. In case such rights are not waived by the extraordinary general meeting, each shareholder may individually either exercise, assign or not exercise its preferential rights. Preferential subscription rights may only be exercised during the subscription period. In accordance with French law, the exercise period shall not be less than five trading days. Preferential subscription rights are transferable during a period equivalent to the subscription period but starting two business days prior to the opening of the subscription period and ending two business days prior to the closing of the subscription period. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under Delaware law, unless otherwise provided in a corporation&#8217;s certificate of incorporation, a stockholder does not, by operation of law, possess preemptive rights to subscribe to additional issuances of the corporation&#8217;s stock or to any security convertible into such stock.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Sources of Dividends </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under French law, dividends may only be paid by a French </font><font style="font-style:italic;letter-spacing:0.2pt;">soci&#233;t&#233; anonyme</font><font style="letter-spacing:0.2pt;"> out of &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">distributable profits</font><font style="letter-spacing:0.2pt;">,&#8221; plus any distributable reserves and &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">distributable</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under Delaware law, dividends may be paid by a Delaware corporation either out of (1)&#160;surplus or (2)&#160;in case there is no surplus, out of its net profits for the </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">France </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Delaware </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:84pt;white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.833pt 0pt; width:174pt;">
              <div>
                <font style="font-style:italic;letter-spacing:0.2pt;">premium</font><font style="letter-spacing:0.2pt;">&#8221; that the shareholders decide to make available for distribution, other than those reserves that are specifically required by law.</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">&#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Distributable profits</font><font style="letter-spacing:0.2pt;">&#8221; consist of the unconsolidated net profits of the relevant corporation for each fiscal year, as increased or reduced by any profit or loss carried forward from prior&#160;years.</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="font-style:italic;letter-spacing:0.2pt;">&#8220;Distributable premium</font><font style="letter-spacing:0.2pt;">&#8221; refers to the contribution paid by the shareholders in addition to the nominal value of their shares for their subscription that the shareholders decide to make available for distribution.</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">Except in case of a share capital reduction, no distribution can be made to the shareholders when the net equity is, or would become, lower than the amount of the share capital plus the reserves which cannot be distributed in accordance with the law or the bylaws. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.833pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">fiscal year in which the dividend is declared and/or the preceding fiscal year, except when the capital is diminished by depreciation in the value of its property, or by losses, or otherwise, to an amount less than the aggregate amount of capital represented by issued and outstanding stock having a preference on the distribution of assets. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 13.583pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Repurchase of Shares </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 13.583pt 0pt; width:174pt;">
              <div>
                <font style="letter-spacing:0.2pt;">Under French law, a private corporation may acquire its own shares. Such acquisition may be challenged on the ground of market abuse regulations. However, MAR provides for safe harbor exemptions when the acquisition is made for the following purposes:</font>
              </div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">to decrease its share capital, provided that such decision is not driven by losses and that a purchase offer is made to all shareholders on a pro&#160;rata basis, with the approval of the shareholders at the extraordinary general meeting deciding the capital reduction, in which case, the shares repurchased must be cancelled within one month from the expiry of the purchase offer;</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">with a view to distributing within one year of their repurchase the relevant shares to employees or managers under a profit-sharing, free share or share option plan; not to exceed 10% of the share capital, in which case the shares repurchased must be distributed within 12&#160;months from their repurchase failing which they must be cancelled; or</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 13.583pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under Delaware law, a corporation may generally redeem or repurchase shares of its stock unless the capital of the corporation is impaired or such redemption or repurchase would impair the capital of the corporation. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">France </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Delaware </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:84pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.75pt 0pt 0.5pt 0pt; width:174pt;white-space:normal;">
              <div style=" float:left; line-height:12pt; text-align:left; width:8pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" line-height:12pt; text-align:left; margin-left:8pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">to meet obligations arising from debt securities, that are exchangeable into equity instruments.</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:174pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:84pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 2.833pt 0pt; width:174pt;white-space:normal;">
              <div>
                <font style="letter-spacing:0.2pt;">A simple exemption is provided when the acquisition is made under a buy-back program to be authorized by the shareholders in accordance with the provisions of Article&#160;L. 225-209 of the French Commercial Code and in accordance with the General Regulations.</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">All other purposes, and especially share buy-backs for external growth operations by virtue of Article&#160;L. 225-209 of the French Commercial Code, while not forbidden, must be pursued in strict compliance of market manipulations and insider dealing rules.</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">Under MAR and in accordance with the General Regulations, a corporation shall report to the competent authority of the trading venue on which the shares have been admitted to trading or are traded, no later than by the end of the seventh daily market session following the date of the execution of the transaction, all the transactions relating to the buy-back program, in a detailed form and in an aggregated form. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:174pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 7.833pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Liability of Directors </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 7.833pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under French law, the bylaws may not include any provisions limiting the liability of directors. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 7.833pt 0pt; width:174pt;">
              <div>
                <font style="letter-spacing:0.2pt;">Under Delaware law, a corporation&#8217;s certificate of incorporation may include a provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for:</font>
              </div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders;</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">intentional or negligent payment of unlawful dividends or stock purchases or redemptions; or</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">any transaction from which the director derives an improper personal benefit. </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">France </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Delaware </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:84pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Voting Rights </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">French law provides that, double voting rights are automatically granted to ordinary shares being held of record for more than two&#160;years, unless the bylaws of the Company provide otherwise. Our bylaws do not provide otherwise. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such stockholder. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4pt 0pt 2.833pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Shareholder Vote on Certain Transactions </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2.833pt 0pt; width:174pt;">
              <div>
                <font style="letter-spacing:0.2pt;">Generally, under French law, completion of a merger, dissolution, sale, lease or exchange of all or substantially all of a corporation&#8217;s assets requires:</font>
              </div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">the approval of the board of directors; and</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">approval by a two-thirds majority of the votes cast by the shareholders present, represented by proxy or voting by mail at the relevant meeting or, in the case of a merger with a non-EU company, approval of all shareholders of the corporation. </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2.833pt 0pt; width:174pt;">
              <div style=" float:left; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation&#8217;s assets or dissolution requires:</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">the approval of the board of directors; and</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">approval by the vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 6pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Dissenters&#8217; Appraisal Rights </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 6pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">French law does not provide for any such right but provides that a merger is subject to either shareholders&#8217; approval by a two-thirds majority vote, or unanimous decisions of the shareholders, as stated above. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 6pt 0pt; width:174pt;">
              <div>
                <font style="letter-spacing:0.2pt;">Under Delaware law, a holder of shares of any class or series has the right, in specified circumstances, to dissent from a merger or consolidation by demanding payment in cash for the stockholder&#8217;s shares equal to the fair value of those shares, as determined by the Delaware Chancery Court in an action timely brought by the corporation or a dissenting stockholder. Delaware law grants these appraisal rights only in the case of mergers or consolidations and not in the case of a sale or transfer of assets or a purchase of assets for stock. Further, no appraisal rights are available for shares of any class or series that is listed on a national securities exchange or held of record by more than 2,000 stockholders, unless the agreement of merger or consolidation requires the holders to accept for their shares anything other than:</font>
              </div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">shares of stock of the surviving corporation;</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">shares of stock of another corporation that are either listed on a national securities exchange or held of </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:2.5pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">France </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Delaware </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:84pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:174pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.833pt 0pt; width:174pt;white-space:normal;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">record by more than 2,000 stockholders;</font>
              </div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:8pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:8pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">cash in lieu of fractional shares of the stock described in the two preceding bullet points; or</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style=" float:left; line-height:10pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:8pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:10pt; text-align:left; margin-left:8pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">any combination of the above.</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style="margin-top:8pt;">
                <font style="letter-spacing:0.2pt;">In addition, appraisal rights are not available to holders of shares of the surviving corporation in specified mergers that do not require the vote of the stockholders of the surviving corporation. </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Standard of Conduct for Directors </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">French law does not contain specific provisions setting forth the standard of conduct of a director. However, directors have a duty to act without self-interest, on a well-informed basis and they cannot make any decision against a corporation&#8217;s corporate interest (</font><font style="font-style:italic;letter-spacing:0.2pt;">int&#233;r&#234;t social</font><font style="letter-spacing:0.2pt;">). </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:84pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">Shareholder Suits </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:174pt;">
              <div>
                <font style="letter-spacing:0.2pt;">French law provides that a shareholder, or a group of shareholders, may initiate a legal action to seek indemnification from the directors of a corporation in the corporation&#8217;s interest if it fails to bring such legal action itself. If so, any damages awarded by the court are paid to the corporation and legal fees relating to such action may be borne by the relevant shareholder or the group of shareholders.</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">The plaintiff must remain a shareholder through the duration of the legal action.</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">There is no other case where shareholders may initiate a derivative action to enforce a right of a corporation.</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">A shareholder may alternatively or cumulatively bring individual legal action against the directors, provided he has suffered distinct damages from those suffered by the corporation. In this case, any damages awarded by the court are paid to the relevant shareholder. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:174pt;">
              <div>
                <font style="letter-spacing:0.2pt;">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must:</font>
              </div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiff&#8217;s shares thereafter devolved on the plaintiff by operation of law; and</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and the reasons for the plaintiff&#8217;s failure to obtain the action; or</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">state the reasons for not making the effort.</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style="margin-top:8pt;">
                <font style="letter-spacing:0.2pt;">Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery. </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:40.5pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">France </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:174pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Delaware </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 2.833pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Amendment of Certificate of Incorporation </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.833pt 0pt; width:174pt;">
              <div>
                <font style="letter-spacing:0.2pt;">Unlike companies incorporated under Delaware law, the organizational documents of which comprise both a certificate of incorporation and bylaws, companies incorporated under French law only have bylaws as organizational documents.</font>
              </div>
              <div style="margin-top:6pt;">
                <font style="letter-spacing:0.2pt;">As indicated in the paragraph below, only the extraordinary shareholders&#8217; meeting is authorized to adopt or amend the bylaws under French law. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.833pt 0pt; width:174pt;">
              <div>
                <font style="letter-spacing:0.2pt;">Under Delaware law, generally a corporation may amend its certificate of incorporation if:</font>
              </div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">its board of directors has adopted a resolution setting forth the amendment proposed and declared its advisability; and</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">&#8226;</font>
                <br >
              </div>
              <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:10pt;">
                <!--blacklining:none;-->
                <font style="letter-spacing:0.2pt;">the amendment is adopted by the affirmative votes of a majority (or greater&#160;percentage as may be specified by the corporation) of the outstanding shares entitled to vote on the amendment and a majority (or greater&#160;percentage as may be specified by the corporation) of the outstanding shares of each class or series of stock, if any, entitled to vote on the amendment as a class or series. </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 7.583pt 0pt; width:84pt;">
              <font style="letter-spacing:0.2pt;">Amendment of Bylaws </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 7.583pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under French law, only the extraordinary shareholders&#8217; meeting is authorized to adopt or amend the bylaws. The extraordinary shareholders&#8217; meeting may authorize the board of directors to amend the bylaws to comply with mandatory legal provisions, subject to the ratification of such amendments by the next extraordinary shareholders&#8217; meeting. The board of directors is authorized to amend the bylaws as a result of a decision to relocate the company&#8217;s registered office in France, subject to ratification by the next ordinary shareholders&#8217; meeting. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 7.583pt 0pt; width:174pt;">
              <font style="letter-spacing:0.2pt;">Under Delaware law, the stockholders entitled to vote have the power to adopt, amend or repeal bylaws. A corporation may also confer, in its certificate of incorporation, that power upon the board of directors.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:20pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Listing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our ADSs are listed on the Nasdaq Global Market under the symbol &#8220;IVA.&#8221; Our ordinary shares are listed on Euronext Paris under the symbol &#8220;IVA.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transfer Agent and Registrar</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Bank of New York Mellon, as depositary, registers and delivers American Depositary Shares, or ADSs. Each ADS represents one ordinary share (or a right to receive one ordinary share) deposited with Soci&#233;t&#233; G&#233;n&#233;rale Securities Services, as custodian for the depositary in France. Each ADS will also represent any other securities, cash or other property that may be held by the depositary. The depositary&#8217;s office at which the ADSs are administered and its principal executive office are located at 240 Greenwich Street, New York, New York 10286.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tLASO1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LIMITATIONS AFFECTING SHAREHOLDERS OF A FRENCH COMPANY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Ownership of ADSs or Shares by Non-French Residents</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Neither the French Commercial Code nor our bylaws presently impose any restrictions on the right of non-French residents or non-French shareholders to own and vote shares. However, non-French residents must file a declaration for statistical purposes with the Bank of France (</font><font style="font-style:italic;letter-spacing:0.2pt;">Banque de France</font><font style="letter-spacing:0.2pt;">) within twenty working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In particular such filings are required in connection with investments exceeding &euro; 15,000,000 that lead to the acquisition of at least 10% of our share capital or voting rights or cross such 10% threshold. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Further, any investment: </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(i)&nbsp;&nbsp;&nbsp;by (a)&#160;any non-French citizen, (b)&#160;any French citizen not residing in France, (c)&#160;any non-French entity or (d)&#160;any French entity controlled by one of the aforementioned individuals or entities; </font>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(ii)&nbsp;&nbsp;&nbsp;that will result in the relevant investor (a)&#160;acquiring control of an entity having its registered office in France (such as us), (b)&#160;acquiring all or part of a business line of an entity having its registered office in France, or (c)&#160;for non-EU or non-EEA investors crossing, directly or indirectly, alone or in concert, a 25% threshold of voting rights in an entity having its registered office in France; and </font>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(iii)&nbsp;&nbsp;&nbsp;developing activities in certain strategic industries related to: </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(a)&nbsp;&nbsp;&nbsp;activities likely to prejudice national defense interests, participating in the exercise of official authority or likely to prejudice public order and public security (including activities related to weapons, dual-use goods and technologies, IT systems, cryptology, data capturing devices, gambling, toxic agents or data storage), </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(b)&nbsp;&nbsp;&nbsp;activities relating to essential infrastructure, goods or services (including energy, water, transportation, space, telecom, public health, farm products or media), or </font>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">(c)&nbsp;&nbsp;&nbsp;research and development activities related to critical technologies (including cybersecurity, artificial intelligence, robotics, additive manufacturing, semiconductors, quantum technologies, energy storage or biotechnology) or dual-use goods and technologies, </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">is subject to the prior authorization of the French Minister in charge of the Economy, which authorization, if granted, may be subject to certain undertakings. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;2, 2020, the French Minister of Economy informed us that we are subject to this regulation and therefore holders of our ordinary shares or ADSs will have to request the prior authorization of the French Minister of Economy if the above mentioned conditions in paragraphs (i)&#160;and (ii)&#160;are met. This request for prior authorization must be filed with the French Minister of Economy, which has 30 business days from receipt of the completed file to provide a first decision, which may (i)&#160;unconditionally authorize the investment or (ii)&#160;indicate that further examination is required. In the latter case, the French Minister of Economy must make a second decision within 45 business days from its first decision. In case of lack of response from the French Minister of Economy within the above mentioned timeframe, the authorization will be deemed refused. If the authorization is granted, it may be subject to the signature of a letter of undertaking aimed at protecting French national interests. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the context of the ongoing COVID-19 pandemic, the Decree (</font><font style="font-style:italic;letter-spacing:0.2pt;">d&#233;cret</font><font style="letter-spacing:0.2pt;">) No. 2020-892 dated July&#160;22, 2020, as amended on December&#160;28, 2020 by the Decree (</font><font style="font-style:italic;letter-spacing:0.2pt;">d&#233;cret</font><font style="letter-spacing:0.2pt;">) No. 2020-1729, has created until December&#160;31, 2021 a new 10% threshold of the voting rights for the non-European investments made (i)&#160;in an entity with its registered office in France and (ii)&#160;whose shares are admitted to trading on a regulated market, in addition to the 25% above-mentioned threshold. A fast-track procedure shall apply for any non-European investor exceeding this 10% threshold who will have to notify the Minister of Economy who will then have 10&#160;days to decide whether or not the transaction should be subject to further examination. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If an investment requiring the prior authorization of the French Minister of Economy is completed without such authorization having been granted, the French Minister of Economy might direct the relevant investor to nonetheless (i)&#160;submit a request for authorization, (ii)&#160;have the previous situation restored at its </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:80pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">own expense or (iii)&#160;amend the investment. The relevant investor might also be found criminally liable and might be sanctioned with a fine which cannot exceed the greater of: (i)&#160;twice the amount of the relevant investment, (ii)&#160;10% of the annual turnover before tax of the target company and (iii)&#160;&euro;5&#160;million (for an entity) or &euro;1&#160;million (for an individual). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any violation of one of these requirements may be criminally sanctioned by five&#160;years of imprisonment and a fine of up to twice the amount of the relevant investment. This amount may be increased fivefold if the violation is made by a legal entity. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Foreign Exchange Controls</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under current French foreign exchange control regulations there are no limitations on the amount of cash payments that we may remit to residents of foreign countries. Laws and regulations concerning foreign exchange controls do, however, require that all payments or transfers of funds made by a French resident to a non-resident such as dividend payments be handled by an accredited intermediary. All registered banks and substantially all credit institutions in France are accredited intermediaries. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Availability of Preferential Subscription Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our existing shareholders have waived their preferential subscription rights with respect to this offering. In the future our shareholders will have the preferential subscription rights described under the section of this prospectus titled &#8220;Description of Share Capital&#8201;&#8212;&#8201;Key provisions of our bylaws and French law affecting our ordinary shares&#8201;&#8212;&#8201;Changes in share capital (Article&#160;7 of the bylaws)&#8201;&#8212;&#8201;Preferential subscription right.&#8221; Under French law, shareholders have preferential rights to subscribe for cash issues of new shares or other securities giving rights to acquire additional shares on a pro&#160;rata basis. Holders of our securities in the United States, which may be in the form of shares or ADSs representing our shares, may not be able to exercise preferential subscription rights for their securities unless a registration statement under the Securities Act is effective with respect to such rights or an exemption from the registration requirements imposed by the Securities Act is available. We may, from time to time, issue new shares or other securities giving rights to acquire additional shares (such as warrants) at a time when no registration statement is in effect and no Securities Act exemption is available. If so, holders of our securities in the United States will be unable to exercise any preferential subscription rights and their interests will be diluted. We are under no obligation to file any registration statement in connection with any issuance of new shares or other securities. We intend to evaluate at the time of any rights offering the costs and potential liabilities associated with registering the rights, as well as the indirect benefits to us of enabling the exercise by holders of shares, including shares represented by ADSs, in the United States of the subscription rights, and any other factors we consider appropriate at the time, and then to make a decision as to whether to register the rights. We cannot assure you that we will file a registration statement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For holders of ADSs representing our ordinary shares, the depositary may make these rights or other distributions available to ADS holders. If the depositary does not make the rights available to ADS holders and determines that it is impractical to sell the rights, it may allow these rights to lapse. In that case ADS holders will receive no value for them. The section of this prospectus titled &#8220;Description of American Depositary Shares&#8201;&#8212;&#8201;Dividends and Other Distributions&#8221; explains in detail the depositary&#8217;s responsibility in connection with a rights offering. See also &#8220;Risk Factors&#8201;&#8212;&#8201;The right as a holder of ADSs to participate in any future preferential subscription rights or to elect to receive dividends in shares may be limited, which may cause holders of ADSs to be diluted&#8221; in our most recent Annual Report on Form 20-F. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDOAD1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Bank of New York Mellon has agreed to act as the depositary for the American Depositary Shares. The Bank of New York Mellon&#8217;s depositary offices are located at 240 Greenwich Street, New York, New York 10286. American Depositary Shares are frequently referred to as ADSs and represent ownership interests in securities that are on deposit with the depositary. ADSs may be represented by certificates that are commonly known as American Depositary Receipts, or ADRs. The depositary typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Soci&#233;t&#233; G&#233;n&#233;rale Securities Services. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">You may hold ADSs either (1)&#160;directly (a)&#160;by having an ADR, which is a certificate evidencing a specific number of ADSs, registered in your name, or (b)&#160;by having uncertificated ADSs registered in your name in the Direct Registration System, or DRS, or (2)&#160;indirectly by holding a security entitlement in ADSs through your broker or other financial institution that is a direct or indirect participant in the Depository Trust Company, or DTC. If you hold ADSs directly, you are a registered ADS holder, also referred to as an ADS holder. This description assumes you are an ADS holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of ADS holders described in this section. You should consult with your broker or financial institution to find out what those procedures are. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">DRS is a system administered by DTC pursuant to which the depositary may register the ownership of uncertificated ADSs, which ownership is confirmed by periodic statements sent by the depositary to the registered holders of uncertificated ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As an ADS holder, you will not be treated as one of our shareholders and you will not have shareholder rights. French law governs shareholder rights. The depositary will be the holder of the ordinary shares underlying your ADSs. As a holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the depositary and you, as an ADS holder, and all other persons directly and indirectly holding ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADRs. In the event of any discrepancy between the ADRs and the deposit agreement, the deposit agreement governs. A copy of the deposit agreement is filed as an exhibit to the registration statement of which this prospectus forms a part. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of ADR. For directions on how to obtain copies of those documents, see the section of this prospectus titled &#8220;Where you can find more information.&#8221; Unless otherwise indicated or the context otherwise requires, references to &#8220;you&#8221; in this section refer to purchasers of ADSs in offerings hereunder. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividends and Other Distributions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How will you receive dividends and other distributions on the ordinary shares?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary has agreed to pay or distribute to you the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities, after deducting its fees and expenses. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Cash.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;After completion of the offering, we do not expect to declare or pay any cash dividends or cash distributions on our ordinary shares for the foreseeable future. The depositary will convert any cash dividend or other cash distribution we pay on the ordinary shares or any net proceeds from the sale of any ordinary shares, rights, securities or other entitlements into U.S. dollars if it can do so on a reasonable and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of the ADS holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest. Before making a distribution, any withholding taxes or other governmental charges, together with fees and expenses of the depositary that must be paid, will be deducted. See the section of our most recent Annual Report on Form 20-F titles &#8220;Taxation&#8221;. It will distribute only whole U.S. dollars and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="font-style:normal;letter-spacing:0.2pt;">cents and will round fractional cents to the nearest whole cent. </font><font style="letter-spacing:0.2pt;">If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some or all of the value of the distribution. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Ordinary Shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The depositary may distribute additional ADSs representing any ordinary shares we distribute as a dividend or free distribution. The depositary will only distribute whole ADSs. It will sell ordinary shares which would require it to deliver a fractional ADS, or ADSs representing those ordinary shares, and distribute the net proceeds in the same way as it does with cash. If the depositary does not distribute additional ADSs, the outstanding ADSs will also represent the new ordinary shares. The depositary may sell a portion of the distributed ordinary shares, or ADSs representing those shares, sufficient to pay its fees and expenses in connection with that distribution. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Rights to Purchase Additional Ordinary Shares.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;If we offer holders of our securities any rights to subscribe for additional ordinary shares or any other rights, the depositary may (1)&#160;exercise those rights on behalf of ADS holders, (2)&#160;distribute those rights to ADS holders or (3)&#160;sell those rights and distribute the net proceeds to ADS holders, in each case after deduction or upon payment of its fees and expenses. To the extent the depositary does not do any of those things, it will allow the rights to lapse unexercised. </font><font style="font-style:italic;letter-spacing:0.2pt;">In that case, you will receive no value for them</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The depositary will exercise or distribute rights only if we ask it to and provide satisfactory assurances to the depositary that it is legal to do so. If the depositary makes rights available to you, it will exercise the rights and purchase the ordinary shares on your behalf and in accordance with your instructions. The depositary will then deposit the ordinary shares and deliver ADSs to you. It will only exercise rights if you pay it the exercise price and any other charges the rights require you to pay and comply with other applicable instructions. U.S. securities laws may restrict the ability of the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Other Distributions.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The depositary will send to you anything else we distribute on deposited securities by any means it determines is legal, fair and practical. If it cannot make the distribution in that way, the depositary may adopt another method. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what we distributed, in which case ADSs will also represent the newly distributed property. However, the depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that distribution. In addition, the depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor the depositary are responsible for any failure to determine that it may be lawful or feasible to make a distribution available to any ADS holders. We have no obligation to register ADSs, ordinary shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. </font><font style="font-style:italic;letter-spacing:0.2pt;">This means that you may not receive the distributions we make on our ordinary shares or any value for them if it is illegal or impractical for us to make them available to you.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Deposit, Withdrawal and Cancellation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How are ADSs issued?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary will deliver ADSs if you or your broker deposits ordinary shares or evidence of rights to receive ordinary shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or share transfer taxes or fees, the depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons that made the deposit. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How can ADS holders withdraw the deposited securities?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You may surrender your ADSs at the depositary&#8217;s office. Upon payment of its fees and expenses and of any taxes or governmental charges payable in connection with such surrender or withdrawal, the depositary will deliver the ordinary shares and any other deposited securities underlying the ADSs to you or a person </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">designated by you at the office of the custodian or through a book-entry delivery. Alternatively, at your request, risk and expense, the depositary will, if feasible, deliver the amount of deposited securities represented by the surrendered ADSs for delivery at the depositary&#8217;s office or to another address you may specify. The depositary may charge you a fee and its expenses for instructing the custodian regarding delivery of deposited securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How can ADS holders interchange between certificated ADSs and uncertificated ADSs?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You may surrender your ADRs to the depositary for the purpose of exchanging your ADRs for uncertificated ADSs. The depositary will cancel the ADRs and will send you a statement confirming that you are the owner of uncertificated ADSs. Alternatively, upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to you an ADR evidencing those ADSs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Voting rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How do you vote?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You may instruct the depositary to vote the number of whole deposited ordinary shares your ADSs represent. If we request the depositary to solicit your voting instructions (and we are not required to do so), the depositary will notify you of shareholders&#8217; meetings or other solicitations of consents and arrange to deliver our voting materials to you. Those materials will describe the matters to be voted on and explain how you may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary will endeavor, in so far as practicable, to vote or cause to be voted the amount of deposited ordinary shares represented by those ADSs in accordance with the instructions set forth in your request. The depositary will only vote, or attempt to vote, according to the instruction given by you and received by the depositary. If we do not request the depositary to solicit your voting instructions, you can still send voting instructions, and, in that case, the depositary may try to vote as you instruct, but it is not required to do so. In any event, the depositary will not exercise any discretion in voting deposited securities and it will only vote or attempt to vote as instructed or as described in the following sentence. If (i)&#160;we asked the depositary to solicit your instructions at least 30&#160;days before the meeting date, (ii)&#160;the depositary does not receive voting instructions from you by the specified date and (iii)&#160;we confirm to the depositary that: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we wish to receive a proxy to vote uninstructed shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we reasonably do not know of any substantial shareholder opposition to a particular question; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the particular question is not materially adverse to the interests of shareholders, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">the depositary will consider you to have authorized and directed it to give, and it will give, a discretionary proxy to a person designated by us to vote the number of deposited securities represented by your ADSs as to that question. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your ordinary shares. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. </font><font style="font-style:italic;letter-spacing:0.2pt;">This means that you may not be able to exercise your right to vote and there may be nothing you can do if your ordinary shares are not voted as you requested.</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to give you a reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to deposited securities, if we request the depositary to act, we will give the depositary notice of any such meeting and details concerning the matters to be voted upon at least 30&#160;days in advance of the meeting date except where under French law the notice period for such meeting is less than 30&#160;days. If we request that the depositary act less than 30&#160;days in advance of a meeting date, the depositary shall use commercially reasonable efforts to distribute the information and otherwise comply with the voting provisions described above. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Except as described above, you will not be able to exercise your right to vote unless you withdraw the ordinary shares. However, you may not know about the shareholder meeting enough in advance to withdraw the ordinary shares.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fees and Expenses</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">What fees and expenses will you be responsible for paying?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the terms of the deposit agreement, the holders of ADSs will be required to pay the following fees: </font>
        </div>
        <table style="width:456pt;height:383.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;min-height:18.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:222pt;">
              <font style="letter-spacing:-0.16pt;">Persons depositing or withdrawing ordinary shares or ADSs must </font>
              <br >
              <font style="letter-spacing:-0.16pt;">pay: </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:222pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">For: </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:29.25pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 2.833pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.833pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">Issue of ADSs, including issues resulting from a distribution of ordinary shares or rights </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:43pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:222pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">$0.05 (or less) per ADS </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">Any cash distribution to you </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:55pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">A fee equivalent to the fee that would be payable if securities distributed to you had been ordinary shares and the shares had been deposited for issue of ADSs </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">Distribution of securities distributed to holders of deposited securities which are distributed by the depositary to you </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">$0.05 (or less) per ADS per calendar year </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">depositary services </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:43pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">Registration or transfer fees </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:222pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Transfer and registration of ordinary shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:43pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">Expenses of the depositary </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:222pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Cable (including SWIFT) and facsimile transmissions as expressly provided in the deposit agreement </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:19pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5.5pt 0pt 3.5pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">Converting foreign currency to U.S. dollars </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:55pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">Taxes and other governmental charges the depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, share transfer taxes, stamp duty or withholding taxes </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:222pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">As necessary </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:45pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">Any charges payable by the depositary, custodian or their agents in connection with the servicing of deposited securities </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 2.833pt 0pt; width:222pt;white-space:nowrap;">
              <font style="letter-spacing:0.2pt;">As necessary</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.7pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing ordinary shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide for-fee services until its fees for those services are paid. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From time to time, the depositary may make payments to us to reimburse or share revenue from the fees collected from ADS holders, or waive fees and expenses for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the ADS program. In performing its duties </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">under the deposit agreement, the depositary may use brokers, dealers, foreign currency or other service providers that are affiliates of the depositary and that may earn or share fees, spreads or commissions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The depositary may convert foreign currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as an agent, fiduciary or broker on behalf of any other person and earns revenue, including, without limitation, fees and spreads that it will retain for its own account. The spread is the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives in an offsetting foreign currency trade. The depositary makes no representation that the exchange rate used or obtained in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or as to the method by which that rate will be determined, subject to its obligations under the deposit agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Payment of Taxes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">You will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until such taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs registered in your name to reflect the sale and pay you any net proceeds, or send you any property, remaining after it has paid the taxes. Your obligation to pay taxes and indemnify us and the depository against any tax claims will survive the transfer or surrender of your ADSs, the withdrawal of the deposited ordinary shares as well as the termination of the deposit agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Reclassifications, Recapitalizations and Mergers</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:144pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">If we: </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:300pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Then: </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Change the nominal value of our ordinary shares </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:300pt;">
              <font style="letter-spacing:0.2pt;">The cash, ordinary shares or other securities received by the depositary will become deposited securities. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Reclassify, split up or consolidate any of the deposited securities </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:300pt;">
              <font style="letter-spacing:0.2pt;">Each ADS will automatically represent its equal share of the new deposited securities. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Distribute securities on the ordinary shares that are not distributed to you </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:300pt;">
              <font style="letter-spacing:0.2pt;">The depositary may also deliver new ADSs or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities. The depositary may also sell the new deposited securities and distribute the net proceeds if we are unable to assure the depositary that the distribution (a)&#160;does not require registration under the Securities Act or (b)&#160;is exempt from registration under the Securities Act. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:144pt;">
              <font style="letter-spacing:0.2pt;">Recapitalize, reorganize, merge, liquidate, sell all or substantially all of our assets, or take any similar action </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:300pt;">
              <font style="letter-spacing:0.2pt;">Any replacement securities received by the depositary shall be treated as newly deposited securities and either the existing ADSs or, if necessary, replacement ADSs distributed by the depositary will represent the replacement securities. The depositary may also sell the replacement securities and distribute the net proceeds if the replacement securities may not be lawfully distributed to all ADS holders.</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.9pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amendment and Termination</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How may the deposit agreement be amended?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes and other governmental charges, registration fees, facsimile costs, delivery costs or other such expenses, or that would otherwise prejudice a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30&#160;days after the depositary notifies ADS holders of the amendment. </font><font style="font-style:italic;letter-spacing:0.2pt;">At the time an amendment </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">becomes effective, you are considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended</font><font style="font-style:normal;letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">How may the deposit agreement be terminated?</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The depositary will terminate the deposit agreement if we ask it to do so, in which case the depositary will give notice to you at least 90&#160;days prior to termination. The depositary may also terminate the deposit agreement if the depositary has told us that it would like to resign and we have not appointed a new depositary within 60&#160;days. In such case, the depositary must notify you at least 90&#160;days before termination. In addition, the depositary may initiate termination of the deposit agreement if (1)&#160;we delist our shares from an exchange on which they were listed and do not list the shares on another exchange; (2)&#160;we appear to be insolvent or enter insolvency proceedings; (3)&#160;all or substantially all the value of the deposited securities has been distributed either in cash or in the form of securities; (4)&#160;there are no deposited securities underlying the ADSs or the underlying deposited securities have become apparently worthless; or (5)&#160;there has been a replacement of deposited securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After termination, the depositary and its agents will do the following under the deposit agreement but nothing else: collect dividends and other distributions on the deposited securities, sell rights and other property, and deliver ordinary shares and other deposited securities upon cancellation of ADSs. At any time after the termination date, the depositary may sell the deposited securities. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the pro&#160;rata benefit of the ADS holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the termination date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After the termination date and before the depositary sells, ADS holders can still surrender their ADSs and receive delivery of deposited securities, except that the depositary may refuse to accept a surrender for the purpose of withdrawing deposited securities if it would interfere with the selling process. The depositary may refuse to accept a surrender for the purpose of withdrawing sale proceeds until all the deposited securities have been sold. The depositary will continue to collect distributions on deposited securities, but, after the termination date, the depositary is not required to register any transfer of ADSs or distribute any dividends or other distributions on deposited securities to the ADS holder (until they surrender their ADSs) or give any notices or perform any other duties under the deposit agreement except as described in this paragraph. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Limitations on Obligations and Liability</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary to ADS holders. We and the depositary: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">are not liable if either of us is prevented or delayed by law or circumstances beyond our control from performing our obligations under the deposit agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">are not liable if either of us exercises, or fails to exercise, discretion permitted under the deposit agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">are not liable for any tax consequences to any holders of ADSs on account of their ownership of ADSs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">are not liable for the acts or omissions of any securities depository, clearing agency or settlement system; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">may rely upon any documents we believe in good faith to be genuine and to have been signed or presented by the proper person. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances. Additionally, we, the depositary and each owner and holder waives the right to a jury trial in an action against us or the depositary arising out of or relating to the deposit agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Requirements for Depositary Actions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Before the depositary will deliver or register a transfer of an ADS, make a distribution on an ADS, or permit withdrawal of ordinary shares, the depositary may require: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">payment of any tax or other governmental charges and any stock transfer or registration fees charged by third parties for the transfer of any ordinary shares or other deposited securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The depositary may refuse to deliver ADSs or register transfers of ADSs generally when the transfer books of the depositary or our transfer books are closed or at any time if the depositary or we think it advisable to do so. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Your Right to Receive the Ordinary Shares Underlying Your ADSs</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">ADS holders have the right to cancel their ADSs and withdraw the underlying ordinary shares at any time except: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">when temporary delays arise because: (1)&#160;the depositary has closed its transfer books or we have closed our transfer books; (2)&#160;the transfer of ordinary shares is blocked to permit voting at a shareholders&#8217; meeting; or (3)&#160;we are paying a dividend on our ordinary shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">when you owe money to pay fees, taxes and similar charges; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">when it is necessary to prohibit withdrawals in order to comply with any U.S. or foreign laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This right of withdrawal is not limited by any other provision of the deposit agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Direct Registration System</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the deposit agreement, all parties to the deposit agreement acknowledge that the DRS and Profile Modification System, or Profile, will apply to ADSs upon acceptance thereof to DRS by DTC. DRS is the system administered by DTC under which the depositary may register the ownership of uncertificated ADSs and such ownership will be evidenced by periodic statements sent by the depositary to the registered holders of uncertificated ADSs. Profile is a required feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder of ADSs, to direct the depositary to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the depositary of prior authorization from the ADS holder to register that transfer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer and delivery as described above has the actual authority to act on behalf of the ADS holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary&#8217;s reliance on and compliance with instructions received by the depositary through the DRS/</font>&#8203;<font style="letter-spacing:0.2pt;">Profile System and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the depositary. </font></div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:368pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Shareholder Communications; Inspection of Register of Holders of ADSs; ADS Holder Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. The depositary will send you copies of those communications or otherwise make those communications available to you if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those holders about a matter unrelated to our business or the ADSs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each holder of ADSs will be required to provide certain information, including proof of taxpayer status, residence and beneficial ownership (as applicable), from time to time and in a timely manner as we, the depositary or the custodian may deem necessary or proper to fulfill obligations under applicable law. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Jury Trial Waiver</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The deposit agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You will not, by agreeing to the terms of the deposit agreement, be deemed to have waived our or the depositary&#8217;s compliance with U.S. federal securities laws or the rules and regulations promulgated thereunder. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDOW1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:202pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF WARRANTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Warrants (</font><font style="font-style:italic;letter-spacing:0.2pt;">bons de souscription d&#8217;actions)</font><font style="letter-spacing:0.2pt;"> may be offered separately or together with ordinary shares or ADSs. Each series of warrants will be issued under any separate warrant agreement to be entered into between us and one or more purchasers of such warrants. The applicable prospectus supplement will include details of the warrant agreements and terms and conditions covering the warrants being offered. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The particular terms of each issue or series of warrants will be described in the related prospectus supplement. If warrants for the purchase of ordinary shares or ADSs are offered, the description will include, where applicable: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the designation and aggregate number of warrants offered; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the price at which the warrants will be offered; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the currency or currency unit in which the warrants are denominated; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the date on which the right to exercise the warrants will commence and the date on which the right will expire; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the number of ordinary shares or ADSs that may be purchased upon exercise of each warrant and the price at which and currency or currencies in which that amount of ordinary shares or ADSs may be purchased upon exercise of each warrant; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the date or dates, if any, on or after which the warrants and the related ordinary shares or ADSs will be transferable separately; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the minimum or maximum amount, if any, of warrants that may be exercised at any one time; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the warrants will be subject to redemption or call, and, if so, the terms of such redemption or call provisions; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other terms, conditions and rights (or limitations on such rights) of the warrants. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We reserve the right to set forth in a prospectus supplement or applicable free writing prospectus specific terms of the warrants that are not within the options and parameters set forth in this prospectus. In addition, to the extent that any particular terms and conditions of the warrants described in a prospectus supplement or applicable free writing prospectus differ from any of the terms described in this prospectus, the description of such terms and conditions set forth in this prospectus shall be deemed to have been superseded or supplemented by the description of such differing terms and conditions set forth in such prospectus supplement or applicable free writing prospectus with respect to such warrants. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tTAX1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:572pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">TAXATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The material U.S. federal income tax consequences relating to the purchase, ownership and disposition of any of the securities offered by this prospectus will be set forth in the prospectus supplement pertaining to those securities. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:388pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless the applicable prospectus supplement indicates otherwise, the validity of our ordinary shares, including ordinary shares represented by the ADSs, and certain other matters governed by French law will be passed on for us by Gide Loyrette Nouel A.A.R.P.I. Unless otherwise indicated in any prospectus supplement, Cooley LLP, New York, New York, will be representing us in regards to certain matters governed by U.S. law in connection with any offering. Additional legal matters may be passed upon for any underwriters, dealers or agents by counsel that we will name in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The financial statements of Inventiva S.A. as of and for the&#160;years ended December&#160;31, 2020, 2019 and 2018 appearing in our <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1756594/000117184321001782/f20f_031521.htm">Annual Report on Form 20-F for the year ended December&#160;31, 2020</a>, have been audited by KPMG S.A., independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. KPMG S.A.&#8217;s report dated March&#160;2, 2021 refers to the change in Inventiva S.A.&#8217;s method of accounting for leases as of January&#160;1, 2019 due to the adoption of IFRS 16 &#8220;Leases.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The offices of KPMG S.A. are located at Tour Eqho, 2 avenue Gambetta, CS 60055, 92066 Paris la D&#233;fense Cedex. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tEOCL1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:120pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ENFORCEMENT OF CIVIL LIABILITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are a corporation organized under the laws of France. Half of our directors are citizens and residents of countries other than the United States, and the majority of our assets are located outside of the United States. We have appointed an agent for service of process in the United States; however, it may be difficult for investors: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to obtain jurisdiction over us or our non-U.S. resident officers and directors in U.S. courts in actions predicated on the civil liability provisions of the U.S. federal securities laws; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to enforce in U.S. courts judgments obtained in such actions against us or our non-U.S. resident officers and directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to bring an original action in a French court to enforce liabilities based upon the U.S. federal securities laws against us or our non-U.S. resident officers or directors; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to enforce against us or our directors in non-U.S. courts, including French courts, judgments of U.S. courts predicated upon the civil liability provisions of the U.S. federal securities laws. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Nevertheless, a final judgment for the payment of money rendered by any federal or state court in the United States based on civil liability, whether or not predicated solely upon the U.S. federal securities laws, would be recognized and enforced in France provided that a French judge considers that this judgment meets the French legal requirements concerning the recognition and the enforcement of foreign judgments and is capable of being immediately enforced in the United States. In the absence of any applicable international convention, a French court is therefore likely to grant the enforcement of a foreign judgment without a review of the merits of the underlying claim, only if (1)&#160;that judgment is enforceable in the jurisdiction of the U.S. court which rendered it, (2)&#160;that judgement was rendered by a court having jurisdiction over the dispute (the condition will be met if the dispute is clearly connected to the jurisdiction of the U.S. court and French courts did not have exclusive jurisdiction over the matter), (3)&#160;that judgment does not contravene French international public order and public policy, including the right to due process and (4)&#160;the U.S. judgment is not tainted with fraud and is not incompatible with a judgment rendered by a French court in the same matter, or with an earlier judgment rendered by a foreign court in the same matter. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, French law guarantees full compensation for the harm suffered but is limited to the actual damages, so that the victim does not suffer or benefit from the situation. Such system excludes damages such as, but not limited to, punitive and exemplary damages. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a result, the enforcement, by U.S. investors, of any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities law against us or members of our board of directors, officers or certain experts named herein who are residents of France or countries other than the United States would be subject to the above conditions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Finally, there may be doubt as to whether a French court would impose civil liability on us, the members of our board of directors, our officers or certain experts named herein in an original action predicated solely upon the U.S. federal securities laws brought in a court of competent jurisdiction in France against us or such members, officers or experts, respectively. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tWYCF1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:344pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are subject to the reporting requirements of the Exchange Act that are applicable to a foreign private issuer. Under the Exchange Act, we file annual reports on Form 20-F and other information with the SEC. We also furnish to the SEC under cover of Form 6-K material information required to be made public in France, filed with and made public by any stock exchange on which we are listed or distributed by us to our shareholders. As a foreign private issuer, we are exempt from, among other things, the rules under the Exchange Act prescribing the furnishing and content of proxy statements and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&#160;16 of the Exchange Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC maintains a web site that contains reports and information statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is </font><font style="font-style:italic;letter-spacing:0.2pt;">www.sec.gov</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus and any prospectus supplement are part of a registration statement on Form F-3 that we filed with the SEC and do not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Forms of the documents establishing the terms of the offered securities are or may be filed as exhibits to the registration statement of which this prospectus forms a part. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. You may inspect a copy of the registration statement through the SEC&#8217;s website, as provided above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also maintain a website at www.inventivapharma.com through which you can access our SEC filings. The information set forth on our website is not part of this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tIODB1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION OF DOCUMENTS BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The SEC allows us to &#8220;incorporate by reference&#8221; information that we file with them. Incorporation by reference allows us to disclose important information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. We filed a registration statement on Form F-3 under the Securities Act of 1933, as amended, with the SEC with respect to the securities we may offer pursuant to this prospectus. This prospectus omits certain information contained in the registration statement, as permitted by the SEC. You should refer to the registration statement, including the exhibits, for further information about us and the securities we may offer pursuant to this prospectus. Statements in this prospectus regarding the provisions of certain documents filed with, or incorporated by reference in, the registration statement are not necessarily complete and each statement is qualified in all respects by that reference. Copies of all or any part of the registration statement, including the documents incorporated by reference or the exhibits, may be obtained upon payment of the prescribed rates at the offices of the SEC listed above in &#8220;Where You Can Find More Information.&#8221; The documents we are incorporating by reference are: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;letter-spacing:0.2pt;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;letter-spacing:0.2pt;">
          <!--blacklining:none;-->
          <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1756594/000117184321001782/f20f_031521.htm">Our Annual Report on Form 20-F for the year ended December&#160;31, 2020, filed with the SEC on March&#160;15, 2021;</a><font style="letter-spacing:0.2pt;"> Amendment No. 1 to our </font><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1756594/000117184321002040/f20fa_032521.htm">Annual Report on Form 20-F for the year ended December&#160;31, 2020, filed with the SEC on March&#160;24, 2021;</a><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1756594/000117184321002551/f6k_041921.htm">our report on Form 6-K furnished to the SEC on April&#160;19, 2021</a>, including <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1756594/000117184321002551/exh_991.htm">exhibit 99.1</a> thereto (regarding the appointment of Martine Zimmermann as an independent director to our board of directors); <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1756594/000117184321003443/f6k_051221.htm">our report on Form 6-K furnished to the SEC on May&#160;12, 2021</a>, including <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1756594/000117184321003443/exh_991.htm">exhibit 99.1</a> thereto; <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1756594/000117184321005192/f6k_072821.htm">our report on Form 6-K furnished to the SEC on July&#160;28, 2021</a>, including <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1756594/000117184321005192/exh_991.htm">exhibit 99.1</a> thereto; and our report on <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/0001756594/000110465921098859/tm2123561d1_6k.htm">Form 6-K furnished to the SEC on August&#160;2, 2021</a>, including <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/0001756594/000110465921098859/tm2123561d1_ex99-1.htm">exhibit 99.1</a> thereto; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;letter-spacing:0.2pt;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;letter-spacing:0.2pt;">
          <!--blacklining:none;-->
          <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1756594/000110465920081719/tm2024125-1_8a12b.htm">the description of ADSs representing our ordinary shares contained in our Registration Statement on Form 8-A filed with the SEC on July&#160;7, 2020, including any amendments or reports filed for the purpose of updating such description.</a><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are also incorporating by reference all subsequent Annual Reports on Form 20-F that we file with the SEC and certain reports on Form 6-K that we furnish to the SEC after the date of this prospectus (if they state that they are incorporated by reference into this prospectus) prior to the termination of this offering. In all cases, you should rely on the later information over different information included in this prospectus or any accompanying prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless expressly incorporated by reference, nothing in this prospectus shall be deemed to incorporate by reference information furnished to, but not filed with, the SEC. Copies of all documents incorporated by reference in this prospectus, other than exhibits to those documents unless such exhibits are specifically incorporated by reference in this prospectus, will be provided at no cost to each person, including any beneficial owner, who receives a copy of this prospectus on the written or oral request of that person made to: </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Inventiva S.A.</font>
          <br >
          <font style="letter-spacing:0.2pt;">50 rue de Dijon </font>
          <br >
          <font style="letter-spacing:0.2pt;">21121 Daix France </font>
          <br >
          <font style="letter-spacing:0.2pt;">Tel: +33 3 80 44 75 00 </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You may also access these documents on our website, </font><font style="font-style:italic;letter-spacing:0.2pt;">www.inventivapharma.com</font><font style="letter-spacing:0.2pt;">. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should rely only on information contained in, or incorporated by reference into, this prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus or incorporated by reference in this prospectus. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tEAWR1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:436.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPENSES ASSOCIATED WITH REGISTRATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following is an estimate of the expenses (all of which are to be paid by us) that we may incur in connection with the securities being registered hereby. </font>
        </div>
        <table style="width:416pt;height:100.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">SEC registration fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">32,730</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">FINRA filing fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">45,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Legal fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(1<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accounting fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(1<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Printing expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(1<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:371.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Miscellaneous expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(1<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt; width:371.29pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">(1<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:11pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">These fees will be determined and calculated at the time of each issuance of securities pursuant to this registration statement and accordingly cannot be estimated at this time.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.8pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.8pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="position:relative;margin-top:77.15pt; text-align:center; width:456pt;">
          <img src="lg_inventiva-4c.jpg" alt="[MISSING IMAGE: lg_inventiva-4c.jpg]" height="98" width="261" >
        </div>
        <div style="margin-top:100.77pt; text-align:center; width:456pt; line-height:15.5pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Up to $58,000,000</font>
          <br >
          <font style="letter-spacing:-0.28pt;">American Depositary Shares representing Ordinary Shares</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:24pt; text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">PROSPECTUS SUPPLEMENT</font><font style="font-weight:normal;letter-spacing:0.24pt;"> </font>
        </div>
        <div style="margin-top:120pt; text-align:center; width:456pt; line-height:20pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:18pt;">
          <font style="letter-spacing:-0.36pt;">TD Cowen</font><font style="font-weight:normal;letter-spacing:0.36pt;"> </font>
        </div>
        <div style="margin-top:120pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">September 28, 2023</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:98.36pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 98.36pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.81pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.80999999999995pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>fc_deeppipeline-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_deeppipeline-4clr.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !&
M  #_X0,O:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C M8S P," W.2YD86)A8V)B+" R,#(Q+S T+S$T
M+3 P.C,Y.C0T(" @(" @(" B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7 ](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UP.D-R
M96%T;W)4;V]L/2)!9&]B92!0:&]T;W-H;W @,C(N-2 H36%C:6YT;W-H*2(@
M>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#HS-S0T-T9",34V-#8Q,45%.#=$
M0D%$1D-#-S4T.$%%,B(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#HS-S0T
M-T9",C4V-#8Q,45%.#=$0D%$1D-#-S4T.$%%,B(^(#QX;7!-33I$97)I=F5D
M1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7 N:6ED.C,W-#0W1D%&-38T-C$Q
M144X-T1"041&0T,W-30X044R(B!S=%)E9CID;V-U;65N=$E$/2)X;7 N9&ED
M.C,W-#0W1D(P-38T-C$Q144X-T1"041&0T,W-30X044R(B\^(#PO<F1F.D1E
M<V-R:7!T:6]N/B \+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@
M96YD/2)R(C\^_^X #D%D;V)E &3      ?_; (0 ! ,# P,#! ,#! 8$ P0&
M!P4$! 4'" 8&!P8&" H("0D)"0@*"@P,# P,"@P,#0T,#!$1$1$1%!04%!04
M%!04% $$!04(!P@/"@H/% X.#A04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@#> >> P$1  (1 0,1 ?_$
M .\  0 " @,! 0             !!@4' @0( PD! 0 " P$! 0
M   ! P($!08'"!   0(#!0,%!@X." (%"@$-  $"$0,$$A,%!@<A,11!42(R
M%=&B(S-3"&%Q0E*CTU2DM-06-E88@:&Q@K*#LR0TA#55A1>1P4-$);6&-^%B
M<F.412;P\9+2<Y-D="<XPL25I>1E=4:V">+#EB@1 0 ! P$$!@8'!0@! P,"
M!P !$0(#!"$Q41)!@3(3% 7P8:&QT5)QP>$B,Q4&D4*"TN)B<J*RPB,T%O&2
M0S53@R1$<^.S\F.CTU3_V@ , P$  A$#$0 _ /?P
M
M
M
M
M
M
M
M
M
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M4NRG:Q-S&^I,-/===;66.*9F-K:G21415W[C96OH
M
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M9L=Z/.7X=579<LLS=$O3T(\NQ3HMI.R,>0"0
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MG:*8=P'!KP]-3V>(XJW^CRI<8W;>M'<:FERW7UYIJIP7S=6KT8;S8
M          #Q_K%KUJ'D35S%<'PS$K>6J'A[&%W%*EJ^H9,Q?#/D3)B0F3%?
MO]#<<O-J+[<DQT?8T\F6ZV[8]-X+F>CS)EJ1F/"'PH*JW<N@[I7<YTEVR8UK
MD@YJ[VG1BZ+K:PVHNK%6@/-OU:U!S]C>)46;L9X^GD7%RG#4LFS;EU+G>(E2
MU6*RV[^8TM-FNOFDRU\-]UT[7J!J*JQ=L7E3G.@VG%42TD&QCNV[X $1R=)R
MP3U2\_-Z4 )145$=:BWTH 8C,V8)&6<%JL;J6VY=+=QEQ5(WDQLO>C7>NYC"
M^[EBJ)FD*?HYJ%6ZD8$[,=33<'+GPN:2VV;8L39TIW327+C&[M;6E6')SQ5A
MCOYH;%9:<V\8MYZW99CR*;"R/6^X                  \Q>>'6SJ?+F#4$
MM82:GB;QFS;=S:-R;52._P!$Y^LFD1#5U&Y??-LP:1A>E."39;8553Q7$3(K
MT[NMJ4;L551((O(6Z:*8X6X8I:NV9<@Y3S;44=7F+#^.JZ"]X-U]/DV+]&M?
MXJ8Q%BC&]:)??CMNFLPLNMB=ZKZT8!G;&\HOP7(#(U4^%])C3I:L3Y,QO2JG
M-1((UZ[%_J*L]MTVTM89+9F*0\N9[T Q33?*;LZXAF".,2X1PS@V)UI\NG\<
MRHF,ZDQ']3T/1.??IYLMK7:U+L4VQ6KT!D_,>(YI\WZ1C.*3+ZNGV[Z=!C(V
M,4?+;T6-:FYJ)L0W++INQ5GTVMFV:V/,NB>1,RZF+BF6\.QCLC!&</VE.X:3
M5;[Z=*Z+YDI_7E*G1=R[=AH8<<WUBNQJ8[9NV59W)$[,6C&LR9+7$+VAI_TQ
M;F4V\O,/?42_+*VRL[U+]O*9V5Q9.7TW,K9FR^G0NGG,9_S/4YMDZ?X!-N6R
M+7&R;,E]];D4U5+Z4V6EFS!R]%^WEYBW59)KRPSS7S6D*QGW0?->EF0:[%:/
M'^.PR=<]KT7!R)-BQ52V2/".GS7+%TVUT$]!2O+@NQVUKL8W8YMAM3S2XKD:
MMZ4$\%LAO_.:LV=)V5N#<J'FAUTK#69ZK9ZPIY79-MNU8VEJVIM1%7>I3HII
M%W4QP3O4W!\*S7YT&<:^IK*[LO"Z*YO7W4BIX>^IU1-C5I7/MNI>3='^FN(N
MSW;5<1.66&UOT[S+IM,P7!L5Q?M?"'<5V9/X:32P@DB9.Z+)DQW6F(G37DV&
M&?'-E(E&2V;:178];ZT8+GK,&4'87DA+=9,A?ROS9(V9\E[>E4N:FYKUV+_4
M=//;==;2UMWQ,QL>8-0/-^J],LL3<V3LS<1BU/9CAW -9XR=+D>-2HFMZLVU
MU?0.?DT_=VUJU;\7+%:MR8;EK$-<-!L'?BV+\'73^)OZSAFS;5C$UL^#8Z0B
M020C=GI^GM6VSEQ16?2J^G/9M:.T$T7=J;.Q'%$QOLM<'N8R^%XF]XM)[-]]
M*LV;KF6,34P8>>NVE&OCQ\RS:SYVQ/4#4Z9D2EQ+@<O2H69]PR=UJ.34KT7,
MEOZ\N'7Y>;89YKYOOY>AGDNYKJ*],JZWS>\RX?799Q_Y0X947U\S@VT%N[DV
M6[9R5#D@ZH=N3U/H[,*]S=]V:L9_VYV35[IPS$9&,44NMD;::=&[W^H<K5WH
MB[TYCL6S6*M[>T=YU-=-7*%-EV4GYQC=N*13^YSZ6;RI#=_S)]DT]7/W:<5.
M;=1NO+^"T^7<(IL'H?!TM/;NF;7>,F.F+M<YR[W+RFW;;$11=$4ADD:Q%Z.Q
MZ[OL&;)]@@
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MQT[9K#;MG8S'H&;)R
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M-K%=,XYKZ;5METS8P/F5=?.BP@Y.R^EOA'C>0PT6^>KZV.GZ7KLZ;<
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MO+FQ>>(ES(0O&];GV%63+;9OEA=?%N]:6N1R-N]K5C8_YN??N@6PR=@
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M--LWM7?3EC9D\.WH6[OQ?1V,^V5]W;S5Z4<L5KTK,6)
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MRU0<%3OA>MOITZ,%<Y-LY[UWO<768[;-D,[;8A95C#86,B*;6D#D2
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M8JFU>L!Q;THN9TEY>2()%1=D>B[^D(W.6U-B;F[T],)?4
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MC>KGG8L;(SW23I*67/O(KOC"FI$Y2O5]ICG[3VY)\6G_ )<IUX;T.?*I(D
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M!J.M;%\(GC-G/N$CDQ[5VHN_=L =98)L<GJO^! X)&,4V<W_ "]V)([
M                /E"%F&R6D=@'%-BQ1-G]FG-S@<]SEBL(;E('%JM5K59T
M4VP=O@2F4HJJMJ'0Y A,46*-ZR<OIB@ET5@R._>H$)95(HFP#Z  /DKD:JVN
MCS)O"4*JHBN5=J=9>>.X(AS5>1%LN7[) 06'-Z)(Y@
M  TOYQ&=\T9&RDS$LJUW 5JQC.NI,^,)].SJSF/3<]R;N4U-1?-EM84Y;YMC
M8TOEO,_G@9RP6ES'EZKXW!ZN\X:JN\!DQNICI3^A-:QW68Y-K35LOSW16/J4
M6SEF*Q]2P:7:[Z@2<_2\BZF+Q%=-M6I_YK+N+-+-J4Z-'(@^VEVG7V?TH9XL
M]\7<M[*S+=6DO52-="Q&*\J'2VMQ]@@
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MH3QEZY(.FKZLRMKCR<L>FQ-M;;Z/<:[8=*+7;MFZ!V&_T/J$
M
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MXV;D9+.6'J;2Y8Y'PJQ_\19?^LS8[#HXNQ#;Q]E=BYD
M
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M2:RJXRJ2-NJNVRK47*J=!NQ()L.O$=;?=JTC?03^F @E]"0
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M=^+Z<'MK?L5-CMR^D=AO5?<
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MIFP-_#V(;./<NA<S
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M+MC8JF]T=T?0+F;[
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M>6)D/*3'/79%WKN<ZUMO+%&[;%(9\S2
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MR555=J=7^L@%3U'59R)OB2(58HB0@G,!]@
M                                                           '
MR1;,8;&IU4], BNA&,'<O* 7:V"I!J;V_P#$ V+4;!L%6,&1_K!*+,'*Y4BO
M* 5$@D>DC=_)")"9-T70B[FYB4)3>UZ)L6-IW-]@)192+>28D;*_="$PBJ.<
ML4;';Z8$HBPVKMYP(BJPM)OW 3&S!RK'T><"%Y%38Y-_V0.,%8Y8)%/4_P!9
M(E&-;U4@[F(2*JVX(FQ>I_S<_I0(E"$M)LZSV=;DW[B1]P
M
M         <.?9Z2\Y!O$3I13[)(^;FJL8.@Y^]81W <HI;V)OZO]&T@1!;2O
M5L7)NV[N0F@E-O62*IO('#I.78EI%W\EGNQ)')$5$V[8]9^[TMA%$RF"6EBD
M&MZJQWQWDH0U%;TH0]<F^',0)5.E'?#J^AS@(1V^I7?Z,"1**MKT.52!#8MV
M+R;P/J2                 !\EBD53:Q.0A*.6Q&TSE3= E Y'<J1<FYW_
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MK.S#-LU>F(K;M-;&/7V[MFPZ#:?<
M                                                J-1\^:/\;\&*
MI[3#I6XM9@                     $)N J6;?VYE_]<_)L*;]\,9WPMQ<R
M                      (4"@:E>/P;]9^Y+*,O0PN; +V8
M         !4,P?/K)W\3^#-*KNU;UL)WPMY9#,)
M "GY?^?><OX9\&<56]J[J81OE;TWJ6LT@                      -2:?_
M .^&L?\ IG_+IAK8_P 2_J]RFWMW=3;2[T-E<D
M      @8+./S<K?Q7Y9AC?N1.YW,!_9-/]_^&XFW<1N9$R2
M
M                                                 %1J/GS1_C?@
MQ5/:8=*W%K,                      A-P%2S;^W,O_KGY-A3?OAC.^%N+
MF0                     !"@4#4KQ^#?K/W)91EZ&%S8!>S
M           *AF#Y]9._B?P9I5=VK>MA.^%O+(9A(
M   4_+_S[SE_#/@SBJWM7=3"-\K>F]2UFD                      !J33
M_P#WPUC_ -,_Y=,-;'^)?U>Y3;V[NIMI=Z&RN2
M      0,%G'YN5OXK\LPQOW(G<[F _LFG^__  W$V[B-S(F20
M
M                                                   J%1\^J/\
M&?!BJ>TPZ5O+68                     !"[@*EFW]N9?_ %S\FPIOWPQG
M?"W%S(                      A=P% U*\?@WZS]R649>A7<V 7K
M                "GYB^?.3OXG\&:57=JWK83OA<"R&82
M        %0R_\^LX_P ,^#.*K>U/4PC?*W)O4M9I  <$:B[EV+_4!%KI(B;5
MYB 2-KT?6DH3S*B@<PD               U)I_\ [X:Q_P"F?\NF&MC_ !+^
MKW*;>W=U-M+O0V5R0      82OS)AN&UK*&J?=SGQL)![MS4<O5:J;EYSBZK
MS?!@RQBOG[W7PKP9,JD6O1K=S>NOI[CM,83%;2,W\Z\P'%KHJCFK::_JINA#
M> 5[H*UK8JW?MW1 EKT>D6K&4[JKZ6_T=X!458P7;S\X^D^A-GH[4CS^B0D5
M5VM7J<Y*$)'8J;EWKS$)<9DUDO:Y(<R[5(NNBV*RAA\,S9A.+5"R*6;&8D+*
M67\RJO68G,<7R_SG!K9F,<[OI]?&(X)Z6;M+N58+RL_XG;!K5M1W)ZW_ (DU
M11QAMM-7:G5;S<^T"51VQ6K'UR[O2 ^P  0,%G'YN5OXK\LPQOW(G<[.!K_A
M5.L8(EOD_P"=PMW$-;8MK139=SE6Y<QBCNZ&GNOSR]5UFW3I-\7+DN58JY&]
M;T3B9/,^[RS9=%8X\-GT-2[51;?-LMI4=7(KZ=E73/O:6;&RZ"MZJJU=BHB[
MT.W9DB^(NMW-NL3#[M1$78D%7>A8.:F*4;47T A&[=_YB4M>YIU,7+.9J7+S
M<,XE)UY&??W?4DMF]6Z=ZZ'6.-J?,NYR3;RUZ_L47YN6Z+:;VPE_IAR;CL57
MB[XQW<G,20XJK]BMZ2KR[@)VHL(]#D($*CD@YG258Q7=$D(P:Y8]+9%24*?G
MO43"\BRZ5:YM[45=Y<2HO;XI9=KI-EO3<]%VG,UNMC3QLCFF>KZE63-;CWK)
MAE;VC0RZQ4NUFQLI&U"RY6\R<QMXLG>61=NJMB:PX8UB:X3ADW$4D\0DFS&7
M:L1MO:S?!>?F(U&7NL<WTK0F:0TG]9E-Z97C'?\ G\/_ ,F.'^<_V/;]CF^.
M_L^W[&0P7SB<-KZV73XAA'9LAT;4[B7U%F#7*G193HJQ5$3[(CSJ.:.:REO3
M-?JHLLUEMT[8HW6B(J=#8WGWGI&^F"JL4V>NY?2('!7,E,6:Y8,;N7;R[!,T
M@53)&?,/SO-Q%,,99I:"XA-BY;R_1_J7RV*D%8J<ISM)K8U%UT1%.6G77J58
M\L7[F+F:GJS4?Y IAG1Y<2O_ /X3BO%77WG7]'T#&=?34=SR]=?57@J[_P#W
M.2G6V#%&Q5VR$#IMN4[D1SDLP^R$"JU$VI!.7T"22+H\[><BJ46=G2=NW;-Q
M*%(Q74[!,.S*S*U.G$XLL;^7X278\"DYNU92M6+5Y''*S>86V9(LB*\?5[%$
MY[8NY>E>>9(PYT.JO.DJ+'H\W*!S
M                                                       *A4?/
MJC_&?!BJ>TPZ5O+68                     !"[@*EFW]N9?\ US\FPIOW
MPQG?"W%S(                      A=P% U*\?@WZS]R649>A7<V 7K
M                   "GYB^?.3OXG\&:57=JWK83OA<"R&82
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M[>>(%VSWKI@&2\,P7&9=/VCA6-\5PM1;FT_Z&^7+?T5D/=UGPVHF[E I&/\
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MLW.S;6FW>RFV,6K]@V:,G,
M                                                 J%1\^J/\9\&
M*I[3#I6\M9@                      "H9N_;>7_US\FPJOWPPNWPMY:S
M                     .*\I(H.I7C\&_6?N2S7R]#"YL O9@
M           %0S!\^LG?Q/X,TJN[5O6PG?"WED,PD
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M213I1W.W1AZ![-UW)%180VJG+NW@<P
M                                                        "H5'
MSZH_QGP8JGM,.E;RUF                       *AF[]MY?_7/R;"J_?#"
M[?"WEK,                      XKRDB@ZE>/P;]9^Y+-?+T,+FP"]F
M                   5#,'SZR=_$_@S2J[M6];"=\+>60S"0
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MRQ1FH118I")N,W,
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MBFP]IH];;J;>%T;XX<-M'=Q7Q?%86?>Y=FQ=Z\YT5A%4Z6Z.]-X2^@
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M)8;&[N8@<R0
M                                           X+'9#9Z('G#SBD1,4
MPM6K"UQ&WTF4YYCSG?9U_4Y^KW-)GGW(   "/L@/L@2  C[(#[($@ (W  )
M      Y?1"3FV[4W>@$     C: V@2    (^R ^R!(    C[(#[(#[(#[($_
M;@$FQ42.U4W?9"                       !&SEVPW .5?1W 2
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M-;CWK/A=;VG12JVQ=WEKP<;4++E;O@G,;>')WED7;JKHFL.\7I
M     ./H+O4$BQA#E4@<B0     #XKNL1V\B@<X)'=!5W\H'!JVDM.2*+R[@
M0YJJ[VI&'(!"N6TB1LKS0B$5(*JKS)N7G"7T
M                                    $.ZJ@></.,_:N%_K'X%.>8\Z
M[5G7]3GZOLM('GW'    $@ "0(" !NBBIZ02G['V E'HKN0(3M], B1]%$WK
MN )'8O+RA*-D-J[.1 A.V$8;%!O1]C=N GT>3D A=VT"?2"4)#<NT(3#GV<Z
M\P  ! 0  E($! !(2 0$ $H$B@1 ! ""0 DA    2$@$! !(2 -P#>!   H$
MJ! 0 ($I( ( ( 20 $ 2   0$ " 20 D ! 0  D D ! $@  $!  4)$ D !
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MUT<J;9LMB;F.,L.KQ99I;-9^B6-F6R_LS5:C:6@
M                                     !#NJH'G#SC/VKA?ZQ^!3GF/
M.NU9U_4Y^K[+2!Y]QP   !(!($  @ ;O2YPE9,AX11X]FS#\*Q"7>4=1?6VQ
M<WJ2)CTVM5J[VIRFQI[(OR1;*[!;%U\1.YZ&K](M+<,1BUU!=I,C!;ZM=U8>
MMG+SH>CR:'38^UL_]7Q=6=-BCH][XKHOIYC%*Y<'D7#MD)UNJ?ZKULR<G,J&
M'Y?ARV_[<T]>WZY/"XYW1[VE,%R8RGU%D90QR7>HVW?,C9WTCI[=LM_I;G'"
MQ89[V++X^G]E7/MQ1WO+/IL;MK]*-*</F++JZ&[>[<E[6NW(B^IFKSG>R:/2
MX]EVS_U.A.FQ1T>]P?HKI]BU+>X++X='=2;&JF;G079,G)S*A'Y;ARVULFGK
MV_7)X7'.Z/>\X9BP.HRWC-1@U6L*BFL6MW]I+;,3JN<FYW.>;OLNLGENC:Y&
M2SENF&ZM+])\LX_E6FQK,%)?3*FW=K>3F0NY\V6OBIK?6MY#N>7Z"S+CY[MM
M=W56.+HX--9=96Z-K6>IN5I&4\UU>&T3+&&LN^&VJL8R)3W]9SW=9_*IR=5C
MC%FNLCHI[FGJ,7)=2-SL:59;PK,^:)&&8M)OZ:9;BRT]G5DS7[V.:N]J<ICI
M<<9-199/9FM>J*LM-9;==M;LJ]*=*,/<DNKH;IR[FWM<[=!?4S5YST.31Z6R
M?O;/_4Z$Z;%'1[WS;I!IKBTJ9+PF1=SVP\);JW0BL=SYR)N13&-!I\L3W<^_
MZY/"XYZ/>\]9NRU493QVJP6IZ3I%W%VQ.O+9,Y'/]?SGG,MDX[YLNWV_6Y67
M'-DT8,K4@$! !(2@ $  )2! 0 2@2*!$0$0() "2$   !(2 0$ $A( W@-P$
M  )0"$ ! !(2 0$ $A(  A0)  0$ $A(   0$  ) )   ( D ! 0 %"1 )
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MMZ_J8Z[?'7]3=N5WH[!*56[DO(_^\<=S1_A6]?O=&V=C-FXS
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M]4*-7?%UU(:S-!H   !(2 02! D   @(  $A*  0D)( (   $( 4!N) @
M( $"4D '*0)7<! 0 2FX)1R@-P#> " !$)(    ( )"0" @ D)   "  $@
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M+38M7KM1Z;6JY-SDY3RU+HWQ27"OMY9HZ05@$!    02E) D   @(   )2
M@(3$)(@  $( 4  ) @  0 2$@$<H$KN @( )3<$HY0&X!O !  @$D0   $ $
MA(! 0 2$@  !  "0  !  !"@ @ ($B@  $@  $!"Z:<Y K<]XHZG8ZXPRFAQ
ME5!K[N\9,5G0O);EBZ7#HFQ@TU^HNY;=G&>'5TU;>GP]Y/J>ML&P?#<"H)>&
MX3*N**7:NV6GOA:<YZ[7JY=[EY3W&#!9ALBRR*1#MQ;$12&5+V0       !J
M33__ 'PUC_TS_ETPUL?XE_5[E-O;NZFVEWH;*Y(
M      ! P6<?FY6_BORS#&_<B=SN8#^R:?[_ /#<3;N(W,BA*0D   #CM1%A
M]@A+C&/V-_V0.48HB\G*2@6$?3W 1%=D-W,!"*C42SN7E ;>7E($P7TEY]X-
MZ-VQ$M1^P2"QA!$C'=R <D7E3=SA"42!"7!5W.7D)#>OHJ0")N]4J[UW$A9<
MB0<Z,.6 -J%;ZU-B\O,!*K!80CS(!,%2.S:H#I*FW8O/O(@ES)
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M7MY'=)6HL'<B<P0\N^:G\_M66[U7Y._!:H#U0
MAW54#SAYQO[5PO\ 6/P*<\QYUVK.OZG/UG9:0//N. >P<RYC7*V1)F+W'$I3
MV;<FW=VK=2V6G2LNA"U'<>PRYIQ:?FI7_P O0Y+^2RK6V'ZKY#RW+?68!@=W
M7/A:E\74NW*K4VS93DW.<<+!J\.#;CQ4F?[4_6U?$X[=L-6IG;%G9K;FV<ZW
MB;8[8,3?(N.1EGJ_\IS^]R<W/,_>XT^IH]]//S=+9N-ZFZ=9KERJW,6!W];+
MM>!XNK9"TK6]:5*8FYC5.EFUV+-2Z_%6?[\_5#>NSX[HV_6^U)KIA,[".SJO
M"KAGJ/SA[X>$5Z]61_6)\TGEG'W>S^]U\$QJ[:;=BM:7:FX?D>CK*:KI>)6I
MNK"WCI<+MTU5ZLI_KS6T6LG2W7SR\W-3IINK]/%1I\]MD4EKK&:YN(XE/KF-
MLLF6>C&/58UN^"<W,:-M:-/)=S75;#U!U,HLW8'2X93TMS,I[R+KQSXVYDM^
MY93/6<YN:G679XMCEY>6O37>V\^>V^VD-7<B-0U6@SN3<<E9<S)1XS.9>2Z:
M]Z$5;&\DOE[T:[UW,68\LX[HNB*TZ%V*^+;ZSN6[5?46BSZW"TI*;A^ XB/A
M'3(W]UZZ7+\GZ)MZS6SJ>6MO+RUZ:[^I?J,UN2E.AK3F5>4T&DSN3,<DY;S+
M0XU/EWLNGO?!VE;XR2^7O1KO7<Q9CRSCNYHBM.A=ANBVZ)EFM2\Z4V=,4E5M
M-(N&LM=&VK][);=ZL9ZSF,]1J)SY)OFWEZZKM1EB^8HI&S<BPAO*&HW'E+5[
M#<GY1D8104%O$66[<^^>D8SWS$Z+I+V]5ZIO.EIO,;L./DBS;QKZ^%'2QZFV
MRRD-/S9KY[UF3%B]=Z[$Y(<AS+;8MBD.;,UE>M+M0?D'75,R9*OJ.MN[]EJQ
M&Y;-1NU)<Q=\SD-W2ZN[3W5B*QTPVM/FC'.WI6-VJ6"-S\W.,JC@KXWTJ\F;
M84O#MVK*^SL:8^+F=5&?DZJ_V>7?]C9\39SU5G4[.])G?$:>LI9%PV3;BVVY
M\;;)3=[F,]88ZC53GOFZ;>7KJUM3EC),4Z'3T^SS59'QCC6-O*.9^E4\6MMV
M9<QK.E8>J05\=@T^IOP7<UL5]6ZO6QP9N[G;N9?4S.&6\XS&5^'T/"XDV-_,
MO9TR\BDIK=CF,:D&L7<FTC5:CO\ )%\6<M>UMK79L](7:C+9?&S>UR4.> 2$
M@$!     D ;@)W@0$ $A* @"0 $ $A(   0$)"4! I*0A      $A(   0 4
M"0 $!  WA)O D !Q) "8D"8 -P#>! 0        -X2;@ 0   $A(! 0 3R_U
M!DN6G.0*S/F)OIY3[G#Z:'&5,&ON[QDQ6=!9DMSK3I<.CN-G3Z6_47<MNR.F
M[APV=-6S@P]Y.W<]=8/@V'X#0R\-PR3<4,J-AEIS^LY7KM>YR[W+RGML&"S#
M9%ED4B'<MB(V0[\57<N[>I>ES)        #4FG_^^&L?^F?\NF&MC_$OZO<I
MM[=W4VV;"X)                         I6HF;*K*V7YU7A<GBL8F6> I
M[39=[9FRVS.D]CFMLM<J]+?R JP^JNKV$:1X91=I_P"(YAQ2][&PWPDCC.&?
M*O\ PK),YDJZ9.1_3A:A!-H&'\WS4O&]7M*<.SCB$OA,2KK^*1ES87-;44_J
M94EO5DIZD#)X)G=F?=,W8ZLJXJI\.(IK5NQ8K'2F].Q+18I+CL0PO[+&[<V#
M@/[)I_O_ ,-Q-NY,;F10E(2   !\EAMM+%$ZR[MX%!U'U&^0W!4TNBXFIK[V
MP^]N[%Q=JNQ9;T6*/] XWF.OG34I;6OKW;O4U\V;DHO]K8BHW?Z)V6P1WHJP
M<F_[(!8[.;E9_P 0"=%ME5BO*H$.6*HB.@G- A.\BJ+TTLQW<I*#:F];3TY=
MPZ0M17H[53=R$)-KH(W8G](0H&HVHWR&2@IY='Q=3B-]!][=6+B[7<LMZ+%'
M^@<?S'7SIJ4MK7IKNW>I1ES<E(WU7Z"K!5Z*NWIOW'97N2HNYRQ<[<F[< 55
M15M)!%WJ0(54BB<^XD:>U0U0QK)V,2J"@E]!;7JI?)+E.]5*?Z]>4\WK]=EQ
M9)MMFE/HX1ZFEGSSCFD-P,=:1+6U[MZ>D>DB6[1@<YYGEY0R_5X[.D<3+IKO
MP5M9=N\FLE;T:^$+?,:>KU$X,<WQ'-,=&[IXJ\E\66UEK_(F?,_9QQ"55,PS
M_P /+:OZB_I?!]&8UO1NV/6+V0V?<.3I-5J,U]8VV]36Q9K[]M-C;RQBU[MF
M^UR^D>B;J55V^&Q=Z^D0DMI9547:W?Z$3)"5W)#;Z)B3#Z$@          =>
MHI9%9+67/9;8[>D53<L>14YC"ZR+HI*)AT^PL*WW&Q>6V_\ ]8J\-CX>]'+"
M.P\+38M-T4W]-^SOAX;'P]Z>6':K*2FKY+J6K9>REA:2*MY4<G55.8LOQVWQ
MRSN32KK8;@6&82UTN@D7,MT(LMO?"$5WN<O.I5CT^/'V8]Z(MB'UIL-HJ1]J
MFEW;UW+%SH0CSJO.66XK;=L01"9.%T--.2IDRH3DW.M.7DAN553<I%N&RV:Q
M!$1&YSJ:&FK&-94R[Q&QL])6[X1W*G,9WX[;MY,5<Y=+3R922);(2F[FQ79%
M8[U419$6TZ$Q#A24-)0VFTS+M'0M)%SHPC#>J\Y%F.VW=!$4<%PVCXE:U)4*
MKU]IW-9W1AN([JVO-3:BCZ5%)(JY;I51+ML6$6VE3<L=Z*G,9761=LE,H914
MTF4DF5+@Q/4Q7GCO52(QVQ%(W(I$0^4K"J"0R9+E2K,N=9O&6G+&SM3:J[($
M6X;+8F(C>4=>CP#"<-F7E'374QW+;>Z,$5/5.7G*\>FQXYK;'O(MB-S(5%-*
MJY3Z>H;;E/A:;%4C96*;45.8OOMBZ*3N2XT]-(I)=W)98E,W)%5WK'E55WJ+
M;(MBD(3-DRI\E9,UMN4O6;%4Y8[TV[Q=;%T4G<ETZ' <,PQZ/H)%RY.JMM[^
M>/6<O.I1CTV/'-;8H6Q$/M)P^DD.6;)EV7KO=:<L8;-RJ6VXK;9K$(Y7)F'4
MC*I:QDK\YY'VG>ML[HPW$1BMB:TVE(<YU+)K&*V>RVU=[8JF[TE3F,KK(NBD
MDQ$IIZ6512[JF99E^I;%5AMBNU57G%MD6[B-CKUV&T6)RDD5\J^E-W):<S>J
M+ZE4YD,,N&W+%+HJ3%=Z:#":'#$L44BZ;SVW.Y_7*O.1CP68^S%"(B'WF4TF
MHDOE5$NU+F0M)%4C96*;EV0+;K8NBDIG:FGII%'*;3R&V9*1LMBJ\L=ZJJ[U
M(MLBV*0/IM15VP3FWF8^@ #$9@P9F/85/PA\VZ946+4RS:A=O;,38BM];SFK
MJ<$9L<V3-*T]Z+HK%&!R?IKEO)Z-G4,BUB.V-5;G)'KIU'3'M2#7JAK:;R_'
MAV[[N/I*O'AMLW+EMYH.7>ATUI!.5+/VP2Z==14V*4<ZBK&7M#-LQ9%6VK+D
M=O:J*D%0$L1DK).6M.\M4F4,GT'9F7*"\X6BOIU1=7\Y\]_A)[YDQUJ9,<[:
MY81AN ^V;LGY=SU@-5EC--%Q^"UMWQ5+>S9%JYFLG,Z<E['I![&KL=R<P%$Q
M7S;]&,=P' <KXIEKB,!RSQ?8%)QV(2[CM&:DZIZ;*EKWVWM1?".=#U,$ VHU
M&R9:,EI!K-[(\ZQWJ!5\^Z=91U-P:=EK/.&]K8'.LWE-?SZ6%B9+G)TZ:9*?
MUY3%ZW)S1"7VH\B93P_*C<BTV'7>5F1NZ*^GNWSUJ5\(LQ9GC%M=?T-VP@:O
MJ/,\\W2NJDK*K)=JI=O?VIBR;FV=S:Q$W(3*&U\L9.R[DNA3#,L4/ T+>K+O
M9L[>YSUVSGO7>]W*0,)@^C^G67\X5N?<)P;A\V8C=<97\55S+=Q3K32_!/G.
ME)"4Y6]%B<Z[=I,D+LB.C%=D-S/6Q]'EB!5\IZ<Y-R378QBF5L/X&MQ[ANTY
ME]43KW@FO9)V3ICT;91[NHB1Y8D)6\E                      !#NJH'G
M#SC?VKA?ZQ^!3GF/.NU9U_4Y^L[+2!Y]QP#:V;-8)69<HS\LMPFX?-L1J.(5
M\+,]D[JW+?6PZQTLOF$Y,?=\M/77UUX.AEU,76<L0U3LBJQV<YS6@GD (B;%
MAMYQ(;XQVJ 554)-B;>1/ZPA$-D$VJ 3;Z7("$KZ.Q>8"$1%V;TY%%2E3T>7
MF E-L$A&/*!$.;E ;=R?^<)2O/R+]H"(@%YMW.$'+'[9(E=F_P!3_60(]'^E
M0)W;6_84)0&(!(2 0$    )2$ !.\" @ D)0$$0DB " "0D    $! A*0A
M D) (" "0D   ( * "    ;@DW 2  XD@!," B!.\!N @(        &X)-X
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MM1W5] QT>DR9K8RW7TGZ.I&+'=-)F>JC=!Z=N
M
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M4+]S^^:7VX>!S_+[8^)X;)P]Q_*+4+]S^^:7VX>!S_+[8^)X;)P]Q_*+4/\
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MI[^N]SUVO<Y=[EY3W.+%;AMY;=D0[5ML6Q2-S*)L55WJN\N9.8
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M?'-[X3J8ICHVQDMB2LLT+&IL2^_+/.]Y?%,%O7[Y;EFY8CH,P
M
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M->KNJWTMY\L_2WZBNNU-UF?9WM*?PVW5W6_0[_F&BBW'$V?N[^NB^'V-YH
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M57G-K%BC';%L=#.(I#OEJ0
M                                                  5&H^?-'^-^
M#%4]IATK<6LP                     "$W 5+-O[<R_P#KGY-A3?OAC.^%
MN+F0                     !"@4#4KQ^#?K/W)91EZ&%S8!>S
M             *AF#Y]9._B?P9I5=VK>MA.^%O+(9A(
M     5#+WSZSG_"_@SBJWM3U,8WRMR[T+620 $*(&GO.%^;=-]_^6ISSGG/[
MG7]32U?8>8H0BB'FW%73(&G.)YYK72J=W#T$F'$U<&/L6VS%9T%F,<L7,L[#
M8TVGOU%_+;NC?/#ALZ:MK#@G)]#UQ@V#T.!8?)PS#9=S0R+5AEISNNY7KM>K
MEWN7E/;X,%F&R++(I$.Y;;RQ2&0CZ.WE-A+F             #4>G_\ O?K'
M_IG_ "Z8:N/\2_J]RJWMW=3;4438OV397->9FJ)N/8NS":5\9$B-XL$]7+:]
M.M97>WG/BOZDU%_F>NC2XNS9T_3;;=TTX<7J=#9&GPSDNWS\9AW<T8=3XA0R
MG89TIU):Z&U/&N;RO5$W(IT?U3H,6IT]LZ::W8J[-L=J;?FF.$\6OY=GG'?/
M>;KOJKP9O+&*)BF&,>J_G#(WK.:+W(W;!$W)R'KOTQYI&MT<3,_>MKS==UU.
MB(W1T.=KM/W62G1T?LAFD1(PCM3<G,>L<^KK5E7+HJ=U5.6$F7"T_;ZI4:FQ
M$5=ZA#2N:-7J_%,FKCN5J:YI9WBZJ\:^-BH;*7H3I**D%1R;@E=UU"MUU/A5
M52<#B-7;X)UY?6[IMN9L;+LI!OKE]($0TDN;L]2:)'SL_P#^*KUJ3L>F]=LZ
M:,L]7I 6#3S-&?Y^<\$H\>Q_C*2JXKB*+@Z63:NZ>8YOA)38I!8.V>D"CN9B
MU1S5/P',V-8%(CE^9P'8&(6Y"6+,ULNI\%,E6UB^+?")Z+=@H-D8+G+$ZV?)
MIJ[!^%E.M7M5Q+)EF".5.@UB*L51$V!$M.KJQGC,4G,M#E^19S)6\#\G:.W3
M+=7*VJKPDV4V6ZU+:YWA5V;F[0FB]Y%U:K\?Q?#LN5V#7$ZIOK59Q37^+EOF
M^+;*:FYJ-ZWH@F&L<S:FZD8=GRFII.*\%A\^W9PWAZ2==V*9JKX592N=:<MK
MT-P31L7#<[9DQ3/E-ADV?=X9T_!V)+H_FROWHQ'=9.<(4''-0=1Y&+O9A6<.
M.7#X1I^S:23?W\MJ]9\OH6-J\L0,CIUGO.>)9BIL-KLY\>V=;O*7LNGD6;$J
M8].FV6D8P1=_(149C435+-N$UM/E=M-V5B%=;A4WDBIL7+9<[J72M6+5AUN4
MD9O ]6<1Q[%Y.#X;0WU7.M7<F]8SJ2W3%Z3Y34W-5=X%#K<^:GMQ^768;CU]
M@ZVN/H.$HV<+"4C9?A'R[4R\=%W1ZNY0+)D?,F=V9QP'#<8S5V]A^)\7?4_9
M]-16.&IWO;TI;;2Q=!=BIN]$%%[QC,V)56<*3+.7)_0H[SY0S;#/S>]D).I=
MDUJ6[<'>*=T?5$H]:<+S55T6;ZW+F89_0J;KY/3;#?SF[D+-JMDIJW=W%OC7
M=+U)B*)G'&<\5.8:J;@&=^QL.6[N</[*IJNQX)B.\+-1'+%R.=MYX<A+)AJ3
M'=2\-F]HU&>^U*6F\=1=DT=-;O$5C?"(U52"K:V)R0"*-X9O^;E:V$(W5I.;
MPK/Z8F%_98W;F1P']DT_W_X;B;=Q&YD3)(    /F[;%OJEW$!LC%-R[R1+5M
M[EV<Q ;8;-R?; XQ@L$2*)N)H)5'(L$W\B\X@0]J.14?L1?ZB.@8-,FY9;-2
M;P7A.1;V=LV0]>:/@,%:\OMGXL(LAFT8K4L,Z+$W<L#>V0S<U:B02'13E],D
M<518[=B)U5^Z(0Y*Z#=FQ>1 E"NA#;#[8#8D&[O0WD"%5^]$@G.30J)'U._U
M2?<(2YKL3:A*#T%VHH0Y!(
M                                                         *C4
M?/FC_&_!BJ>TPZ5N+68                     !";@*EFW]N9?_7/R;"F_
M?#&=\+<7,@                     "% H&I7C\&_6?N2RC+T,+FP"]F
M                   5#,'SZR=_$_@S2J[M6];"=\+>60S"0
M           J&7OGUG/^%_!G%5O:GJ8QOE;EWH6LD@ (40-/><+\VZ;[_P#+
M4YYSSG]SK^II:OL-+9 T[Q3/=:Z73OX>@DPXNJ@R9=VVS%9T%F2W.M.EPV;C
MAZ73W:B_EMW1OGAPV=-7/PX)O^AZXP3!Z# <.DX5A<NYHI%J[EQ<_KO<]=KU
M<N]R\I[?!@LPV199&R'<MB(BD,@NU53=SJ7I0G)LBU=[MQ(^@
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MN0
M                                      5"H^?5'^,^#%4]IATK>6LP
M                     "%W 5+-O[<R_P#KGY-A3?OAC.^%N+F0
M             !"@4#4KQ^#?K/W)91EZ&%S8!>S
M *AF#Y]9._B?P9I5=VK>MA.^%O+(9A(                      4_+_P ^
M\Y?PSX,XJM[5W4QC?*X%K(  ?-8_97DYQ!*DZB9,GYTD46',==TZ7M]/@CK&
MV6]O15[%6*LAL4X_F&DOU'+%LTI7;PW*<N/GBBT8/@]!@-!*PS#)5Q0R+5AE
MIS^NY7KM>KEWN7E.A@P68;(LLBD0MB.79#O[8;-O.;"7,
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M(-=,F=)K41ME$1>DNV.P@^EB*#4C"YS.U*K"N#N/V=,XA\VW;563=B2]D/\
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M;&STPE8LWP^3M:D;3FW6S=",UAADW,;MSOX#^R:?[_\ #<3;N(W,BA*0D
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M6@;2LI)3:)(4J6KOK>N6/6V[SW6.+8M^[N=;H=G9&"J6)<P
M
M                       J%1\^J/\ &?!BJ>TPZ5O+68
M       !"[@*EFW]N9?_ %S\FPIOWPQG?"W%S(
MA0*!J5X_!OUG[DLHR]#"YL O9@                     %0S!\^LG?Q/X,
MTJN[5O6PG?"WED,PD                      *?E_Y]YR_AGP9Q5;VKNIC
M&^5P+60  X1L];9$!92TBQ@]?Z@&R,.?E CF1$Z/*H'T
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M4E'C?,OQY].B'/S?B1U^YZ @CD1$VM3>>R=!YCR:JKKC10_ZV"?PUYXO0_\
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M4F*_YI=''%+5K2/I'36))
M                                                         5&H
M^?-'^-^#%4]IATK<6LP                     "%W 5+-O[<R_^N?DV%-^
M^&,[X6XN9                      $+O0#7^I/C\&_6ON2RC+OA7=T-@EZ
MP                      I^8OGSD[^)_!FE5W:MZV$[X7 LAF$@
M              !4<O?/G.7\,^#.*K>U=U,(WRMK=Q:S2
M        U)I__OAK'_IG_+IAK8_Q+^KW*;>W=U-MFPN"0
M            0,#G'YN5OXK\LPPO[*+MSNX#^R:?[_\ #<96[B-S(H2D)
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ME-2/+=/%T71;MCUS\55N"RW="Z'27@
M
M       *C4?/FC_&_!BJ>TPZ5N+68                     !"[@*EFW]N
M9?\ US\FPIOWPQG?"W%S(                      A=Z :_P!2?'X-^M?<
MEE&7?"N[H;!+U@                     !3\Q?/G)W\3^#-*KNU;UL)WPN
M!9#,)                      "HY>^?.<OX9\&<56]J[J81OE;6[BUFD
M                    !J33_P#WPUC_ -,_Y=,-;'^)?U>Y3;V[NIMLV%P2
M                           "!@<X_-RM_%?EF&%_91=N=W ?V33_ '_X
M;C*W<1N9%"4A(   '!>C%RKL(@<=Z;=OH$B8;U5=_*$I1%3I;X\NX(0L43H[
M([@)C'>L% A-BP3:H$I%-L+*KOY=Q B"1A#8OVH 3TH)':[F +!86D@(!(;H
M$CDNQ-@'%5@BJI*$+#=O0A(Y(JU5VKM@0/H2
M
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MDT_W_P"&XFW<1N9$R2
M
M                    %0G_ #YH_P ;\&*OWF/2MY:R
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M&_<B=SN8#^R:?[_\-Q-NXC<R)DD
M
M                             *A4?/JC_&?!BJ>TPZ5O+68
M            !";@*EFW]N9?_7/R;"F_?#&=\+<7,@
M   "% H&I7C\&_6?N2RC+T,+FP"]F                      5#,'SZR=_
M$_@S2J[M6];"=\+>60S"0                      I^7_GWG+^&?!G%5O:
MNZF$;Y6]-ZEK-(                      #4>GW^]^L?\ IG_+IAK6?B7]
M7N4V=J[J;<-A<$@                           @8+./S<K?Q7Y9AC?N1
M.YW,!_9-/]_^&XFW<1N9%"4A(
M
M                          *A4?/JC_&?!BJ>TPZ5O+68
M         !";@*EFW]N9?_7/R;"F_?#&=\+<7,@
M"% H&I7C\&_6?N2RC+T,+FP"]F                      5#,'SZR=_$_@
MS2J[M6];"=\+>60S"0                      I^7_ )]YR_AGP9Q5;VKN
MIA&^5O3>I:S2                       U'I]_O?K'_IG_ "Z8:UGXE_5[
ME-G:NZFW#87!(                           (&"SC\W*W\5^688W[D3N
M=S ?V33_ '_X;B;=Q&YD4)2$@
M
M                          J-1\^:/\;\&*I[3#I6XM9@
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MR)W.Y@/[)I_O_P -Q-NXC<R*$I"0
M
M                             5&H^?-'^-^#%4]IATK<6LP
M             !4,W?MO+_ZY^3857[X87;X6\M9@
M $*!0-2O'X-^L_<EE&7H87-@%[,                      J&8/GUD[^)_
M!FE5W:MZV$[X6\LAF$@!&Y (<Y&):<3$51,T<B$@                !4,N
M_/C.7\,^#.*K>U=U,(WRMY:S                       &H]/O][]8_P#3
M/^73#6L_$OZO<IL[5W4VX;"X)                           (Y5 P><?
MFY6_BORS#"_<B=SN8#^R:?[_ /#<3;N(W,BA*0D
M
M                                        %0J/GU1_C/@Q5/:8=*WE
MK,                      A-P%2S;^W,O_ *Y^384W[X8SOA;BYD
M                <5Y210=2O'X-^L_<EFOEZ&%S8!>S
M      *AF#Y]9._B?P9I5=VK>MA.^%O+(9A( 1R"2&,S#^R*C[S\HTNP]J%6
M7LR\O:+:U8CA6(4V6LRU%Y@<RW<SK#&\/9;.G.Z,F2KWVWJU-KMGI'KO,_+;
M;[9OLC[WOW1TR\KY=YC=;=%E\_=]V^>B'K)KO0Z/.>+>O<P
M  %/R_\ /O.7\,^#.*K>U=U,8WRN!:R                       &I-/\
M_?#6/_3/^73#6Q_B7]7N4V]N[J;;-A<$@
M@8'.7S;KOQ7Y9AC?N1=N=W ?V33_ '_X;B;=Q&YD4)2$@
M
M                                              J%1\^J/\9\&*I[
M3#I6\M9@                     $)N J6;?VYE_P#7/R;"F_?#&=\+<7,@
M                     #BO*2*#J5X_!OUG[DLU\O0PN; +V8
M           !4,P?/K)W\3^#-*KNU;UL)WPMY9#,) ".020QF8?V14?>?E&E
MV'M0JR]F7YR03>BP=R'U)\RH]":*ZW/PR;394S.[_#.GPU9!/ [)T]_@Y,A7
M.M.5K=KMF\\QYGY7S1.2S?PX[HZ9>E\N\SY9BR_=T3^V>B'JL\<]:
M        4_+_ ,^\Y?PSX,XJM[5W4QC?*X%K(
M:DT__P!\-8_],_Y=,-;'^)?U>Y3;V[NIMLV%P2
M     "!@<Y?-NN_%?EF&-^Y%VYW<!_9-/]_^&XFW<1N9%"4A(
M
M                                                 <=L>=><"H5'
MSVHT]4EY\'*OWF'2N$4+69% $4 10!% $4 10!% $4 10!% $4 D    1% $
M4 10!% ."[.DG*!5,V03',OKR?GD/_=L*K]\,;M\+=%"UD10!% $4 D !$4
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M#Z              J&7_ )]9Q_AGP9Q5;VIZF$;Y6\M9@
M       #4FG_ /OAK'_IG_+IAK8_Q+^KW*;>W=U-M+O0V5R0
M               1RJ!@\X_-RM_%?E6&%^Y%VYV\ _9-/]_^&XFW<1N9)24A
M(
M
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MW^IZU/%/8             5#+_SZSC_#/@SBJWM3U,(WRMY:S
M            &I-/_P#?#6/_ $S_ )=,-;'^)?U>Y3;V[NIMI=Z&RN2
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MWJOI* 2*.15=%5WK"$!4F$N6$([$7JIS0$$IBY$MN2S'K)OA #Z@
M       (3>H'E[SI?TO#?Q_X-*=SR3_D>G"7GO.?PX].#SB>\>/ )W;>0%1=
M^U=@!=X!=P0@) )4($ ;5Y=@3 B_T B4  )B! $M .   B$!(!*! H$!(
M  !02Y!#B$@  !,0&U0&\(-X$H@2*H$!!O @) )4(.0"5"9<0$0A, )0,G%
MQ<HD,B '$E      " 00 *!*@ R ("      /0FC>NDK Y;,O9OGV,*;'AZN
MPJW45G37]"1(<YUISFIM=L/,^9>53D^_CC;[]W&7I/+_ #.+/N9-W_GA#U)3
M5$NJDMJ)*QE.C!=NV"JG+!=Z'C[K:327JXFNV'VW;T,4BHCD@NUJA+D
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M1L^G?MXK-1I<6JQ]Y9OZ)V_1ZN#QVK5;T5W\JGN7B9>AO-GR*VLQ&9G.L2'
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M[6KOY#QKUKZ         *?E_Y]YR_AGP9Q5;VKNIA&^5O3>I:S2
M              U)I_\ [X:Q_P"F?\NF&MC_ !+^KW*;>W=U-L^J-E<Y
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M@>O2  $#!9Q^;E;^*_+,,;]R)W.Y@/[)I_O_ ,-Q-NXC<R*&20
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M674YMN_KIE0SH2GSW)!T]K>B]>X&J\Z>95@[L1;C^D6._(><L>(H^$F8S?\
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M8^[[M[TT>3>I        *?E_Y]YR_AGP9Q5;VKNIA&^5O3>I:S2
M              U)I_\ [X:Q_P"F?\NF&MC_ !+^KW*;>W=U-L^J-E<Y
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MJE<L7+:V^D*C8N2]*,KY$Q2MQ'+TCA75UU>2;<Z99N6/8G2FS9D8WCEW"HV
M  $#!9Q^;E;^*_+,,;]R)W.Y@/[)I_O_ ,-Q-NXC<R*&20
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MUUX       !3\O\ S[SE_#/@SBJWM7=3"-\K>F]2UFD
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M+6;RT $#!9Q^;E;^*_+,,;]R)W.W@/[)I_O_ ,-Q-NXC<R2$I"0
M                                  X*B11%WNW_ & &U8*NU>1"2HL8
MP1=J[O0(!46'H>M_XA*-B=*$'<J;R4"-@L.3U*_=(-R=B0;#;ZE/N@(I%?7<
MJ@>?=1-%,?S3J!7YGHYEFAJ+FPVS*6%BEER5VNG-7>WUIZ;1^9V8L$63OCXU
MX/.ZORV_+FF^-T_#Z7H+?L<N_P!2>9>B%2$57;$!!7;]B<K?^(!(INW\C?\
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M52"MM)U8P7FB2A",@Z*NM6>JL(68_=B0ES6**MG9'>[F^P"J()""=%/4KO\
M3(2Y\BPV^@2BKBD4W+:=RIN"7T"               ".50/+WG2?I>&_C_P:
M4[GDGX_IPEY_SGL1Z<'G+E/>/'2<H&7R]FC',J5K<2P&IX:O;&Q,L2YF]KF+
MLFM>WJO=R%.7!9ECEOBL+<6:_%/-9VFU*?SEL[2V69RW\SUWYNS[E,<:?)<,
M^K]OQ=B/.,L>O]GP5?,>M6?\R274=9B5F@?#P%Q2K&"M=UFR6NZS8FYA\MP8
MIK%NWZ9^+4R^8Y\NR9V?1'P=7(FJ..Z?R:J5@G02MN^(=X)8W*S%;LF2IGE%
MW&>KT./44YNCTXL--K<F#L]/IP5K,6/5^9\9J<<Q-]NNJ[%MT&I"ZEMEIL8U
MJ;FIR&UAQ6XK(LMW0U<V6<E\W7;Y8V5,?*>V9+6#VQ@[?".S<I;,*HF:^M?\
MWZNYDSIA*83C+KR4D8.A);#IL?NER6>L3E.;I_+L>"[FM^OXNEJ-?DS6TN]/
M8P&4\\9DR54OJLNUG"S)D+Q+N3-M64>B>-8^$+;C9U&EQYXI?%?V_4U=/J;\
M,ULFD^G%LEOG+9T65=S&VG+ZN-.D(+'<E,<K\EPU_P#/Q=7\XR^E/@I>:M6<
M[9QD+1XQB%[0K_87-.V$%8[K2Y3%WL13?P>7X<,UMC;],_%HYM=FS;+IV=7P
M4F*IMYCH-'I0J<B_8#&5]RAJ]G3)TG@L.K/\/]S75/SO=UWR7NZSU4YNH\NP
MYIK=&WK^+HX-?FP[(G9U?!F,P:_Y]QNG6EDU?"4[NO+NZ:;:@K7)M6G:J05I
M1B\IP6368K/7\5V7S7/?%(FD=7P53)&>\7R)6SJW"5\)/LV]DOU#7M3KRYGE
M%-S5:6S46TN:NFU-^"ZMN]CLT9CK<UX]59AQ%;595W=\[HIXJ4V4W8QK$W,3
M<TNP88Q619;NA3GR][DF^=\[U^R[YP&>,"HY=%-J.+II5JZ2Q32K-ISG.W4[
ME6*NY3FYO*,.2:Q%/V_%T<7FV:R*3/N^# 9WU5S7GMB4V+U$:&7U::Q(Z-I6
M*O3ERI:K%9:*;.ET&+!MMC;U_%KZG79,_:W<-GP1D;5/-&04F2<)G_F4VS>2
M+$GI6;:ITGRIBI!9BJ-5H,6H[4;>OXHTVNR:>L6[I^CX+%B/G"Y]KJR34RZJ
MXII-KP5W2OM6VHG66G14@J1-6SRC!;%*;>OXMF_S;-,UW1'T?!7\S:GXWFC%
MJ'&:Y(5M#>P=&7MOF-E[FRFHD$:G(;6#0V8K9MC=/IQ:^;6WY;HNG?#Z9VU7
MS%GNDE46+.M,E6K"0E)UG,<O4E2_)H8Z708\$S-OI[4ZG79,\1%WI[%3P3',
M4R[B4G%L(G\/7T]JZGV&3(7C',7HS&N;U7*FU#=RXK<ELVW16):F++=CNBZV
M:3Q;4JO.2S[-I[JGG7%1RS[-*_E1>JM-#=L./;Y-@B=WO^+K7>;YIC_Q\%:Q
MK5S,^8<K.ROB\SB*69",RS)E]6<V=NER6KO:GJC;Q>7X\>7O+=D]?"G%JY-?
MDR8^2[;'5QKP?7*NLF9LI8#*R]ACK-%*M6-DE>M-=-7KR7KO>OJC'/Y;CS9.
M>[?U_%.#S')BLBVW=Z>I3\MX[698QFFQR@6%726[KJKXV6Z6O6:Y-SEY#>S8
MHRV3;.Z6EAR3BNBZ.AG<^ZCXYJ"ZA=C3K2X?>W*0EIX^[M>+ER_)IOB:VDT5
MFGKR?O?4V-7J[]13F_=^M],E:J9LR,Q])A%58H7PO)%W(6,%>Y.E,E/7>]5(
MU.@Q9]MT;>OXLM-KLF#9;.SJ^"Q8_P"<'GG&J291R:GA),V%OH4TWJN:Y-].
MU=[35P^48;)K,5_;\6QF\US7Q,5I'5\&L<-Q*MPBMEXCATRXJY5J[FV6OA::
MK%V/14W*O(=>^R+XI=N<JV^;+N:WJ;;I?.2SU*E6:B9Q$Y/[:%,R&U?4I30W
M;#B7>2X)G9]?Q=FWSC-3;]7P:WS3G#'\X8AVGCU3Q-0WJK=RI<(L:Q?%,8FY
MB<AUL&FLPV\MD4AS,VHORW<UT[6"]#^E38:T;$!(     $Q"" $!(     $Q
M"" $!(!,0)@$HB&)$" D   )@ B$("0       ! (3$!S)_Y*$KAIUI_B>H>
M--PRB?<4LN/&5D&/NK4N8]G0=,EJZTLNST5V&CK-7;I[.:>J&[I-+=J+^6.C
M?ZGMW*.4<)R7A,O",(E7<B5:M.M/=&T]\S=,>]=[UY3Y_J-1=FNYKGO,&GMP
MV\MK/PC&&Q4W*:S8<R         I^7_GWG+^&?!G%5O:NZF$;Y6]-ZEK-(
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M .&XFW<1N9)"4A(
M
M               ?-%2U".WD \P^=#^DX5S_ )Q]RE.YY)^/Z<)>>\Y[$>G!
MYRVGO'CS: !4!4BH*D5!5(0 1M"3: V@-H$[0&T!M ;0(V\X$A" D ;]VT"8
M[^1$@"NQ  !M )$(A(2 1'T0$?1 F(14B"J(J$U(J"IM ;0'V05/L@JB 00
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M7LG(D    0,%G'YN5OXK\LPQOW(G<[F _LFG^_\ PW$V[B-S(H2D)
M
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MD_(Y^?V?:CZI];])O>+?C9/Y_'R?XOZ3\BGY_9]I]4^L^DOO%OQLC\_CY/\
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M[F _LFG^_P#PW$V[B-S(H2D)
M
M                         !4:CY\T?XWX,53VF'2MQ:S
M          %0S=^V\O\ ZY^3857[X87;X6\M9@                     $
M+N H&I7C\&_6?N2RC+T*[FP"]8                      5#,'SZR=_$_@
MS2J[M6];"=\+>60S"0 *!C,P_L>I^\_*-+<7:A5E[,OSCV;4W\WHGU-\RZ:>
MDBPBGHA*X:?:=8UJ'B<RBPQ+-)(AQM7X-;JVR8Z7T'S):NM++5O1W<IHZS66
M::VMW5#=TNCNU%U(ZY>W<H92PC)6$LPC!Y=B1*C:6U,6U:>^8GC'O5(*]>4^
M?:C479[^:Y[S3Z>W#;RVPL1K-@            "HY>^?.<OX9\&<56]J[J81
MOE;6[BUFD                      !J33_ /WPUC_TS_ETPUL?XE_5[E-O
M;NZFVEWH;*Y(                           ! P6<?FY6_BORS#&_<B=S
MMX#^R:?[_P##<3;N(W,DADD
M
M                         *C4?/FC_&_!BJ>TPZ5N+68
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MK\LPQOW(G<[> _LFG^__  W$V[B-S)(9)
M
M                                   "H5'SZH_QGP8JGM,.E;RUF
M                   0FX"I9M_;F7_US\FPIOWPQG?"W%S(
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MFG^__#<3;N(W,BA*0D
M
M                   %0J/GU1_C/@Q5/:8=*WEK,
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M_AN)MW$;F10E(2
M
M               "H5'SZH_QGP8JGM,.E;RUF
M*AF[]MY?_7/R;"J_?#"[?"WEK,                      XKRDB@ZE>/P;
M]9^Y+-?+T,+FP"]F                      5#,'SZR=_$_@S2J[M6];"=
M\+>6LP                      !4<O?/G.7\,^#.*K>U=U,(WRMK=Q:S2
M                      U)I_\ [X:Q_P"F?\NF&MC_ !+^KW*;>W=U-M+O
M0V5R0                           "!@LX_-RM_%?EF&-^Y$[G<P']DT_
MW_X;B;=Q&YD4)2$@
M
M                 J%1\^J/\9\&*I[3#I6\M9@
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M/]_^&XFW<1N9%"4A(
M
M                  *A4?/JC_&?!BJ>TPZ5O+68
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M_P##<96[B-S(H2D)
M
M                 !4*CY]4?XSX,53VF'2MY:S
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M/]_^&XRMW$;F10E(2
M
M                  "HU'SYH_QOP8JGM,.E;BUF
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M-/\ ?_AN)MW$;F1,D@
M
M                   !4:CY\T?XWX,53VF'2MQ:S
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MLFG^_P#PW$V[B-S(F20
M
M                     J%1\^J/\9\&*I[3#I6\M9@              $<D
M-Q"4;57F5-R@<B4   !"[@*EFW]N9?\ US\FPIOWPQG?"W%S(
M           XKRDB@ZE>/P;]9^Y+-?+T,+FP"]F
M 5#,'SZR=_$_@S2J[M6];"=\+>60S"0                      J.7OGSG
M+^&?!G%5O:NZF$;Y6UNXM9I                       :DT_\ ]\-8_P#3
M/^73#6Q_B7]7N4V]N[J;:7>ALKD@                           A-Z@8
M+./S<K?Q7Y9A7?V47;G=P']DT_W_ .&XRMW$;F1,D@
M
M                                           !4*CY]4?XSX,53VF'
M2MY:S               .O35,BKD-J*=UN0^-ET%3<JIRHB[T*K+[;[:QN6Y
M,=UEW+=O??9R\A8K22@   (7<!4LV_MS+_ZY^384W[X8SOA;BYD
M             <5Y210=2O'X-^L_<EFOEZ&%S8!>S
M   *AF#Y]9._B?P9I5=VK>MA.^%O+(9A(                      5'+WS
MYSE_#/@SBJWM7=3"-\K:W<6LT@                      -2:?_P"^&L?^
MF?\ +IAK8_Q+^KW*;>W=U-M+O0V5R0                           0F]
M0,%G'YN5OXK\LPKO[*+MSNX#^R:?[_\ #<96[B-S(F20
M
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M&82                      %/R_P#/O.7\,^#.*K>U=U,(WRN!:S
M                 &I-/_\ ?#6/_3/^73#6Q_B7]7N4V]N[J;:7>ALKD@
M                         $# YR^;==^*_+,,;]R+MSNX#^R:?[_\-Q-N
MXC<R*$I"0
M
M          5"H^?5'^,^#%4]IATK>6LP              #Q7R0W-Y3X:^^-
MCZ?:ES,L-9A=?+MX7MLNBB77C'[FRW.=:<Y.78>E\J\YG31W=T5L]V^>%9K+
MRWF_DL:JN2R:7^_='&(BD0]"TU3(JY#:FF=;D/C9=!4W*J<J(N]#Z19?%\<U
MNY\RR8[K+N6[>^^SEY"Q4DE !"[@*EFW]N9?_7/R;"F_?#&=\+<7,@
M               "% H&I7C\&_6?N2RC+T,+FP"]F
M   5#,'SZR=_$_@S2J[M6];"=\+>60S"0                      I^7_G
MWG+^&?!G%5O:NZF$;Y7 M9@                      #4FG_\ OAK'_IG_
M "Z8:V/\2_J]RFWMW=3;2[T-E<D                            @8'.7
MS;KOQ7Y9AC?N1=N=W ?V33_?_AN)MW$;F10E(2
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MOOR0W&;!&_T%3<H$KN)0J6;?VYE_]<_)L*;]\,9WPMQ<R
M       .*\I(H.I7C\&_6?N2S7R]#"YL O9@                     %0S
M!\^LG?Q/X,TJN[5O6PG?"WED,PD                      *?E_P"?><OX
M9\&<56]J[J81OE;TWJ6LT@                      -2:?_P"^&L?^F?\
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M8KB6.:*Y9Q;%)W$8A4\?;G66,\7B%2Q.BQ&MZK43<0-LI92,$W[F^EZ('W
M  '!RHB;]A"6N,U9EPW+&;J&IQ*98DK>Q6R]?[!B>H:Y=[D.;J]9CTU+KYV>
MG!MZ319-5DY;(V]7UTX/O_.3)WNGV.H]I.?_ -@TO'V7?RNW_P!<U?R^VW^8
M_G)D[W3['4>TC_L&EX^R[^4_ZYJ_E]MO\Q_.3)WNGV.H]I'_ &#2\?9=_*?]
M<U?R^VW^8_G)D[W3['4>TC_L&EX^R[^4_P"N:OY?;;_,G^<F3_=/>3_:2/\
ML&E^;V7?RH_ZYJ_E]MO\Q_.3)_NGO)_M(_[!I?F]EW\I_P!<U?R^VW^9'\XL
MG>Z>\J/:1_V'2_-[+OY3_KFK^7VV_P Q_.+)WNGO*CVD?]ATOS>R[^4_ZYJ_
ME]MO\Q_./)WNGO*CVD?]@TOS>R[^4_ZYJ_E]MO\ ,?SCR=[I[RH]I'_8-+\W
MLN_E/^N:OY?;;_,?SCR=[I[RH]I'_8-+\WLN_E/^N:OY?;;_ #'\X\G>Z>\J
M/:1_V#2_-[+OY3_KFK^7VV_S'\X\G>Z>\J/:1_V#2_-[+OY3_KFK^7VV_P Q
M_./)WNGO*CVD?]@TOS>R[^4_ZYJ_E]MO\SS>?+WU< >AN1=Y*&Q=--0FY8F/
MP_%7_P"$S(6'0\7928Y=C);G.M.<G+L/3^3>:QIIFR_LS[-_"*S67EO._*)U
M41?C[<>W=QF(BD0]#4U3(JY#:FF=;D/C9=!4W*J<J(N]#Z/9?%\<UNY\RR8[
MK+N6[>^^SEY"Q4+N)0J6;?VYE_\ 7/R;"F_?#&=\+<7,@
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MRC3KS>*N;,51J;'28K%8IN.;?^H*6\]N/FM_O4_TNIC_ $Y6[DNR<MW]VO\
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M&_C_ ,G(/'_J3\./3IM>L_3/_)GTZ+FJSYV^H@    $@0!(  ()0  " 28I
M  "_:>:@SLKU#:&M=:PE\>1$N[*3'>IEN<L7.Y]AZ/RGS:=-=RW=B?9O]4SO
MEYKSCRB-5;S6=OW[O7$;H>C:2JIZR2VHI76Y+XP=!6[E5/5(B[T/IME\7QS1
MMB7RN_'=9-+MDOLD8(62KA4LV;<;R_#_ .,_)L*;]\,;M\+>7,@
M            "% H&I7C\&_6?N2RC+T,+FP"]F
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MDN5W65J;&H)%9ROG^BP[#JC#-*LC<?ALBQ8G]K.D0MO<]>C6RU=UEF)OY/2
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M1<$HH)!/"P_]Y)/1?J/\*WK]]KS/Z8_&NZO=<Y2I\^1HNV93NLS=MA8(L/\
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M^SXM5;U53<>A\MT^3#BIDG[W3^V>&S<\WYIJ<>;+_MQ]V-V_A'';O6DZKD
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M3%8?+9MF)I*JYM3_ !S+_P"N?DV%=^^%4[X6\N9
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M..MV:[?T4M]?3#B^::K2Y*6X;-W[U;O5T2NZ6DBN]?6G=>><R4
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M)57BV79\AUJ4_C;#X*G58U%V+!=Z'TGGBZDQNVOE&6R;+J3OA=38
M              "% H&I7C\&_6?N2RC+T,+FP"]F
M  5#,'SZR=_$_@S2J[M6];"=\+>60S"0                      J.7OGS
MG+^&?!G%5O:NZF$;Y6UNXM9I                       :DT__ -\-8_\
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MVP)3]P@0O.B=(!R^ER <B4 '%=_IA*5YTWD"24   !Q6.]4V*0D3?]T#D2@
M                     X*B;UY2(2U'KG%:##%=UDO_ +$72#QWZG[%G7_I
M>W_2W;O_ (?]2Q:0HU,C4"_^VC_VF<='R&/_ ,2WK_S7.5^H9_\ S;^K_+:Z
M6KF:<1R[A])(PU]U/KKR,Z#'6;E\E>J]KD6*.5"GS[79--CMBR:3=7V4XPO_
M $]H<>IR73?%8LILV]/-PE5\(R;AN,Y69FK':_BY,R,4N7RK-F<LC^R>U5BK
M4]2<K!Y?9ET\9\MW-U4Z:=$_4[&H\RR8=3.#%;RS'KB>CFZ8^MB=%D1<R+':
MBP_(SC1_3OX_IPN;OZE_X_IQM8>OQ"5A.?IE?.\3*LVEV^JI4:FY%7>O,:>7
M-&+6\\]'\K?PX9RZ&+(WS_,WIGG'*'#LLSZJ=,@V98NVV7=*S.8U=S5A")[_
M ,SU-F/3S,SO^,/G/E>EORZB(B-WPE3-$:&:F$8C.5;#:FXNW01?%S)Z+LB<
M/]-XI[JZ?FI[)N=_]3Y8[VR/EK[8M8W^0D_;_C,/U5-OLYJ_]7N_^I_A_J;?
M_:X_^G_B_I;8RS@[LOX)2X0Z;?.I[R,VS8C>3'3-T7>NAO/8:/3S@Q1CK6E?
M?5XO6ZGQ&:[)2G-39]$1#3.I/^X#5W[XK^JRSQ'G'_-]/EA[WR7_ (/I\TM^
M;=K=R)N]$^B/FKR_AN7N%SPS ,7G<.K(VYEF\A&F6:FR6Y8QBGJCY1@TG)J^
MZR3R^O?^[7H?7L^LY]'.;'%?9^]3I7;-V2\N9<D2.V<3A+J+=VEQ-VW:LCXM
M[O7(=W7>78-/$=Y?LGU3T4X2\_Y?YGJ-3,]U9MM_M1TUXPSN,8S\D-.Y#\O3
M[RQ;X:KL6=]6B/Z$UK_7N3:;^HU'A-#'=37A/\6W9->+G:?3>,U\QFBG&/X=
MFV*<&'RKD2ES9@=+F+'*_B$JKRU*N5EPNICI2;9<QGK$7JFGH?++=5AC+ENY
MJUZ*=,QT3'!OZ_S6[29IPXK:<OKKOB)Z8GBI>FJ4Z:BX7PNR1X>QO]R3(];;
MO.%Y/R^.LY=VW_++O>=<W@+^;?L_SP^N:YB8#J/53ZE.A)N[2?\ 3I&)R6O7
M&>NGN-?,W=%/\L,-!'B/+[8MZ:_YY;<U*QZBHLI5#E6W,J;'#-Z26[N?+M[;
M*PA'E/9><:JRS33T\V[JF*O$^2:2^_51T<M:]=LT5/0'Q>/_ *G]VH./^E]V
M3^'_ %.U^K-^+^+_ $MSH>V>#"0        XJD=BD)0B)L5-Z\H2YDL0#XN1
M'6D<D;,(KNWA)&"KZJ8G+NB$4?2$%@N]-R@0B(BQ7:J[U](#C&S_ ,T-Z[@$
M$M(B[T )LCLBG(1!)93JJMIJ[F[H?9)DA]0 'SBVTC8]->4"47=%>F)(0J)%
M$AL=O^P":"1C"&WU7H 0K55$:Y;3-MI=T>8 F]5WJL(+Z0)<DA",>CR@<47:
MG(B[OL!+DMI=R[>0(<&HK51805WJ8[X>B!SWJJ.38G+Z9":H=&,42+O6_P#$
M"$@B0W1W-_XDFY*JY4C"*KZGTO1"$\VV"+'9Z02)%52*653DW[R$'*JHD7>F
M2EQV0]<CMZ[MPW(?4    1R$H:"UU_;6&_C_ ,G(/'?J3\*/3IM>L_3/_)GT
MZ+FJ3YZ^H@$D)%$ $ "(21 @E !)BD (3(*( @ $20B 10! A>6*;>124+YI
MW48Q,QO#*971PR1?V$A+Z-N7,5?^98N/9_IZ_+-U/W(^C^UU[W@?U1CPQRS^
M_->/]GJW/3!] >!                      (4"@:E>/P;]9^Y+*,O0PN;
M+V8                     !4,P?/K)W\3^#-*KNU;UL)WPMY9#,)
M                "HY>^?.<OX9\&<56]J[J81OE;6[BUFD
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M8XLC8LIN+ "$WJ!@LX_-RM_%?EF%=_91=N=W ?V33_?_ (;C*W<1N9%#)(
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MDF\DM4W+ZXU<WFN/'G[F=_7PKP;>'RC)EP=]&[JXTXKF=IP@
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MK%7(FX#!3M2<FT^*)@\_$[&)3.K(N*A>JR\7I)+L]7;O$$K1>;+<8L=]C=L
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MV 7LP                     "H9@^?63OXG\&:57=JWK83OA;RR&82
M                  %/R_\ /O.7\,^#.*K>U=U,8WRMZ;U+620
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M>G1:W?TU^!/ITW-_,1+*)R?=/H<;GS6Y]#)B
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MKBNP^W![73/#U=&DI(2DF/Z7K8)M5 /KYP3\S3/-7S"N<I5WF->"XKI27?\
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M1 -!ZZ)_C&&I"">'_)R#Q_ZD_#CTZ;7K/TS_ ,F?3HN:J^P?/7U!/V !
M          (2 /\ R@2A&_T@+MD;3VMS=-6<]]QATOK3H-?&TCT3HWC')!S(
M'=\L\IOU<UK2WC^WHK'!P/-/.+-'%-]T]'[/5,;I>C\)PVCP6@DX91-L4TBU
M8;%SH6W*]=KE<N]W.?3L&&W%9%ENZ'RO49K\]\Y+M\_^'>3<;#65'-G[<R_^
MN?DV%5^^&,[UO+60                     !"@4#4KQ^#?K/W)91EZ&%S8
M!>S                      *AF#Y]9._B?P9I5=VK>MA.^%O+68
M                I^7_ )]YR_AGP9Q5;VKNIC&^5P+60
M        U)I__OAK'_IG_+IAK8_Q+^KW*;>W=U-MFPN"0
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MUNZ/A'K;/E'F^/2XIMNCW\9]4\6STBB656,-ZGJ8>2ES,F(
M                                         'RA%UI>3JKS<X$)TNLD
M'IO=S1!5+X[45(VH1]"!"7%6KUW=!WJEW^@A*'.Q%+&YB;TYP")N1$@U=_*!
MYQU&J=3\@ZO4^?<)PWMK(5?;[3DW]'2</<T$NFD])Z3)S[<Z8J]!B0AMZ*Q
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M\/=_*?R2R_Y;O9OMX_ZW@X^_^8_[-GX>[^4_DEE_RW>S?;Q_UO!Q]_\ ,?\
M9L_#W?RG\DLO^6[V;[>/^MX./O\ YC_LV?A[OY4?R2R_Y7O9OMX_ZY@X^_\
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MV\ML4B'RK)DNR73==.V785/LIS%BI*;B4*CFS]N9?_7/R;"J_?#&=ZWEK(
M                    A0*!J5X_!OUG[DLHR]#"YL O9@
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MY$ B"+'[@!=Z;-J\A(F,$] @1MV<R$CF$
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MZ0')8.WH"'%R1V.VVOZ@/J       !4*CY]4?XSX,53VF'2MY:S
M      /%GH?T'PU]\-RPCLY2!<,EY!Q/-DYLU&7>&-C>U$6.A%'HWHWC'=9D
M-AV_+O*\FJFL=GCL]?16.#A^9>;8])%-]_1&WU=-)C=+TS14=-AU,RDI&W<B
M5&RR*NZRJ[>Y57>I]3QX[<=O+;LB'R3)DNR7<UVV9=HM5  "H9N_;>7_ -<_
M)L*K]\,+M\+>6LP                     "% H&I7C\&_6?N2RC+T,+FP"
M]F                      5#,'SZR=_$_@S2J[M6];"=\+>6LP
M              !3\O\ S[SE_#/@SBJWM7=3&-\K>F]2UDD
M         !J33_\ WPUC_P!,_P"73#6Q_B7]7N4V]N[J;:7>ALKD@
M                    $#!9Q^;E;^*_+,,;]R)W.Y@/[)I_O_PW$V[B-S(H
M9)
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M;I=Q42]S7.WS9;4W-=RD(JMQ(       J%1\^J/\9\&*I[3#I6\M9@
M        'BODA]L^&/OB\9!R!59MJDGU"7>%2_&3.B[K-F(FQ)C'=9AW_*O*
MKM5=6>Q'V^N)WP\]YOYO;I+:6[;Y^SU3&Z7I*CHJ;#J9M)2,NJ:7&PR*NA:5
M7+M<JKO4^G8\=N.WEMW0^59,EV2[FNVS+L*D5CNAN4M5.1*  !4,W?MO+_ZY
M^3857[X87;X6\M9@                     $*!0-2O'X-^L_<EE&7H87-@
M%[,                      J&8/GUD[^)_!FE5W:MZV$[X6\M9@
M               "GY?^?><OX9\&<56]J[J8QOE;TWJ6LD@
M         -2:?_[X:Q_Z9_RZ8:V/\2_J]RFWMW=3;2[T-E<D
M                @8+./S<K?Q7Y9AC?N1.YW,!_9-/]_P#AN)MW$;F10R2
M
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M8]WA=L70]%4W(!]^NL(P>WJN]/T /J     %0J/GU1_C/@Q5/:8=*WEK,
M            \N9 R7/S9BC&S&V<+EQXB=%%A:9,L]%'L=UF0V'R?RORZ=5D
MI/9Z?V33IC@^P>;>91I,>SMSNCKBO1,;I>F:*BIL.IF4=(R[II4;+(JZ%I5<
MNURJN]3ZGCQVV6\MNR'R3)DNR7<UVV9=HM5     J&;/VYE[]<_)L*K]\,;M
MZWEK(                      $2-?ZE^/P;]9^Y+*,N^%=[8!L+
M               "H9@^?63OXG\&:57=JWK83OA;RR&82
M       %0R_\^LX_PSX,XJM[4]3"-\K<F]2UFD
M!J33_P#WPUC_ -,_Y=,-;'^)?U>Y3;V[NIMI=Z&RN2
M         "$WJ!@LX_-RM_%?EF%=_91=N=S ?V33_?\ X;C*W<1N9)"4A(
M
M                    !3-36PR5B4-EFX@W?&-1*Y0*'YI+47S?,GI&+?\
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M?V47;G<P']DT_P!_^&XRMW$;F20E(2
M
M                               "HU'SYH_QOP8JGM,.E;BUF
M                *AF[]MY?_7/R;"J_?#"[?"WEK,
M    XKRDB@ZE>/P;]9^Y+-?+T,+FP"]F                      5#,'SZ
MR=_$_@S2J[M6];"=\+>60S"0                      I^7_GWG+^&?!G%
M5O:NZF$;Y6]-ZEK-(                      #4>GW^]^L?^F?\NF&M9^)
M?U>Y39VKNIMPV%P2                           "!@LX_-RM_%?EF&-^
MY$[G<P']DT_W_P"&XFW<1N9%"4A(
M
M                             *C4?/FC_&_!BJ>TPZ5N+68
M              J&;OVWE_\ 7/R;"J_?#"[?"WEK,
M   XKRDB@ZE>/P;]9^Y+-?+T,+FP"]F                      5#,'SZR
M=_$_@S2J[M6];"=\+>60S"0                      I^7_GWG+^&?!G%5
MO:NZF$;Y6]-ZEK-(                      #4>GW^]^L?^F?\NF&M9^)?
MU>Y39VKNIMPV%P2                           "!@LX_-RM_%?EF&-^Y
M$[G<P']DT_W_ .&XFW<1N9%"4A(
M
M                            *A4?/JC_ !GP8JGM,.E;RUF
M              *CFW]N9?\ US\FPJOWPPNWPMQ:S
M   (4"@:E>/P;]9^Y+*,O0PN; +V8                     !4,P?/K)W\
M3^#-*KNU;UL)WPMY9#,)                      "GY?\ GWG+^&?!G%5O
M:NZF$;Y7 M9@                      #4FG_^^&L?^F?\NF&MC_$OZO<I
MM[=W4VTN]#97)                           !'*H&#SC\W*W\5^5887[
MD7;G<P']DT_W_P"&XFW<1N9%#)(
M
M                             5"H^?5'^,^#%4]IATK>6LP
M             !4<V_MS+_ZY^3857[X87;X6XM9@
M $*!0-2O'X-^L_<EE&7H87-@%[,                      J&8/GUD[^)_
M!FE5W:MZV$[X6\LAF$@                     !3\O_/O.7\,^#.*K>U=U
M,(WRN!:S                       &I-/_ /?#6/\ TS_ETPUL?XE_5[E-
MO;NZFVEWH;*Y(                           (Y5 P><?FY6_BORK#"_<
MB[<[F _LFG^__#<3;N(W,BADD
M
M                           *A4?/JC_&?!BJ>TPZ5O+68
M          !";@*EFW]N9?\ US\FPIOWPQG?"W%S(
M   A0*!J5X_!OUG[DLHR]#"YL O9@                     %/S%\^<G?Q
M/X,TJN[5O6PG?"X%D,PD                      *?E_Y]YR_AGP9Q5;VK
MNIA&^5O3>I:S2                       U)I__OAK'_IG_+IAK8_Q+^KW
M*;>W=U-M+O0V5R0                           0F]0,%G'YN5OXK\LPK
MO[*+MSNX#^R:?[_\-QE;N(W,BA*0D
M
M                              %0J/GU1_C/@Q5/:8=*WEK,
M              A-P%2S;^W,O_KGY-A3?OAC.^%N+F0
M    !"@4#4KQ^#?K/W)91EZ&%S8!>S                      *?F+Y\Y.
M_B?P9I5=VK>MA.^%P+(9A(                      4_+_ ,^\Y?PSX,XJ
MM[5W4PC?*WIO4M9I                       :DT__ -\-8_\ 3/\ ETPU
ML?XE_5[E-O;NZFVEWH;*Y(                           (3>H&"SC\W*
MW\5^685W]E%VYW<!_9-/]_\ AN,K=Q&YD4)2$@
M
M                                       J%1\^J/\ &?!BJ>TPZ5O+
M68   8JMQO#L/Q;#L'J9UBOQ6^X1EEZV^%8DQ^U&JU(-7U2H83?$3$=,MFS3
MWWX[LD1]VRE?579#((J;MSF[OLF6YKOJ2@               A=P%2S;^W,O
M_KGY-A3?OAC.^%N+F0                     !"@4#4KQ^#?K/W)91EZ&%
MS8!>S                      *AF#Y]9._B?P9I5=VK>MA.^%O+(9A(
M                   5#+OSXSE_#/@SBJWM7=3"-\K>6LP
M         !J33_\ WPUC_P!,_P"73#6Q_B7]7N4V]N[J;:7>ALKD@
M                    CE4#!YQ^;E;^*_+,,+]R)W.Y@/[)I_O_ ,-Q-NXC
M<R*$I"0
M
M        5"H^?5'^,^#%4]IATK>6LP   \R^=S7U>&2LIUM#,NZJ3VC9?9:Z
M%M:1J['(J;E4X_F,TY>OZGT?]%X[;^^BZ*Q]S_6W3IOG*7GW*>'9EDML+5WU
MN5%70NI\R2FU62XQN_6G1P9.\MYGC?-=#.CU%V+A3W1/&>*XE[E
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MN=S ?V33_?\ X;B;=Q&YD4)2$@
M
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MV8                     !4,P_/K)G\3^#-*KNU;UL)WPMR;U+(9I)
M                  "GY?\ GWG+^&?!G%5O:NZF$;Y6]-ZEK-(
M             #4FG_\ OAK'_IG_ "Z8:V/\2_J]RFWMW=3;2[T-E<D
M                       @8+./S<K?Q7Y9AC?N1.YW,!_9-/\ ?_AN)MW$
M;F1,D@
M
M       !4:CY\T?XWX,53VF'2MQ:S   #RYYX\5P_*ZKU?S_ .STJ,X_F/[O
M7]3Z7^B.UF_@_P!;R-MAM^PIQGU-[1\V;55N8L(^1V,/AB]!^B38?I%_,J:A
M^R7*:UEAK4ZSEB=W19^:.6=\>U\@_5?E'<9._L[-V_\ LTBV(WS6:SZMCT1U
MMJ==#IO .9(            !";@*EFW]N9?_ %S\FPIOWPQG?"W%S(
M                A0*!J5X_!OUG[DLHR]#"YL O9@
M   %0S#\^LF?Q/X,TJN[5O6PG?"W)O4LAFDD                      *?
ME_Y]YR_AGP9Q5;VKNIA&^5O3>I:S2                       U)I__OAK
M'_IG_+IAK8_Q+^KW*;>W=U-M+O0V5R0                           "!
M@LX_-RM_%?EF&-^Y$[G<P']DT_W_ .&XFW<1N9$R2
M
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M0S"0                      I^7_GWG+^&?!G%5O:NZF,;Y6]-ZEK)(
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M=\5*L/;9OFJ]FUS418HG(JB+HF:1T-B_!?9;;==&RZM.K>[Z.15V=9.3TR5
MVU#=97D7>$OH2@ ^:K%%;&*IO7TPD5^UK56#UC93TMY Y^@A(D(?.*HB12"\
MV^!%!"JJ=9T?L!*>DB[5V<P0A5=M3=Z!(*MG:FU.7D .6"+ZE$W\N\#DCT@J
MQBG+Z 2(B;HQYT"',
M                 5+4?'*_+F3,2QG#'W=;2W%V^#70O*B7+78]KDW.7D-?
M/?-EDS#J^5Z>S4:JW'?MB:^RV9:,T]\Z["ZR&'Y]D\ UL8XI:?/M1O'>)IJ5
M(0@QF_ECSFAAU\?O_M](>T\R_1^2W[VGGF_L[N'3==],O1V#XSAN.43,0PJ=
M?4DR-E]E[.JY6+L>UJ[VKR'4MNBZ*QN?/<^"_#=-M\4EW]L4^V9J6"S?C$_
M<N5F+4B6ITBZL;43KS6,7K(Y-SN8(5?0O.M=J%I7@&;Z^7<U6(\9>RXM?#AZ
MV?(3:UDM-TM/4H!L-45JVH6N=8P)0T_ICJ;B^<-3]2<G5TNS0Y2[#X.?&6MK
MM2CFU$SHME,5(*Q$Z3G>A BC):,F5FHE5FC-$G..%<%EZGX#Y-5G$4DZ_O)+
MUJ^A3HCV6'HUOA=^]NP(7=B*J)'HJNY-\( ?8    <>LJHO5Y .EBV)2L)H)
MV(SMLJ39V;4ZSD9R(J[UYB!5-*]09&J>0L)S]24G 2L3XBQ2WBS[/#5,VE7I
MNERE6*RH]1-_V3(5;S<M2\5U6T^H\U8S+NJRHO;QD6.\755$A-LN7*3=*3U)
MBEMQ5<J0C%?5?U$HHI%'6ZCKJ+B=%5858T_9<=G8CQ%(ZU&D5TWP34OTA/Z/
M27T4Z(%^                  'RW*C57?N3F@*#R'YX:J[%,M+NAQT/1Z%&
M<3S'?'7]3Z=^AO\ W_X/];S&<I]0   "4WQW>B"1=FS[1"(3'9"._>GI ;X\
MW/5ZER1BD[+V8IMW@%?9LU-E7</<,J)J]"5)>]]M[VIUDL^D=#2:F,<TNW/$
M_J;R6[661DQ16^WH^:O+'3,1%(CK>XFN1R'H7QF82$             5#-W[
M;R_^N?DV%5^^&%V^%O+68                     !Q7E)%!U*\?@WZS]R6
M:^7H87-@%[,                      J&8/GUD[^)_!FE5W:MZV$[X6\LA
MF$@                     !3\O_/O.7\,^#.*K>U=U,8WRMZ;U+620
M                  &I-/\ _?#6/_3/^73#6Q_B7]7N4V]N[J;:7>ALKD@
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MHY4!5Z                 0O*!Y \\?]K9:_7OP*,XOF&^.OZGT[]"[\_\
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MMI7KB)Z*\6?+6B           "HYM_;F7_US\FPJOWPPG?"W%K,
M             A0*!J5X_!OUG[DLHR]#"YL O9@
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MBUL]%B<Z[=H'1U"TBT]U2D2*3/F#]K4]/:N6\354L+Q9;G;::=*7?*9OYO3
MZ^GFC&FNE*3Y6G^"]D2ZFQ>IQ5751N[Q4_2ITWRK]W/Z0&P@
M    #Q_YX_[6RW^O?@49Q?,-\=?U/IWZ%WY__M_ZWF(Y+Z@ 0  D !  #DJJ
MF_D ]G^:5@^.465*_%JYT<&Q*Y[*;"7LX>?5LG;6JK^NJ==$] [GE]LQ;,SN
MG[7R']9YL=V>VRWMV5YM_3%DQZMW!Z-.H^?@         !" 5+-O[<R_^N?D
MV%-^^&,[X6XN9                      $*!0-2O'X-^L_<EE&7H87-@%[
M,                      J&8/GUD[^)_!FE5W:MZV$[X6\LAF$@
M              !3\O\ S[SE_#/@SBJWM7=3"-\K>F]2UFD
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MDL7I3UF(L4F.7:AHZJ.ZR5M]-CU'D5\Z[01;FV\9_BGA3@]SGHWQ0
M          /GLBEG<G6(E,(BD/2Y"42^H #XO8U\$=M;SD)0YRVHV8PWI$FB
M(E*1:Y4:D%V;.<)0QC6.2"[&]1G-'?M"!9;8*U_BTZK?6]V(HFJ5@KH+M1VY
M.: 0B$7KMB]O6;Z>[:*#'?)_"9N,2\>?(M8M)M755;>G7EW3NA:L]79M0#)N
M;L5NZW]J G:G<CI.LN58*V/HQB*H2JKR)T5WO]+T (1JQ@J[/N]R @0BVXP3
M8[J+Z6\B4I3:OX*<W.2A$.FCG;V?_B (EC8[>SJNYX[]@')>CT6MZ/)MW@(H
MBPWHWK)S1W ?4                 \?^>/^ULM_KWX%&<7S#?'7]3Z=^A=^
M?_[?^MYB.2^H $  )  0  V%I'IG7:EYD3#I:W6%2(]H5?1==6Y,Y\KH+-EN
M=:=+L]%=G*;&GPSENIT.%YSYK;H,,W[[I[,<=L5VTF(I$]+]#Z*AIL-I64-'
M*NZ63&PRTKNNY7+M<JKO7G/3VQ$1L? LF2;[N:9VNZ2K          "$ J6;
M?VYE_P#7/R;"F_?#&=\+<7,@                     "% H&I7C\&_6?N2
MRC+T,+FP"]F                      5#,'SZR=_$_@S2J[M6];"=\+>60
MS"0                      I^7_GWG+^&?!G%5O:NZF$;Y6]-ZEK-(
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M:?A,&IN'D)ZF\F/Y7.WS'.7>Y3T&'3V88I9%&[;;$;F56U'8FQ-R1WFPR?0
M (&!SC\W*W\5^6887]E%VYVL"V85(7D6W'_TW&5NY,;F2@L-\3)+D$
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M.ELI%5%@J[$WFT\ZY$@          0FX"I9M_;F7_P!<_)L*;]\,9WPMQ<R
M                     .*\I(H.I7C\&_6?N2S7R]#"YL O9@
M           %0S!\^LG?Q/X,TJN[5O6PG?"WED,PD
M   *AE_Y]9Q_AGP9Q5;VIZF$;Y6Y-ZEK-(                      #4FG
M_P#OAK'_ *9_RZ8:V/\ $OZO<IM[=W4VV;"X) #CNV\A ^%71R*V0^FJ66Y#
MH1;%4W*B\BHN]"C/@LSV39?%;9W]'KZ$*36:5X5.?:I)W#-YK+YG-ZZ:>,U'
MZ2QWS_MW]W']V;O?<RV<'4;I-36MN(;.>Y7VTT;?T;=TY]G]S^M,TX/K+THH
M&+:G5EXQ-[;IS?N338Q_H^(NVY:QPY/ZD3,,A)TSR[+>CWRKQO*EJ:WD_P#:
MG2M_2^EK][;'\7\R-C(RLCY9E1LT447_ *V=_P"N;%GZ9\OC_P!O_%?_ #)J
M^];E3!*ZA[.GTT:?D2W,]<C^1Z+O3G.MC\OP68^[MC[OTS]/%C=;S;WGO.FA
MV/89-?49>7CJ)(19X*3#8Q-\V>J[U<<#4>5WXYK;]Z/V?6YN733&[:U%54LZ
MBF+*JV7<QN]L4="*(N]JKSG)Z:-.8IO?****(K4M>CN%$N_0X+B>)/NZ*3?.
MYK3&<Z^J<G,+(YII#*+9G<O& :*9RQ>HL5M/P%.O]K;IY_([U+9R+O2'V3I8
MO+\U\[J1QV?%=;I[IG;L;4PCS=\ I'I,Q.L[03UMU-D<Z;V5"\Z?T'4Q>3VV
M]N[FZJ?6VXTML;VP<(R%E7 H+AF'W#D]5?3G\_(^8[URG3PZ+#B[,4ZY^+8C
M';&Z%G-U8     !";U P6<?FY6_BORS"N_LHNW.[@/[)I_O_ ,-QE;N(W,BA
M*0D   #@JJB1WJ@@>7/.ASSC7%T>1, G66S[WM.39EK>6&TM3)Z4UG1L])>@
M_;R\QQM=EFL61U^Q],_27E^/ENU&2-U.6=NSM6SNGWPX97\TBF3#&3\SXG9Q
M"=&W3W"K<V'N1.E)J[+K3;*^@,?E^S[T^G[4ZO\ 6<\],5FR.FN_JFS913:3
M2K5+2K4>5\CJ?M.6RUP%;;HJ:_C2+>>#J)LVQ8O7-Z6^$4*(T^7%?]W;^QV+
M_.-!YCH_]^>3YK?O33[VS;$16M(G8]?9FS/A.4,(J<?QVHX;"Z.Q>S+#YD+V
M8V4FR6U[NL]/4G<R9(LMYKMD/DNETF34Y(QXXK=.[=PKTO/>'>>'A=1B3*3$
M,M\'AKHWE?QSYL(,5R>#91VEBZ#?MG,CS&L[;:=?V/>Y/T1?;96W+S7<.6GM
MYV^L4S;0TN5IN;,-9VC12[-RV+J>W:G)(=M>Q52"JN]O(=&[)$6<T;7A\.BO
MNU$8;_NS^WHJT>GG=X*W+_:,S!(XYZG">*F):\+87PR4EA(,Z>[T-YS_ ,PB
ME:;?3U/:?]+R][RQD^Y\W+'#Y>>N_9[5VTDUYPG5&IFX>^A['Q679N:.]?5W
MEI)KG>$N)36V6RK6U=L8&Q@U499I2DN-YS^G<GE\1=%W/;QI2F[HYIG?+-ZH
M:KX)IAA$FKQ*7Q&*55KL_#K4R7?74R4V;X5DJ:UMELU'=+?N0LU&HC%%9WST
M-+RCR;+YADY;=EMO:NV32M:;*Q6M*;&O\A>=+@F;\6[*QG">P'SOT>?Q$RNM
MV&3'NZ,NE9"%A$VKR^@:V+71?-)BGI]#N^8_I'+IL?/CO[RF^*1;TQ'3<ONK
M>J:Z5X53XFN$]K\3;Z'$<+"[?*9ONIOE>;D-C4:CNHK2KB^3>3_F&2;>?DI3
MHKQ]<<&O:'SJ:'&,S4V X3E[BJ>IMV:WC'2_%R5FKX-]*B[T5O6]$UHU\774
MB/;]CO9?TA?BPSDOR4F.CE]=-\7,WJ5YR.5LB5+L,PN1VYC,J'$T=N=1W5I)
M;V>$?33&.M,F*[8NR$-ZEF;6VV32-LM+RO\ 2^?5V\]\]W9.Z=EU=]=G-$Q2
M8?'3/SE<#S]B[,#K\.[%Q&?'@Y5],K+VQ+FS'[6TTMK;+9:+TEVQ] C#K8R3
M28I+/S7]+9='C[RV[O+8W[(MIMB(_>FM:M(^<SJ+4YCS,F5I=)PE+@W7F7B3
M;_BY--.38LMJLL*WURQ] T-;FYKN7@]E^E?+8P8.]K6<GJW<LW1QVU;=TZU4
MH\[:=8W+Q' +%#@?"7M-QCEXGC*N8J=-DIBLL*Q%Y;7H&WAU$7XYK'9IT\7E
MO,_)[M+K,<V9-N3FV\O9Y;8]<UK7J9KS=<7RKB^7ZR?E;+GR=II=U>TW&SJ^
MW:FU")TYR(J05'+]]Z!=H[K9B>6WEZZM']38<^/+;WV3O9V[>6+>BWAZ;'PU
M)\Y7+F1L3;@^%T'R@Q65'C9%]-H;FTR7,E])],]KK37JO179#;O,<^NMQS2-
MOI]"SRO]+9M79.2^[N[?W=D75WQ.ZZ*4ITLKI7KWEW4N>S#7R>R<PSHW&&6I
MM5:LI->[PR2);$@R7;VKRPWF>#5VY-FZ6MYO^G<VACGKSV1^]LCAT<TSOFCZ
M:TZS?RC7!/\ !.V%QGBHKQ7"7?"7/_4SK5J^]"$.4G4ZGN:;*U8^1>0_F?/]
M_DY.7]WFKS5]<<%1SGYV.6LNU[*3+F&?**4L;Z;?SJ"[@UCF[)U(Z,;3DV>M
M]$HR:^VV=D5]/H=;0_H[-FLKEN[KALB[CPN7_%=0L-S#IK5YNRQ/OI"W=A]A
M[(?G:2%V3I;5WM=ZDV;LT78^:WTVN%A\MOPZV,&6*3_37HGZV,T#P:@?HU@=
M'/EWDN?Q=^EIS;5C$)[F[EV0] KT=M<,>G2V?U'GNCS+)='1R_Y+6J->\'Q#
M*N;\!S-CC^W<FRN+X;"8,HN&M2)$E_AI:OFOMS7H_:WHPAN4U-7;-ET3/WHX
M;GJ/TYGLU.GR8L?^WE^[][M<VVZ=T[(I&SULAKM,7 =4\J8]0="OG=H6G;XV
M**1*W.M-ZKEY#+5SRY(N]-S7_3T=]H<N.[='+_FNEZD.P^:        'R5$1
M(PA#>L2$I5$V\MK<GI HY1Y4W+R@(JFQ-J\B$H0JV45RIL(2A$5$L[N8!%$=
M8W*_=]@($BEE(058P0)F'T)0 <([+7] 2U_JQIG_ #0P-,([2[-<S=-N.(WS
M)4S=>RO)<_*:NHP=[%*T=WR;S;\OR]YR\_JK3HF.$\7TTKTW;IEEU,"3$^TU
M3^\7'#?VLV9U;R;Y6&_D)P8.ZBE:H\X\U_,,O><O)ZJUZ(CA'!>E18=+I<R[
MC9<)]0                      %(U5JJC#\A8O64K[%1+X:#X(L+53*;N<
MBIN4#S+H)D343633?"<V9QS3=8;-XCLBA[/I77=FKGR)_A*>9)<L726NZ;=F
MY +EHAJ/FO+^IV8-"M1\4[5Q;#>#[#K>'D4U_P 11S\2J/!TDMS66&NEM\).
M6,(MY4 R_FW9AQ?&<T:AT^)U-]*H^QN&;8ELLWLFI5^UC6JL5:F\A+XZF9@Q
MFA\Y/2/ J6INL+Q'Y1\;3V);KSA\(E39?2<U7)!RQZ*IZ)*'0S^G_P#UEI4J
M=%R_*'I;]V!R^0##:U8QJ'4><+DK)N1L8[&J<5[4LU7#4M78X;"I-1U*E(+%
M+:==-_H(!@==\%S[H#A%-J7E7,_%5%#;XV1P%-+MWTR11R^E/=4(D$J'+T9:
M^CSH2MD_2?5K.&2DS3FW.?#YSG>*INS*&9PUBHN5Z<B:R5,O)3&KU>CZ80SF
ME6NU?B?FX4FJF:)G%XO)O.T9D&RHV\6FT4K9)D(U(-1O5E^GS@5;372[4S5G
M*E%GK43.\<3Q:]N<,[*H_P TX6?,IG>&I)LILR\;*8_:Q+.[G4(6#0?4O,]%
MGK,FB>HV(]HYHP#@>S*^XDT_%\=33\1G>#I):RY=W+5C>G-6U"*06*!+6^F/
M\W-3-2<\9>H,T=CY2PWLKCV\!0U=]Q%)-FRNM=36V9LI>JY8QV[ +;EVHSAH
M_KWES3BIQ_M;*.<.-N:;@Z>EN>R<,=5NZ:7TUUJ;.CMF-A#E38!;M5YFJV<-
M1L&T]R9BOR;RR_B>W<9X>BQ"U"DE55/X"HL3$A,8]G@W^JB[8D -7:TX)G?S
M>,+H]0LK9JO*:FO>TJ+L^G;>7CY-+*\).=4*VRM0YW19MW+SH&P?/!SCF#*>
MF+\<RS4<-7)"[=8E3(QK*.6NR<QZ;GNY /IEO0W/U324>.9OSKVIFA;WC?\
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M"W%S(                      XKRDB@ZE>/P;]9^Y+-?+T,+FP"]F
M                 5#,'SZR=_$_@S2J[M6];"=\+>60S"0
M         J&7_GUG'^&?!G%5O:GJ81OE;DWJ6LT@
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M<^>+>'P;WEE_A?*K\W3?RTZLDQZ^+TT==\Y
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M9@                     %0S!\^LG?Q/X,TJN[5O6PG?"WEK,
M              5#+_SZSC_#/@SBJWM3U,(WRMY:S
M    &I-/_P#?#6/_ $S_ )=,-;'^)?U>Y3;V[NIMI=Z&RN2
M               0,%G'YN5OXK\LPQOW(G<[F _LFG^__#<3;N(W,BA*0D
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MV*RON^)F6G+:N&JQFQ55$@B\B(1%L1,STRNOS7W619,_=MK3KWL@9*
M                                          *#K BIIUC2[X\+:=^M
MR>0#0NC7FVZ,ZEZ295S!G;*_:N*O[0O*CC\0IMU=.E)T:>IE-ZLIB=7D],#T
MSE;*F Y+PB5@F6*+@L*I[5S2WLV="W,=,=TYSWNZSW+M44%,S[YO.D.J&)-Q
M;/>7.U\16-JHXVOI?42V)T::HE-ZLIB;N3TP/I@^@NE.7<4P+&L%P#A<2RQQ
M?8LWC*V;<=HL674;)D]S7VVN5/"(Z') A*PU^GN4<4S7A&>:S#[W-."<3V9B
M%]/;<\9(2FG>";,26ZU+2STV+#>D%VF4(DK=/\HUN;Z#/E9AMO->%7W!XG?S
MTNN)D)33/ MF)*=:E)8Z3%AO3;M,4F>M/<GZF8),R]GG#>T<'G6;VDOY]/&Q
M,9-;TZ:9*?UY3';'<GIDH6'A)"R$I%9&G7>D5V;;7/'>!@<B:?92TTP"GRSD
MO#>R\&D6[JCOY]3"W-?.=X2HF3']>8]VUW+#<!0<T>:MH-G'$G8KF7*7&UKH
M6Y_:.)R=S&L3HR:IB;F-3<!LK+.5<!R;A<K \MTG X73VKJFO)LZS>/=,7IS
MGO<L7/<NU0.CE?3W)V3*O$L0RWAW!5.+W':,Z_J)U[PK7-E=&=,>C;*/<G11
M(\H$8KISD_'<T8+G7%<.XC,N7>*[)K;Z?+N>/DI3S_!LF-ENM2VHWIL=#>D%
MV@8C431/3+56X;G[ NUUI[?#-XNLI;-N[M[:6=*C&Z9OYO3(@8&B\V/0ZBRQ
M79.I,JW>6L3NN,HNT,2=><-.6HE^$=4K,;9F+:Z+DCN78346C&=(=/<Q99D9
M-QC!^)RU2V^'HN)JI=B\G)4.\)+G-F+&8U';7>AN MT^ID8?)?45#KF0V%IT
M%?"*P38B*JQ50/(&,Y_T_P#.@UBR-@F3)W:N7<N]K=IXG9JJ:''T"3)/@:B7
M2S/&4KV=!7;HK!-X>P]KF[^BOJ.>'H@=@             'S15CZ6Y.>(%1G
MP^7%&C%V^%^#%7[S#I7(L9@  !Y<\\=%[/RM%8JG:&V$/5T9Q_,?W>OZGTO]
M#]K-_!_K>1MAQWU-^@&A.F4K3G*UY4R[&/XE^TGQ58\/.GI*V)-F,2#)GJ8>
MCM/2:7!W=O\ :E\*_47FTZ[-LG_;L[/7%M>B)WQTML*[EAN-QY9]"0
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M(HL6KN]&!*"*VH1LN7?R[B-@AT&HYSNBJPM.W[MQ(FVBN:J;ECM(3,/J2@
M       5"H^?5'^,^#%4]IATK>6LP   \N>>/%<.RNN]$X^/H1?1G'\Q_=Z_
MJ?2_T1VLW\'^M2/-VT5^5U6S-^/]'+]/'AJ;?Q=XVHD/Z<J<Q\N[>QJ[6]+T
MBC2:;GGFNW>]V/U-Y]X6WN<?;G?/R]F>F)B[FB>I[:.^^.
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M_P"&XFW<1N9%"4A(
M                                      !TJNH2CE.J(11L+21WQ5$3
MGA"(0\O:(8GKUK1@]!J@FIGR>RSB-]=Y8["PRO\ $3)]&OYY"3,\9)O?%IUK
M.Y(A+=VFU%J1A^$S)6H>)]IXHZS<S[BDI[,'S%=T:55:L6JQ-O-Z8%)\U?/^
M;=1],*',><J_M7&)U[^<7,BFC9K*J5U:>7+;U9;$ZO(0EO8E      'Q1'(B
M(FSF7?9[L2$J-IC0ZBT6&36:C8GVIC#K-F;<4E-"#YO)2*K.HLO^CTR1?P@
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M-^^&,[X6XN9                      $*!0-2O'X-^L_<EE&7H87-@%[,
M                     J&8/GUD[^)_!FE5W:MZV$[X6\LAF$@
M            !3\O_/O.7\,^#.*K>U=U,(WRN!:S
M   &I-/_ /?#6/\ TS_ETPUL?XE_5[E-O;NZFVEWH;*Y(
M            ! P6<?FY6_BORS#&_<B=SN8#^R:?[_\ #<3;N(W,BA*0D
M
M                    UQK+IWA6J&1<1RKC<RQ155S&9!Z^+J9,_=+F2EWR
MD]4!Y;\RSS?LLU67,J:T3)EG'V]H69-F<L(S:W#UZ25",ZB1\5]O:!L_S-%_
M\#5J;T6Z]#^\U@&A/-WT%K];=.Z:1F[&+K)N&WG8>'\,UUKB*NH6H\+(GR)J
M0FR&N\)'F;LWANK2Y<=T-U4PW1*KQ3M;)^/W_P E77$JEX7@:*;B-9L;?S9E
MY-G_ -M-2S#HQ38@4[-V2,:U'\Z3/V4J;%NS,MU_8_;?YO+J+RXP5D^GWOES
M&V9DO^S<D8]+8!G,W8+4>;'DRCR'IG67>/YLO>SJVZ1USV94,J9O@ZQU2QUI
ME3,;TGMAO2*P1 X+YDU30.7,F'9RO-29'BL>[,1L;?@7?FSZU:?]'59>UO\
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M%[,                      J&8/GUD[^)_!FE5W:MZV$[X6\LAF$@
M                !4,O_/K./\,^#.*K>U/4PC?*W)O4M9I
M          :DT_\ ]\-8_P#3/^73#6Q_B7]7N4V]N[J;:7>ALKD@
M                   CE4#!YQ^;E;^*_+,,+]R)W.Y@/[)I_O\ \-Q-NXC<
MR*$I"0
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MP2P1+7!TU5(F;X.2#D]4U/0B!Z=          *A4?/JC_&?!BJ>TPZ5O+68
M  <5BFY0D]!-Q Y$H               (7<!4LV_MS+_ .N?DV%-^^&,[X6X
MN9                      $*!0-2O'X-^L_<EE&7H87-@%[,
M            J&8/GUD[^)_!FE5W:MZV$[X6\LAF$@
M   !4,O_ #ZSC_#/@SBJWM3U,(WRMR;U+6:0                      &I
M-/\ _?#6/_3/^73#6Q_B7]7N4V]N[J;:7>ALKD@
M      CE4#!YQ^;E;^*_+,,+]R)W.Y@/[)I_O_PW$V[B-S(H2D)
M
M              /A,:CT26YEMJ[TC#=M Q^!X%AF6L.DX3@\CAL/D6KN7;?,
MZ[W/7;,<YW6<O* P?+^#Y>D.I\(IN'IG0M,MS'P@JJFV8YR[W*$L%-TRR/58
M73X1-PNWAU+;X9G$5*0O'WC]J34=M<G*H0L6#X-AF 8=*PW"9/#4,JU=RK3Y
MD+3U>NU[G+O<O*$OE39=PB1BT_')=-=XM56.(FVYCK5TQ9;>BKK*0;LV($,D
MO2V+M5-Z 5&3ICDF1BC<:DX9#$61C,OZCU3+O<LVSU?0"?I6_;!6HMIR;TA
M(5#%=,LD8Y7+7XEAG$52]9;^IE^I1J=2:U-S4Y +334LFCD,IJ9EB2R,&15=
MZJN]55=Z@=+ \ PG :=9&#2+BG?#9;>_<KE_M'.7>Y02Q.8=/,F9GK>.Q[#>
M*JW?VE_42]S6MW2IC4W-;R 9O"L*H<$H)=#A\JYII$;#+3G==RN7:]7+O<O*
M0EWE6"[5W[F\\/1%!Y[H:*=I;YP>)5<UMS@6J%Q<[4?=?)O"U:[<LU[K3YO+
M=P_YD)JAO*=@&$3L7D8_.I[6)TEOAI]N8EF]EW3^BCK*Q;LVM"$5&7L)JL9I
M,>G2+6)T=YP\^V]+-[+24[HHY&K%J0VH&5&7" #$X1E["< 9,EX33\,R99BE
MM\SJQ7U;G>N4#)[5BGJF\OI@:C\X#4?%,AY3X/*\GB,ZXK^P:6TR7>\-/IW5
M/3G2YDIMF5,<OA(1]3M RNB&G\S3+3?",HU3+-;0<3>OBBQOZN?/;L;,FINF
M\CE V4          5"H^?5'^,^#%4]IATK>6LP
M!4<V_MS+_P"N?DV%5^^&$[X6XM9@                     $*!0-2O'X-^
ML_<EE&7H87-@%[,                      J&8/GUD[^)_!FE5W:MZV$[X
M6\LAF$@                     !3\O_/O.7\,^#.*K>U=U,8WRN!:R
M                   &H]/O][]8_P#3/^73#6L_$OZO<IL[5W4VX;"X)
M                        (3>H&"SC\W*W\5^685W]E%VYW<!_9-/]_P#A
MN,K=Q&YD4)2$@
M                                   'Q5()!4MJG67=Z1"4I%&HJK%4
MW/\ 3] E#BB])+21]8[='G YJB139%>3DB0D@J;52+W;TYX$T1,D51%VP7E7
MF&TV"KL2";5]3'^L@A$%5%<N]WJ?2]$D2D>BB-AOY0$5W[F<JD"5V*D.7U1(
M)%55>7D0@<43>B+M7=]@D3"UTO4\J<X^@^EP1(+!$Z/JO1 F+K5E>E_S;OM
MF4P1'*FZ&_T2/65Z!L8JG+RKSDCZ@ .&WEVKS[@$=R+MCR HX)%L&PV+U6_=
MV@1X2%ER[7]5FS9#?M(3+[DH         %0J/GU1_C/@Q5/:8=*WEK,
M                  5'-O[<R_\ KGY-A5?OAA.^%N+68
M      !"@4#4KQ^#?K/W)91EZ&%S8!>S                      *AF#Y]
M9._B?P9I5=VK>MA.^%O+(9A(                      4_+_S[SE_#/@SB
MJWM7=3&-\K@6L@                      !J/3[_>_6/\ TS_ETPUK/Q+^
MKW*;.U=U-N&PN"0                          "$WJ!@LX_-RM_%?EF%=
M_91=N=W ?V33_?\ X;C*W<1N9%"4A(
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M8?4,JZ2BNZAD;*WLUV]%:O6>J;E)BRV)J1$1N9N"6HHFU=ZF3)S)
M
M
M
M
=                                    _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>lg_inventiva-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_inventiva-4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ N@'L P$1  (1 0,1 ?_$ /8  0 " @(# 0$
M       )"@$(!PL$!08" P$!  (" P$!              $" P0%!@<("1
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M;C;2;HJOX:[-W6;.G93,96S)9F4'>G)M\%:>])F^->N'(B@% * 4 H!0"@%
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MVSDY3%'6^<]B:F6Y?"2"T=,)X?C[.82?8NR=LU$7C,F2.)),CI0AR"HU3.B
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M3T$2E?FX7USV/'W$,K3D+S"(<P%]41N/, 7M8H#R@)A QQ !L B #?LK+?\
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MN".PFWOVNA-[-H=R-ILC236AMP<.GL6>E4("A2%E6"S=%P!1L(':N#$5*("
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M4$=1.H(]M:9."*!7C)YR\SOQ'^I9R[47.3&,FB<)9 J<>1%GBV-Q$0FDB0;
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M2X@ W#4 X5@^HET(E'V_]&&PW_M;91\6UD2'_P";KT^HET(4,_T8;#?^UME
M>?\ )9$W_A=4?43Z$*#^C#X;_P!K;)__ -K(G_I=3ZB?0A0Y=Z?_ '=_$MB-
M\MI-Z&_4YD>1K[5[@XMGJ, MMQ&1R,RKC$NUE4XY5^3)G1VB;HS;D,H"9Q*
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ML)B^N'+V>3+QK?(YO8S)X_ #OS)$57G29-B3R39QAE1 1?KXZW=#8ESF1(H
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MG*(;-JY*<J2PH59HNW<NF:[=VU55;.6JR:[9PB<Z*R+A(>=)5!=(4U$U4CE
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M'',!WA=95#M\3R(,D@L@PEY$QV0LG)FJK-VR*ZF(:;;#'2"*@=\GW0"8R9!
M0M5HR<758D4(O?Z-ET3?RF]1G]]&!?XNJR>?<ZA0YJZ=O BZ1>F[>C -[\8R
MS>+*LAVXF@R+'X?-)S$7^/&F4FRJ#%\]:QN&13M56+65!=#E7(!5B@(@/"JR
MNSDJ/ 4)L*QDB@% <?[F;4[;;S8E)8)NKA&-Y_B$NBHB_@,HBFLJP5*H0Q.\
M33<IF,V<D WJ*I"15,=2F 0O4QDXNJQ!!'O/[N)TBYPYD)3:C/\ =+9V0=K'
M7;Q0N8?-L09"=3F%LUCI5DQR%%L4MP OUH:UP'6UJR^?,BAH_(>[%[@ \4"*
MZK,.-'BI=$S_ &ZFTGI4KCH<B&0KMS'Y?)8+T\^9%&<_[6>[-[11:K9UO'U%
M9[E94^4SJ'V_QZ#Q!!<Q3@82EEYL<H<E3.4!*( W(;6_,%//N$T)W>F+HWZ=
MND#$"XAL3MU$8JDLD@29R%5,LAF&3*M^84W.1Y*Y*,A)*@<YA*2Y$4[V(F4-
M*I.<INK%#:"J$FIO69T=[;];^T [+;IS680.,#D45DOMN$OHF/F/;H@'!6R0
MKS$/-M?9C@Y-SAW(&'2Q@H")?^C8]$W\IO4;_?1@7I_DZK)&[.*HL"*&\70S
MX56P70'FV8YWM%ENZ60RV;8TCBTJWSR7QN18(QZ$FA*D59)PN+P*Z;KVAN "
M8ZAR\HB'+?6JRDY.KQ"5"3BJDB@(1^H#P'ND_J-WEW#WPS7<#?.,RK<G('&1
M3;#'<@PQK"M7C@B*9THY!]@T@[3; 5 + HLH;RC6579Q7"L"*'$2'NVW1.W6
M26)N9U&"=%5-4@#E&!<O.D<IR<P?DZN)>8H7"I\^YU"A/[CT*UQN @\=8G65
M90$/&0K-1R8AW"C6*9(,6YW!TR)D,L=) !.)2E 37L <*Q-U=7BR3VX@ A80
M 0'B Z@/I#MJ 17=4/@V=#G53D+S,\IP29V]S>264=2V5[22S+$WLR[4U,ZE
MXQY#S>//')S^L=8&9%U!^DH-95>N)4J1V$?TK[LWTSKJB:%Z@][XY$37[J18
M8-+G*'D*JWA88./E(.E3Y]P4.6-B?=\.F_8W=?;K=UCO3O5D4[MKF$!FL/'/
M PAC%/93'GZ<@T0DDT,;6=G9*+) "@)+)'$MP P"-P.]-J@H;V]?7AO[1^(7
M';;QNZN9;AX@EMB^R%_#*8$ZQULH]4R1M'-GA)+Z_P ?G2G32)&DY.Z[H0YC
M7$=+8DZ;0]I&S_1I.CW^6GJ,_P"5=N/\7H]E9'>FU1X,FB)1N@WH!VN\/O!L
MVP+:K+,ZRR*SK*VV72;K/7,$Z?M7[:(:PQ6[$\!"0+<K0S=J!A!1-0_.(^M:
MP!C!O=4 #K0$)G4+X#_2+U';S[A;WY5F&\^-Y)N5/*9)/1.(SN'LL?1E7#=N
MD\78-I'"I1XE[<LB*ZO.NI=90P@( ( %HR<758D4.&?Z-ET3?RG=1G]]& _X
MNJM*[.2I+ -$M'1IT<[6=#NSQ-EMI'61R6/&R.9RM],9<[C7^12<Q->RIKJ/
M745%0S0Z39HQ111*"("4A-1$=:QA(VQH2* TAZQ/#UZ9.N&$:,=Z\.6#(XI,
MR,#N+B3AM!Y]"(G$1,T;32C)\B]C3F&YFKM!RA<1$I2F$1&\9RA@10@FW*]V
M0AEWYEMHNJ"281IS<P,-QL):RCM$HFU+]98V^B4G)BEU WLR5Q[*OY\Q0]!A
MWNQ3T7Q1W!ZK6X1?,7F0PW;LXR!B<P"8"NIN<*V(;E"P"*!N-//GT^XBA*CT
MP>!]T/\ 31D,;F@P&4;S9E%&1<1TKN](Q,W$QC]$XJ)R$=BT1"0D&#HAK<AG
M2;HR8E 2B W$:2G*?BQ)H?==;GA(=-G7=N'C&YFZ$]N3B>1XQAK7!D/R>2F-
MQ3-_"Q\K)2T=[>A,8O.',X9+RZY""F9,O=& O+ZMZF-R4%1"AIB'NV?1, @(
M;F]1@B @( .48$(#8;V'_JZX564W-U8H2&?S<>UG^0O_ ) /Y0=V/R0_[T^T
M7UQC?Y0/J7\H'Y1?J/ZU^S'U-]5_7'X#D]@YO8?P/-?UZ@4V$AM02* 4 J&#
MCS.=UMO=MFQ7>:Y9$P)3E,9%LY6,J_=6$"V:1S4B[YSZPV]1,VM>><Y^J?(?
MI_"-WFW4\ODY2C)QMN7%=GPTKP6H*=R5*JK2V552_#LJ]B-59[K_ -I(]15*
M#A\KR/NQL#A%FUC6:M[6%,[]R1V ?ZY$HU\X:U][WIMDKDH:5DM4S=*TEP6[
M4)=?QSXUWP3ZBBG:W-ON/!A/$%VR?. 1F,7RV%3$H6<%)&R1 $>(G2;NDU]/
M]24WHK6TC[XO3_-WU#5M/U'*6FZ.:5N[%=;49*7L3["DKMJ./$EV?E4V9P'?
MO:;<ONR8GF<8Z>G /_13T%XF5 PWN4K"41:.%>40$+I@<NG&OH7DWUO]+^?)
MJQRYJ^6N9R7^C<<K-[=A;NJ$GCC%-=9=4DJP:?8<P%&X7X^>U@'T>4//7JL)
M<:KMQ_MV]HI0_56 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MMR\/BI5[#DFG"%'"FU]/9U?B:9AJ-S7'36X\U@X\H"-QL%?+N&!#V4H?H/(
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M--IIE6J;&>?6\0* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M>GT7IM) ^8.V_'2_E$?,- .(Z7#7R:>?YZ SZ+>;X_-\50#'$=-;Z#_4'2I
M'SV^;A?[H7IV 7XZ:@&OE_4I^ ,AP]/Q#Q\WIJ 8O:WIL%K\.%A"^HU(%[?$
M%_( ^CSTQ '6PV^?AVZ=E]:)TV$41^3!Y0"^HAJ)1YA*) ,4X>L4Q0&X#Q 0
M"KVYRMR4[;<9)IU6*HZ_BBZINVT-]>GKK-FL(*PQ#<P[W(<42%NT9Y!<RTW
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M=%-OV*K+6[,[[48Q<D]FQ-_@;U[.^&IU:;OB@Z'!1V]@%BHG"<W#45Q[G(H
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MV?==E;9J2RMVM73'I7Z*G(L;T*;^/Q 5V>+PY1XA)Y$10Y?-:-;28#7>=/\
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@ H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2123561d2-tbl_indica4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2123561d2-tbl_indica4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@". .2 P$1  (1 0,1 ?_$ 1@  0 " P # 0$!
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M^U]OG\K;DM^SLX<*$^+?=UC[7V^/RMN2WOG=,8I0<R?%ONZQ]K[?'Y6W)?\
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M(G=E<>LM=TW6=HOFMH.B[!NS:0J6J8^X*PD$XM.UY=R:5%:7=F.BHFJ#4HD
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M[9?D_KYFI7KNGS-DW6=O'2#1JW3.LX<N52(-T$DP$RBJRZHE223(4!$3&$
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MA!$BB:A! 2F 1 0'J&6 @BHX+/NK^V2BX1=[:WH]BY+]VO0.02[9#BG:=P[
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MR<WMM_6UJUYR YXZ;M5-T[6Z#&UV2TVO&S]KCHJ+BKDT=^F-Y9+Q:*Y9$9)
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MHJIVZGZ:@VE9UBR>R%C;2E/KS%DSC48..M$;.,K4K%G9QR!%D%WJR;@42F5
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M)=XKLC4]MKEA2NBVUYH^PMB+LW<_7IYC+,JO6F]?52\B@V<,I [HPF5,=,H
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MPB81,(F$3"@\%R@[Q(/_ /G_ '<>G7_T@,@__+"[\'SA'/(NU[_H"7_O#/\
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M]"3U$]YM _6X>^HU"\]^(3>7MJZV]J41%_,LG#0XNG719%*N0;,ZA?\ HO\
M<E<MCD^:7*V=J6Q6N>XW[:%P(\"3F \CN+$;FT#,?^:AX\_<"DGP@7#GV^Z1
M_C3KZ5RS[U-A_K[/0D]19>\V@?K</?3X0+AS[?5(_P :=?2N/O4V'^OL]"3U
M$]YM _6X>^GP@7#GV^J1_C3GZ5Q]ZFP_U]GH2>HGO-H'ZU#WUGX0+AS[?=(_
MQIU]*X^]38?Z^ST)/43WFT#];A[Z?"!<.?;[I'^-.OI7'WJ;#_7V>A)ZB>\V
M@?K</?5/\@><G%"TZ/VS6Z_NRGRDY.4"T1<3'-G#DR[Z0>Q+E!JU1 6P *BR
MQP*'A\8YU[=G:1LS4-M7UC9WK7W4ML]K6Y),7$4 Q;3OK2U+<6ARZ?/'%<Q.
MD=$X  XDD&@7Y.VKMRQ<H/6:ZS1VU72=-7394Z#ELX14*JBN@NF8JB2R*I ,
M4Q1 Q3!U >N?(K7NC<',)#P:@CD7AH+FFK20X&H/**<".;N+],W=V]XFUW,S
MB]+[IDVS+;C)+S6MV5P9JP8;"8MTRE1;+=3I)I7-(@=#I$*!7I2^4( *=LN?
M5/9CVGLUAC- W \#51A%*: 2C@&.X?C>:@\/SO&]AVINMNI-;I^H. OP*-=@
M!(/7IQ'+Q'*!V$SW1=[4$J/V0;1^WN/_ !9ZZRB+[27SQ]1BP9XSO.^8*=Y>
MLTPB81,(F$3")A$PB815E!?A9V-]J.LOX;L/-:/]+D\QG]M5M^U=T#YU9N;*
ML3"+ " AU >H819PB81,(GBPBP ]0ZAT$/0$/" X19PB81,(F%!X* ZS^Q%#
MZNW+V9S^46WV7])WUBL(_$^,_*5/LO5B81:<\O.2-LXZL=4$I-!BMA6/:VR6
M6NHJ(E[">M-49"49N5F*HR!6+U,H*NTR)F%0"$(4PF$?!G0][[MO=K>Q,L;9
MES<7D_5-:Y^0 G+EQH>)=3&BX+7=6GTJ.#V>)LLT\XC )RXN!IC0\H^+BOE0
M6X>53&*O<_N#1VJ-40%9H\Q8(NR2N[6#NO'GF"C3S5A97[6(54K\"HT.LJN^
M%)4$?) '8'KF,6N[PAMKBZUK3[*SABAS->^Z:6%V9H#7N#3D%"3FH<:#E6$-
M]K;6RRZA;P00,B<X.,PRYAP#CE\%M*DNQH!P5PM^0NK8"JU.8V7M#4E0D[)4
M$[CV?OA0HU]W%$!JF_EZ[,2BD6>:KR#IV0A'8)$*?MEZ@ F ,YFVW1I++&WG
MU6[L8;F:$24;.US"#A6-SLI>RN <!CS+>.JV,,#);R>WC+H\^,C<N7"KFDTJ
MT$CPJ4Q'.OH6'DAH"HE@#VK=6JZX6U1S*8K0S=^K$9Z?1$DFFM'RL2#R31%]
M'/DE2F273[22A1ZE,(9?/NC;=J&.N+^T8V2,2-S2L%6'@\5/BGD/!3-J^DV^
M3VBY@9UH!9FD8,P/ MJ<0>0CBJFWUS0U-HFS:;K,]-5]P7;<J@H,^M:H..K]
M3I(F(56]S3]=P<OI$Y,)TVBQ>C==1)3]U+V! >#W%OO2M O]/L'%DCK^0>&'
MM#(XBYHZUQQJTU.2F#LKO"%%I:IN'3M*D@9<21ADQJ7%[0UC/[QQ)H&<@/ G
MEXJ\=L;$+K[3M]VI%-6MA3J%"GKM'- >>293*<3".)AHB5^@FX[#9^5$H J0
MI_H3=0 <Y[7]7.C;?NM;A:V7V>W=*!6@=E;4>$*T!YP"N3O+KV6QEO& .ZN)
MSP*X&C21CW5S;6[P/D#4=6T[D!L3B]"LM'6D(1RI9JMM%E,3S*-L)RI1KX\
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M#4WQYVLHZI;X6-:9?P'85KAP6LZ\MFW0L7/ NG,S!O*6@TKT550CS)XQ]JX
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M;:NV:]9H23/7-^>1SENF\;/VU.LB[)RS53!5)T@[2C#H+-E41 Q5"F$IBCU
M>F<G'HFL2PBXBM;AT#FY@X1O+2VE:@TH13&M:+8%K=D MAF+3RY'4Z:TX+Y$
M-3K?9%GC>N56RV!>.$@2"$' 2TNJP%4RA$@>IQS-R=L*AT3@7R@%$PD-T\0]
M->UTZ_OG.;9PRRN9XP8USB*\X -%@R&>4D0L>\CCE:74Z: T^-?PG:M:*NJ@
MWL]<GZXX=)F5;(3\-)PRSA(H]#*()235J=8A3> 3% 0 ?!D75C>6+Q'>121/
M(K1[2TTYZ$#!1)%-$:2M>PGR@6_*$>5>SQ\0RGW]=GV,#)"!8V;>0\DUAY Q
MBF,4K"37;)L79C%((@":ANH /R,B2QNXH&W4L4C;9_BO+2&NZ'4H?B1T4S&"
M1S'B,\'%I /02*'XE[\)0;W969I"MTJWV&/(NHV,_@JS-S#('*12F40%U',7
M* +D*<!,3M=HH"'4 ZAE]KI.IWL9EL[>:6(&E6,<X5YJ@$5H0>A2RWN9!FBC
MD<WG:UQ'? *^5,U^?KCSTOL,),0#\$RK"QFXQ]$O02/U["OFL@@W7\F?IX#=
MGH.:US:W-G*8+N-\<PXM<"TBH!&!QQ!!Z%B^.6(Y96N8ZE:.!:>\:%?('KX.
MH^,.N:XHL$Z_(ZX0E8\.2E5GKUZ!Z/H=/V<BG>1.H^(1'YX_V>#&"(/4,)4K
M&2BR("'C_7R,"F*QUR4JO(!Z /C\/BR"*HO'J/R1R460'Y/4/F#D$<R+/@'P
M!X/E#XOG^/'!%X^$/1]$?%DHL]1'T1'(P1/" AX?EB ?K#\O'%%DQNO3IUP!
M1%X@(@/7]G)(19^?\K(1/#X^O3^U\["5*?1?+_MXP3%8R43"5*R'A]'I\W(*
M50>OBZ^#YO4,(5C)4+V&KEPT<-W31=5L[:KI.6KE!0Z2S9P@H55%=!5,2G26
M14(!B'*(&*8 $/#DM>6'.TD.',I!((<W!P-0>4='=KR\B_31W=O>)M=TMX_3
M&Z9%)CMMBS[%>M;Q5DSCMCMFXE(1H8H"W*VN:"'T1T2E,1\0AE2"!P,GGU9V
M8]IS=::S0=>>!JH;2.4D 2@?@NX?C*<#CGH:T=XWL.U-V#4@W3M1(&H >"XT
M E'-W)!RC\+B.4#J14!ZS^T1#T;U'_BRUUGM<7VDOGCZC%WEGC.\[Y@IWEZS
M3")A$PB81,(F$3")A%64%^%G8WVHZR_ANP\UH_TN3S&?VU6W[5W0/G5FYLJQ
M8'Q#\P<(N%>I^\TV%:V.FZ1JS0CBY7G<SG=#B%9VG9#=DSC%=;6F:BUR/908
MQ18S1\E&"=,J29CI@8"  ].N<!M;;,.U-)&D0W-S=,;(]_67#L\AZQQ=2O,V
MM!W H)J<QXE633>]:9J*:W<;6U*YUU!W6!W(A*31K0T?,X;8VE3@K9*:FJLB
MU1<)R#)1,[-<QR'4.8Q>P'3.Q9,$J%7\MWO-E[5<AH/1T(VN3C5D7N"R0EPV
M$%=1:5N?ZK0$)7UQB7#B9M$BT#M^1%)-$H^#MX#>ZE5+WG>?[-N%DM=<TAQJ
M6MB].T14=]SA[G>$*>HPK\W&O9&;AG+3TO>. EHP6*B279**:PEZB8H"'6,H
M'$I7' <B@#GO*-T7G:<-&US5\-&:H?\ $&Y\AY5FYMI$+8[08-4DNPB\0C%T
MV;N,>)+)I$(<2K H"AA 2],TM4TYFIZ;/IKY)(F3Q.C+XSED:'#+F8>1PK4'
MD-% =0U4@I_>M-JY19D+GJYW$2C+15.VOJAD[MR<@]VHK:C%:I5MLY48MC%D
M64L<[=0Z9%0^@Z].N4Z+I#-$TJWTF.:6>.WC#!)*<TCZ<KW<I/*4K04Q)7U]
MW]Z7=='3+Q*R:>HJ<97Y+7<18X,VVF3C8JCR[MF:KQ6&JT=&NR(M8)PX%(PR
M*S,ZHEZE+T'P<IDKTJ<U%V:CW97[!D^(0R9'K1L[*0W3M$*Y1(L4AN@B':*!
M^@Y@I7MX1,*#P4!UG]B*'U=N7LSG\HMOLOZ3OK%81^)\9^4J?9>K$PBY5=Z!
M5&E[2XF5"1+)>E-BY*UJ"EU8E=9H_;QTK'O&+M=J^0*=1BX327$4U@\*9^@^
M,,\;[6K,WT^BVI#S&_4 UQ;4$-<6 FHX<>/(NE[T@CN66%M+7JY+YC30T-'!
MP-#R&AP/(5]#:/$/6?&_BURM?ZY?[ DW=NTW/1\@C;[?(6LA4XMC(K-@CF[E
M$OFJQU'AP.)>HG   ?%ENZ-G:;M_9^JS::ZY?-+:Y:/D=)AG:<!3CAQ4W&WK
M#1=&OWV1E+Y+5X.=Y?XK74I7AQ/!4+3:?%6K>G=LM+'"HRD?$\:YJ4%K(L@=
M,B2+*.9^9F=(+D,@)T#K=HI5 _NP >G4,Z-HUBVYUS:++F+-"W2Q4.;5M6B4
M@&HI6H!%>4+2MX(Y]3T@2@.#;-SL><!M#_*H'RQ;1=%Y-[VG:]9TM>R=LU]7
M&$O5MWZ0+<-3[@81-491C:M:LML$ZEYIB[59$3:J(D9M12==L /T(4 RWG;1
M:?NG4Y[9Q@=)9C,RX@#X)FMB:W)"]N=S> H,D='#QV@8\?KI;:ZW=20R]1)+
M&P.9/!GAG 8!EA>TYJT\$BG&O&F'V=G3K0E1[LS:^QM4,M15&NW.:"\P"-:?
MJ5^H0)1C/2HCR.48.'["*F&S-9ZV9KD.<H*F+]&("8;-8-8MHZI?63;.TBGD
M$K QQ:Q@DB+00074<T.>&FOX7QWW=RQEIH^H7L(MK=DASC*0U@IA44J ZE0#
MCC3&E5U1Y1K-Y'BAO-S%E\HT?:1O2\<5) Y.VV<T^04:@FW$A#D[21R]"=D!
M#Q=,]@WP6S[&U%T&+'V$A;0<0684'1R+NNL$.T:Y+>'LTE/0*YU\8^[ZI6U-
M%Z*N&U-G;BN%8>52O6?[T<K:EFU$CWAD .@Q;1Z":;IO'M1'LE2(<ANP/3M>
M$<\]VMV<66M[=TZZUFYNY+81-?[.74C!Q\&G%HZ*'NKJ&B;5M;[3;6YO9[J6
M!T;7=49/Q0-. :!6G,*\%2W+6VR$]M7E)2$*[4]0/VU0CX&+CT])2.QMH<BH
M]HR6%H\KM@ZH1=9AHPJ/4SE%)15LU#M&.(H]"]6WK<.NM4UFP9;0V4C8F,:!
M Z26Z:PFA8^E&"C6N) !#&FA=EJ-#7;J234+VV BMG=7E#>H,LUR*8%KJ@-:
M#R@.+0:DBB]J/DZM6$NZJV9>VB1=?P6O;U 7&RNX-S,Q;)\2OH1T5$3(MF#Y
M45R2)C)MT%""8IRG[)0[)Q"FV$-G+M#4]29_R$5O.V5Y87 %I< U] <6U% >
M!Z#2UDMO#'H=[<4%FV%[7.I5H.0 -- <:U "]3;U/V+<K%WKT+KAC*O)Q^_T
M>Z/'QC9PK(3M<CG1WUHCHQ)$OE'BR\*BMVDTQ[2A $GA$P -6HZ?JEYJV\(]
M/9(Z1[H74:#5S&S.+LN!S4&) X@$=PUZC;W=R_7H;($S$V]0,2YHQ>T#G+,P
MIRJ9\3*^C<]]:BN4+OB@S,OKS6LA#OJ71..%FUNY)5'L:9NO4[I8AF7L.$O$
M/DRJ$\Y QO*@(D,8QPZ<_M:UM;[7M.O+&\B%U!9D.CCM'L#HBTAT<CQ1N<8D
M./$D$$D@*[;T3KG58;EM[!*^&$MR1VKX2&D>(]QD<*M-#0CC6@Q6MD-KNN%[
MJJ[VGU(L/5FOO%)P,V>*(,__ - M$9&,S).Q1%Z5-O'/%DR@ @7LJ&\'A$<Z
M=H.D0GLAFNI+;_\ ,FWS*.R'K*-C9EY*T&=].3$KBWVUO[BS7&1O7&YKFIC]
MJ&\>/BDCH)6_5'=URF=Y)*/KJQ)%ALC0&N8S7T@_@7*J%AN79K8O0BGZ;%9
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M-O[<VQR*X]4@VQ9ZHP^VN$+2^SOJ90AD3,[U+'G05M48F]C7**,@V.B0R1#
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MQ @\X4XY!\/]<U?C;9]V5RA;&T]8*-L>O5%S3[[<ZU<'UCK]B>L8YK,R#2#
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MNA"E,*@@7H81Z=!\?7IA[F-;60@-[M /Y5!IR\$%5H@W\H91%%J0A1[8B5-
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MYB'-<69L*9VM+14@5.) JK1Q7$1SQNW<T=JLU->6%0Z1SD.NDT\LV,)![)C
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M#\;ODHO3K^U>]=WVKV:F39$?&R &$'+2(:U2",@X 0-TD)4C9/R0$-_R5!$
M\77-:WU7M<W*:6<NH/B>/P6B.,@\SRUK?ZZAEYNV_P (1(&D\0T-']8K9>C=
MV!R:V"HC+\@>2\]$H+ 15>!@)2=L,E_=!Y1LNJX>Q44U$Y>H=I,5P#KUZ#XL
M[;IW8[NO5")MQZDZ)AQRA\DS^Z""YK&](<[H7*0;8U2YH[4;IP;S-))[^ 72
MK27!CCSHXZ$A!U0]FLZ/9$;7=7'I],>4 P'[:'EDTV3?H<H"42I=LO0/HL]5
MV[V7[1VZ]MQ#;BXOF_[V:CWU[@H&CN>#4<Z[+9:'I]CX4;,TOE.Q/Q<RW"
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M%BZC2)$7\H<A_*"IV1 O9'/H:\EN(=JW$^H,ADG98RN<QN;JW4C<<N-'97#
M\N)H>"])A]K_ &?74!$;K([,&9LAXTIF\*A%*UY:KF35N6MATOPCXOW_ %5J
M#748;9&V?O=DUS'+6)C6(]I*S-R,H6!>O9F1DF$@_?111\NZ4>(I'7.84C%
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MJJ)J]SMHE.]1U6#8^TQ:/*G-3ZC@5ZKYP5S'3$!'(HE *Z!/(G2E5#&\'7M
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M'W Z,/\ U"[]&/U5/W?:1_>S]]OJJ*S?<Z:'BYZF12.QMIJ)666E(]TH=>K
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M1JLJT4:E>*M$UVQW)$>WU$@*$$>GC#.4W/HS]P:!=:-'((GW$>4.(S!N(-:
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MU12;MTTT4$4R)(HHIE22123*!$TDDR !2)D(4 *4 Z  9]3L8R-@CC :P"@
MP  X !>L@ "@X!?VS)%!*C_G_:/V]Q_XL]=Y1%]I+YX^HQ8,XN\[Y@IWEZS3
M")A$PB81,(F$3")A%6,%^%K8P?\ DAK/^&[#_;S6C_2Y/,9_;5;?M7= ^=6=
MFRK$PB81,(F$3")A$PB81,(F$3"@\% =9_8BA]7;E[,Y_*+;[+^D[ZQ6$?B?
M&?E*GV7JQ,(J6WMO[6O'*CK7_:,PK%0GG[>(CD&;1>1E9N9=HN'#:)B8]L4R
MKEXL@T54\(E3(FF8QS%* CG [BW)I>U]/_:.JO+82X-: *N>\UHUHY\"<:
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MU=%:N412\H<.S_<]6[2=XZ?NH0;<TB-S]2%]$89&EKF/:]E&N:6FK27N +'
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M4;'/_P"ST?\ B2?7*Z6YZ\NW)A$PB81,(N'GZ2('7N5>;P?]1Z8_G(:=PH/
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M5(FU<OVBZJ:)%?H@)U[ &ZCT\(YR%]M_0]3E9/J%I;SS, #7/C:X@ U J0<
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M81^)\9^4J?9>K$PB81,(F$3")A$PB81,(F$3")A$PB81,(N'WZ2'T^!5YO\
M7T8+3'\Y#3F!Q4'@>@K>W^A7A2N<7Z,A^9<XE_OVXOQTW[)/%0. 7?'(4IA$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A%#Z_]DE\^J\-[%X;*8_M9.D?5"Q;XQZ?F"F&7+),(F$3")A$PB81,(F$
M5:NOPPP7^S6U^RBF9K'],;_AN^LU8?[SXE96;*S3")A$PB81,(F$3")A%7-O
M^S+5'VSV'V 6K-:7[:+SS]0JMWCMZ3\A5C9LJQ,(F$3")A$PB81,(F$42KX?
MY=O'U?C_ &)5O*8O'D\X?5"P;XSND?(%+<N6:\#*$()0.<A!.8"$ Q@*)SB!
MC 0O40[1A*41Z!X>@#D@$\!P2H''E7GD(F$3")A$PB81,(H)4?L@VC]O<?\
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M1,(F$3")A$PBT5W%SLXM<6]H62C[SV<6D6>>:5^V14::J72>%U .8M.&1?\
MG5:KLPR2 \E"N4_)G4*J'D^T)0*8HCW+:G9OO+>-M/J6W;/VBSCGZISNLB91
MXC8\BDCVGQ7M-0*8TK4%=%W-VC[.V=?MT[<5W[/=R1B1K>KE?5A):#5C'#BU
MPI6N%:8BM<_#!]W?_*!3]SG:W\1\[5]Q7:E^[/\ /MOSJZY]^O9=^\O\BX_-
M)\,'W=_\H%+W.=K?Q'Q]Q7:D/_3#^7M_SJ#MU[+C_P"IC\C/^:6/A@^[O_E
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M:6?A@^[O_E I^YQM;]FCX^XKM2_=G^?;?G5/WZ]EW[S'Y&?\VGPPG=W_ ,H
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MRN@U;V0T250780RSATF0KCL^3$QRAU\(99)HNK1:;^V)+:8:5UQBZTM/5]:
M28\W#. "<O'!8,UG29-2.CQW,+M5$(EZD/!DZHF@DR5KD)( =2E58&<8N23"
M)A$PB\>V7Q=?#^K\GI^OBB+R >H=0PB\>V7M=GKX?!_;\7S\)3E6#*%(/0P]
M/!U\0B'3YH!\K"+ *D'T?E^$!\'7Q?/PIH4\J0/1\?RNGZ_R<*%Y <IO '7K
M\CH/H?L81.V7M=GK]%Z =!\/@Z^#Y(81!.4H@ ^,?E#A$*<IPZE$1#P>'H(=
M>OR.H!A%Y81,(F$3")A$PB81?C>[^_\ [:M='_[0](]E-]S[@_A=_P"BM0_]
MX?\ _2VB^&/XF_\ KJS_ /:H_P#CW"XOP4%.6>8CJ_6XB3L$]+NDV45"PS%S
M)RLD\4ZBFU81[--9V[7.!1$"$(8W0!'IX,^D+FYMK.!]U=O9%:QBKGO(:UHY
MRXT '25\\VUK<7MPRTLXWRW<AHUC&ESG'F:T5)/0K:V3QJY#:=B&MAVGI?9N
MOH%\NFV:S-LI\Y"12KE8HG1;>?O6:34CE8I1$B9C 8W0>@#T'.#TG=NUM>G-
MKHVH6=U<M%2R.5CW4Y3E!)H.4TH%SNK;2W5H-NV[UG3[RUM7&@?)$]C:\V8B
ME3R5..-%%M9:@VGNF=>5C4U MFQK#'Q:LX^AJ?"O9V19Q"#MFP6DG#5@DLJD
MR3>R*"0J" %!14I?&(9NZOKNC:!;-O-;NH+2U<\,#Y7AC2X@N#074%:-<:<P
M)6GI&@ZSK]RZST2UFN[IC"]S(F%[@T$-+B!4T!<T5YR H"[9O(]X[CGK=PT?
M,';A@]:+IG2<-'K1<[9TT72, '27;N$S$.40ZE, @/ASDV/CEC;+&0Z-S0X$
M<""*@CN$8@KBG,>R1T3PX2-<6N%#4.!H0>8@X$<05?<AQ,Y01--4V')\?]P,
M*0BP/*+V=Y0+*WB6\8FD==21<.E8\H(,4T$S',J?LIE(':$>SX<ZS%O?9T]^
M-+AU.P=J!=E$8FC+BZM,H&;%U<*#&N'%=GEV-O*"Q.JS:7?LT\-S&0PR!H:,
M<Q);PIC7A3'@M?/HODC\_P 'A\7H].@YVC#D75CA@5D0Z@'3Q]/#_:\>0"HH
M.93:;UML&MTZH["L%/L4/1K^>52I-LD8QTV@;2I!.5&4R6#DE2 VD#1;M(R:
M_DS&\F<H@/ASC[?5M+NK^?2[6>)^HVN7KHVN!?'G +,[1BW,#5M>(X+D;K2=
M5M+&WU2Z@ECTVY+NJD<"&2%A(?E/ Y2"'4X'BH.':\8=0^7UZ?)_:SD<."T!
M7B*K(_($1Z^/H/R_1^7XL?(E01Q-?I_^2!VNGC'I\H?!X?U?1Z8PXJ,> X_#
MZ$$!#P>$/%U ? /AZ^AX!]# (*C$>,*% Z^$>G@#PCZ'3Y^#3ARIDJ*@8+/T
M7A_NO /R_F9%0F-:\BQ^KX?F@(B/RLFI^)00*UPJGA\/A\7C_P#%D8%9 4PX
M$)VAZ>,<FBC'-W%CJ(>(1#Y@CB@652G4?DX4)U'^SY_Z^*!2#3@G4?DC\_%%
M''B@#T#IU$/F84&M:A.IODC\\<4"DGD*=1^2/S\8)3E3J/R1^?BB)U'Y(_/P
MBR4W3QB/3I_;P>XBQU'Y(_/'% B=1^2/SQQ0(L_1"'R0ZB/C]$>@#\_IC!03
MA2J>$1\'7T/!U\'B^;C <5(!*QU'&"('C\/]OPA\[!X8)\JDU,N=JUW:H*[T
MB?DJM;JS)-Y>!L$.N+>1C)%L/:2<ME0^A,;PB4Q#@9-0AC$. E,(#IW]A9:K
M92:?J,3)K&9A:]CA5KFGB".;HH1Q!JMRPO[W2;Z/4=.E?!?0O#F2,(#FD<H/
M/R8U:14.!!7[4N[3[RRJ<RZFA2+PI'53D)58Q$D] @Y228[ :M&O5U<J>W,!
M#E(;R1COH\.THQ./:*)T#%.'Y_\ :WV27NPKTZCIP?-M:9YR/IC 2<(I3\=&
M/X/X8.!"^_\ LE[6[+?]E^SM0R0;I@8,[*C+, ,981QH:5?'Q9QQ:0Y=7_'G
MBJ]H3")A$PB@E1^R#:/V]Q_XL]=91%]I+YX^HQ8,\9WG?,%.\O6:81,(F$3"
M)A$PB81,(JR@OPL[&^U'67\-V'FM'^ER>8S^VJV_:NZ!\ZLW-E6)CC@BY.<V
M^:EBXR;N",AJ5&V8(3C5=]LHJR,[.,$EG\%(R3-.)78,7"<>JV<%; (JG(94
MHC]"(= SK\NU].N=RP[K>^Y&I06[H&M$KQ"6.))+H:]6Y_A&CB"1A3@A<:4Y
M.*J1UWAG+V"30&<TCJ"0<7OC7_Q*:N;5JP7!<0@HMQ$JV&N6@[LP"[E4X>5!
M=)5H""93D[)BF\>=CR@J,R]6Z][T]:PUGM^M];PUPID?#ZKK\-,*RLH &VWL
MA1 7<')^EK=V/I+5VJBAU2(D%TN9,"]I,3=0!HKBHJ5\N<[T[?=,J<@VL.C:
ME(WUKN/76N8:=;GNE4UO;8?8K)PHUD8YO82.[+'R<"_;BDZ(H==,Y0ZEZ=0
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MP:EM[8%]UMS-IAO&"Y?G<YAE%S"V$2FM"\ 2"/-4@!P%*%=AM+7;VFZ]V@6
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M?9N[]1O=HP[" W56-27&.K%8W!%QB"C1HE;VZ]?DI)%R+!8[=5PP<M%CH',
M&*8ZAC<;HO:CJ^DZ)!HD]GIU]'92%]I)<Q.DDM7.-28B'M:16A#7M< :8$
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MMDK3D:!45<X@"N%3@OG/MM[/-Q[_ -<TBWT2-HMHHI^MF>0V.(.=%2OX3G$
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M=V.;=$IAANM3BT%UU[0;%DX;:]96N#1'U@97\$2#N&J]4;VS;C,0GEM-+EW
MVU]G%^^ NNNJ[KC(&.?RYBPCG!%0J8#F[N9G0>+]&KY:[6%^)=FM=LUI;X=I
M*>J=_*V^<=3\J%I._F'D/(-#KO54/)(-&Q3MCF35[8&,(\_]WN@2:GK.HW76
MS-UR&..XB<6]6&Q,#&]71H<TT:#5SG4<*MI0+KI[0]>9I6C:=:]5#+H4TDMO
M*W-UCG2.<]W69G%I!S%M UM6G*[E7]=W\PC[O@IY@YXV<7=>V:USR5HL^R==
M:WEXS84G/ [0?.9!K.3=MGDH4\F\1,=T5H@B5;RI^H?1#D;=V*-NW,4C-6UB
MZLX8C''!/.UT#64+0TL9$POR@T:7.)%!S++<>^6[CM9&.TC1K2]FE$LEQ;VY
M;.YX<'%P>Z1^0N()=E;C4@\JV8:][SO%O=T-GJZ7XT.MGO:/][RZ[&5H5H)<
M[_6$XH\8E'S\PC?"&9H X[#LY8\K,JSA!(#@**94LZB_L.VZ[3CH[=0U=NCM
MN>OB@ZZ/JH9,V;,QO4XFE6@OS4:YU/")<NXM[<MPQZDW67:=H[M9=;=1-/U,
M@FGCRTRO?UW@MJ \AE*N:VIRC*=)[SR5N-\T+I;CR_A*Q&T_1<Y?YZI2T4C+
MDLSUSL.?<6&41FW;V9>QKA"/>.!(T\@U;G*F >4,H;J8?0=.VG8Z;N74-T12
M3/O]1CA9*UV7JP(&!C2P!H<"0*NJYPKPH,%Y[J.\;[4MLZ?M9\<3+'39)GQO
M;FZPF9Y>[,2XM(:31M&MPI6IX[JL^]XW@VN[;:2VE^-3W:CFDAKRX[+7HMK)
M<[[5"1:D>G%3\HC?DR-$0<^2=G]+TV?E7#9(INJ)?(YY])V';==IQT9NH:NW
M11<=?%;B:/JH9,V8N8TPXFE6C.74:YQ'A',O0(NW/7X]0;K3M/TAVMFVZB6X
M,,@EGCRY<CW";P14!QR 5<UM</!6GUEY4W>S<>-0\:W4!3VE)TO?+/L&L2K-
MM.!9WTG:I:8EWK":<N)YQ%N8QLM,'(B5%H@MV"$[2AC=HQN]VFS=/L]TWV[6
M23NU"_MHX9&DLZL-C:UH+ &!P<0T$U<14F@ P'1+K>=_=[5L-H.C@;I^GW4D
M\;AFZPND>]Y#ZORE@+R&T:"0!4UQ-TRO>2;WDN3ETY1)P>N&U@V/26FN-@Z\
M/!3,EJZY4EO',HU>!G8"5L;V5<(/4F"9SF*_*<B@#V!*0YR&Z_#V3[;BVA;[
M-,EV;6TN#/!/G:VXBE+BX/8]L8:"*D>)0CCB 5ST_:ON.7>-QO)D5JVYN[86
M\\!8Y]M+" &ECV.>7&M!B'U![A(7QK1W@NWWTWH^1UU3=1:*B./5@?6?6]3U
M+47\/ H3,LJH>:5GC3<_/S,XUF"NG23E [LB:B3Q<!#J<#%V+/LPT*.WU&+5
M;B^U*?5(A'/)<RM<\M;XF3(QC&%M&EK@TD%C>;&F][4=>EN-.DTFWL-,MM*E
M,EO%;1.:P/=7/GS/>YX=5X<W,T%KW<I!$/WERU;[MK\K#EXT<7=6RECL)K18
M;MK#6\M$W>2EE%DW+HR$Y.6RQ>D[1^N03.$6:2)5>V</ !C=K?VYLE^WKIDY
MU?6+R&*+JV0W$[70M;2@JQD;,Q:/%+R2*#N4T-R;WBW%:N@9H^C65Q++UDDU
MO;EL[G5S&CW2/RAQ\8- K4\,:Z@#\S^SJ.=Y71:A.@CZ'S@PH:G0?D84X5JG
M3Y']@X66%*A8Z#DJ*C@L]!^0/SLA$Z#\@<*#0H)1#T,5"50 '%0LAQP*R/7Y
M ]/D_MX'\JDG#N+'0?D#\[)6-04 /#D%8FB  _('"D\"LB(B(_-^=\C%**<]
M12N"QX>GB_L_:PF;"F"=!Z=<=Q0#S<%C)4UKQ7TH>&E;#*QL%!1SV7FIA\VC
M(F+CFZCM_(R+U8K=HR9MD2F5<.7*YRD(0H")C"&4SW$%K"^YN7M9;QM+G.<:
M!K0*DDG  #$E76]O<7<[+:V8Z2XD>&M:T5+G$T  XDDT'QK]C/===UO"\8(B
M+W5NI@RGN04W').8V)=-6;IAIUH[0635C8IR51T1Y;W;1R)'[],Q2(E$6Z =
M"J+K_"';%VQW&\)W[>V^YT>UXWT<X$@W1!!#G#"D0(JQAQ/CNXAK?NSL>[&[
M?9T+-P[A:V7=,C*M:0"+4$$%K3C64@T>\8 > W\)S^UH!T#IGSZOH%,(F$3"
M*"5'[(-H_;W'_BSUUE$7VDOGCZC%@SQG>=\P4[R]9IA$PB81,(F$3")A$PBK
M&"_"SL;[4-9_PW8?[6:T?Z7)YC/[:K;]J[H'SJSLV58N2W)?B_MJR;0L%RK<
M:-EBY]9-RU*W73!RR!-(B9FJB*RW: "CX0$  H_J9^5_\0/\//:MJ/:7J>Z-
MOZ?)JFC:E/US'0N87Q^ QIC>QSFD9<E0X8.S8 4*%F:A!%>ZJ0C.(6^G#A,4
M:JHP7*(*$4</FK84CAX0$%15* &#I\G/'[/^&?MROG=6S;]Q'4#&62&,=\R8
M'IX%.K((-14?#F71[0\)R/HT6,'L!"%LD0V0.,>=28\I.("BWZ-V97OEE43(
M*J 4OT9#"3Q@/3/O/L T/^(W9<0T#?T-G=;5:/Q9DNA+=0T;X,;'M)!BK0!K
MPYS:&CJ8+-],E0<TE.BO35:8\@.\RV[H^3=P4QQ/FX)ZFJL1E)S]G-(PKU!%
M8R8.VZL/#H%716 @B406+T^7G?MR]L6OZ!<.L[C13;W%2&F:4EK@#2HR1@$'
MD\)=-U#<MW8N+'VC@>0DU'\@6AUF[X;D]9Q.VJE'I=95.!BI^E\7,RRY0$?
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M?E_]E/@&.#_^D=W^Z!%_Q3Q_J3[1/)T[\@[\XH_TV=G/&NH?^(_V$^ 8X/\
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M-FB**O8/T+VB=L@]!Z!U#/G"YD;+<R2M\5SW$=!)*^CK>-T5NR)WC-8T'I
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M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%#Z_\
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MKT'7?/=Y@^=Q;]URDLBKN&<.'<8J-.UH46KARQ<QJZI0+2BD.*C)XHGT, @
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M&^M]2U:_O;YUL0^)DKFY&OXAU&M%2,*='*%S&::3U%LN^_I%5RV!KZHW6S4
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MX.M!%(^K+ TL!PIGIW2OW/\ %FQ;"MO'+2-EVM58^D;$FM95&0MU3BFWF4?
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ME"JTY8X5;R$HWJZ%G1,\F6#-7Z$7)0*F)O &=E&@0PM U&[B@F<T.RD%Q /
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M?7$T6H1S];.&ESVBN8 -=1M*^"W$&A-16@[#I6S-5M=;EUB6.RMXY=.DMQ%
M7!K'.(+35S1FKE\)U <0*>#4^#WNN.2:O==\2^'1)+5X[8TER(B=IW%V-HF0
MJ"U;9;'V-;5DH68"L"_>R8QEL; 5)5F@F*P'*)P H&-/OOHXWI?[ARS^PW-H
M8F>"W/F,<;?"&:@%6G$$FG)S0S9.KMV58;=+H/;K:[;*\YG9,HE>\T.6I-'#
M @8UQ6X6K>)O)#37>9<A^2U:6U-8>/W*>*UT2\'F)FS1^SJ2ZUQ3Y*'8,*W
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MUM!\>[VQXK<I.2NYH]R^Y)<G=>7F?EX\S<[A_3JB%=?MJ1KJ(3 3KIHL8I%
MZR12@8SPQQZ>'*;B\B-_!9VY LX'@=)KBX_'P[BD1GJRYWCD? +@\UTHAI:?
MT3N[D/M?F;QYT_MGC=6*+&7_ (S1+N04KUSIUCE'3NM;(B6U)N4Y%Q\BPDS+
MM%2H)IBJW,4P]>ST[:;P70EM+..UFN8YRZDII5K@!5IS-!I3'I6MD+0'.)#2
M.1=-.[[C^[WM7*&I3E1Y@<QN3^Y*_'R)M>Q7(V)N[.L5M1=LH5\_BBNM9TR&
M&2.@ ]DRZQS )0Z>AG!ZU^UX[(B2WMH+9Q\+JR"3TT<33XE?"8R[!SG'N_\
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ME:U((!K2F &+JC*#4*^_WGI]I-8PV\4US^T(R^$Q &M " 0XM(K7$G!M"7$
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M6+V,D%) ".Z*_*OHL6#2-:H,6#5LR9-4B(-FC-!)JU;HIAT(D@W1*1%%,@>
MI2@  '@Z9BYSGDN<27'E.)[ZD-:T4: !W%[F8J4PB81,(F$3"+ AU#I\P?G#
MUPB_/!SVX2\I;[RCVSNG0>G;%&;*MNO:1":(Y2<:^52W&NQU.SP$%)18Q7,K
M7UHE9*L[OU]6[ X0?1BL9!3C\8GR[ 6B1_)*F5[Z=WX?#E^%53&Y>[#Y"J[J
MY36.SZ8V#RN;<J"4.V1MJUEW@&W>(^N:[L,./^N]*[+KN_M0UN^5*-G==2L[
M0 DV\G7HJPS2\(^4CEV@^:MBC!Q4C#$*Z^2'=?[BD]Y<58[0476(CCKL*AZ2
MTKW@\<I<'2HK:PXFW.M[+TNVKP6QPYM-\&=/Z=U=V=8QWOI8Z3.Y,8G@)/!.
M*K'DQW8>W9+E5S:V2PT3LSDE2>7\E3[-0U-?\_MK<4:?K^<8:7J6GK13^1>O
M:S?*HSN- >K51%ZC)P$=8Y@\2LLP49#Y- #.X@P6S&D.[?V!4[%WANM9.,BM
M:ZBY$\*^)W%_4UIKEK<W5.*<:ST;M75]T%BG/S![\YBZ>]M;,&RLT+9U*(?1
M=OM=LQ2QI_*M>.#W=I[/UCMSATYVEQ=O,),<5VAO5=O*_=XYO#=FL)"TP>KY
M?7L?9^,&@G=ZL"$<RN+AZ;RS*UQ-:1@H5VHV02=J)I@,<JRKA3BKNYV7#:]&
M[X3N[[#J#3J&]+ VXE\VTI6@H7&KT2SNZ^XL>@DG3^G6&[+1]1+-,'QVYE&S
M]_&HN&7E^RX!4J:2DIR=_P"9:XV[NRN1+B@UZV[ T'5-O6?8?,'EQRUV53-#
M[[F=%<F>.\[R3?L'M,B>./)+U1ZWJTH2K1T2C'W=M(+1[.PG4,[:^4\BF@K!
M^'P^'TACCP/P^'PPG6C^)O>4:"V5QPY?;%A1Y9[!H>LN37'VSZ<F-TTPV\:G
MH_:&WJULK12H[EMD=3=8;1V)0(FK$B[4NY<1A':;@IVCIZ*'5:5%*\59'&G@
MERAI')SCQR+VE6*/&/ISE%WBG)G=%:H]L82\%IMOR=UQ1Z9JND,9"1;P,A>I
MQ-I3$?3J1CF(MSRJ[E?P(G(H=W$H:U546C@[S3C:$ZK*5.V79=56#G[R^W=M
MS2FA.3T3QTVIM'6>TGY7VD;!&;;B;56DFL)!RI%74O7E)Z%>."J)"<3F2!$5
M<.ZE#FXX?_!:^U#NLN2\'JW9E8NG#NB6*JR//-_R-@-:4GEG:HK=U4U_-Z0C
MZ? 6OCWRK=6JGV.)W70[$W4:39;1Z7,; DZ<&0= DFBHJXH!17["<$^\+L:7
M"%SLM^:[,-)<PN1.R82(WYLBL[IO>F./MYXR;9UEK6J[RO4<M74]\3B5ZMB(
M2*$,=\=O%O 9E>N4VIG9GTJ<.CBOL]WWPEYG<==\Z04K^O;/Q7T?5*O<(WE3
MJ\.5:F]N*^U)I6O*,:2/#W3L\\N5WTK$L[>(RAC23BL PBB%8%;/#*',6"E.
M_P##X?*OT<$#H0@?(*4/D>@'H#X0R5"_&_W]O"KE?R6YKU^Y:$T-?MJ5:$T/
M1ZK+3M38LW;!A8FUIOLPXB'!W#YL<KQ*,FFJQ@ H@!%RCU\.>Z]D^Y-"T;1+
MNVU2ZB@G=?%P:XD$M,,(!P!PJTCXEX+VH[:UW6=?BNM+MI)H&VC6DMI@X/D-
M,2,:.!Z%Q,^"=[R'^1SN?_4T;^S+9ZE[];0_>%OWS]"\V]Q-W?J$_P#5]99^
M"=[R+^1QN;_4\9]=\GWZV?\ O&V[Y]5/<3=_ZA/_ %?66/@G>\A_D<[F_P!3
M1O[,L&#OK: _]0M^^?H3W$W=^H3_ -7UD^"=[R'^1SN?_4T=]=<CW[VA^\+?
MOGZ$]Q-W_J$_]7UD^"=[R'^1QN?_ %-&_7;'OUM#]X6_?/T*?<3=W+83_P!7
MUEGX)[O(?0X<;G^7_D>-\7ZLL&/?K:'+J%OWS]"@[$W=7] GI_1]9/@G>\A]
M'ASN?_4T:/ZTMCWZVAR:A;]\_0I]Q-W?J$_]7UD^"=[R'^1SN;_4T:/ZTMCW
MZV@>&H6_?/T)[B;N_4)_ZOK+'P3O>0_R.-S_ .IXSZ[8]^]H?O"W[Y^A/</=
MW+83_P!3UEZ@]U;WB99%**-Q"W$$BLS<2"3(8F,!=1DU7;-G#DI?3;PI(KO4
MBB/R3AD>_NSLV7]HV^:E:5/#O)[B;N_4)_ZOK+W1[IWO(.O@X<;GZ?4>,']:
M6R??K:!_]0M^^?H3W$W=^H3_ -7UEX_!.]Y#_(YW-_J:-_9EL>_6T/WA;]\_
M0H]Q-W?J$_\ 5]9/@G>\A_D<;G_U-&_7;)]^MH<FH6_?/T*?<3=WZA/_ %?6
M3X)WO(?Y'.YO]31OUVQ[];/_ 'A;]\^JH]Q-W?J$_P#5]99^"=[R'^1SN?\
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M%B(OQ<,G2!D5TR* (!&/*AIR*+<CN\ JV@=MN-(PFE-Y[_V-!Z=#D!>*[H^
MJ$S(4G4:UAL-88V1RTMEWJ#RTRTM+U*33:0L"E*3"Y61S V #)>4E/E50;8[
MV;6NMK%;JY <>.4NVW- XSZ^Y<7I>@ZZ@F(4[2-_9VV11FK,PV!<*5,Q-F@V
M%-='=U]1MZ=G.!DT&RIT7!4AK_*HP[J^[J+O5])[7NU+JBVL]^ZZB=OZ8N/(
M/C_=;[KE-"%WQJC7[6)D+?/4:#K4W9;TPD(V,L$>Z0BYJ)BY1^U>I*-VZ@&Z
M 3Y5#![U&NS5JA-13NA.1''?8^Z=$[DV]QME=V56AQ\=L%CJR@J7F6\M!5Z^
MVRRTN=C8-=!^:)LT=%O!3*HDHF18BB01Q4T .*A'=^\S-^[ZW?HRE;+LL5+5
MZ]=TKQ;Y8V-HSK4)$JN=U[1V-?:[<)]NZCF:"[6,>Q4"V(FP((-$#%$Q" (B
M.2HKCW%LER+[R'7FA-J7?3L+J/>N_+KJ+5<7O+>;'1M0@[$AIC4TT\FFT/9+
M>XL-JK'IG,S:-;D'+" ABR<\]:,5UDFADR]1*13XU&+[WIVI*])W8FNM0\@^
M0-/U'KRD;5WKL;3E#B92HZ?I&PJ4WV77UIHMFM%7L%MLY=;.DIYU UMC,S+2
M.<(F4;@HNDD<5&"T@W7WCF\HW;W,YCJ;857E-7ZUM7=%&TK(LZW7)AHI4>8M
MYEHW:KT)55FJO-HVNOH-Q9JK'.+'^Z0$AA$<(:T[O_Q7Z'@^1\C]H,(LX1,(
MN$W>&;OV[K#D,K#:]V'9ZA%/J/5Y5Y'PD@+1LXDE599DH]53 ANTN=HR13$?
M[U,,^#_XG]_;SVIOVUL-MZG=V5G)I,4CF1/RM<\SW#2XCG+6-%>9H7W]_";V
M>;'W=L'4=0W/I=G?7T>M21M?*S,YL8M;1P8#Y(<]SJ<[BM&?^+GDW[=^P?\
M71__ )//G ]LG:IR:]J7Y4_0OJ/[DNR0?_X]I?Y$?2O+_BYY->W?L'_79_\
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MI[O"H]KK>)K:.X 2$"@<"7 D"@MS\T=M:FMTJ"EBXY2K*,NS*#+JN >6>T[
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MY4\EW.S8^F/[;"<8VQG!H%K(*4VSM&;4SMH]&&DW2LDR:2)#"BZ9*.5A 2G
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MDU1<': 8Q!4.)>WD]G][N6U[3][7>K1V(W##8VI/XUT5J]S&.R2%[PYT43P
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M<W)P7VCL[=NQ-?[,-Q;WN-E;;9>:"+0,C$ +9NOD$;C(2,P(&(R\O%;)1^_
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MQY!:'QL9)1L3&Y0(>-0YQDJY=>UKMGT:]VYH^UM$T,:?H^BZTV]A:VY=*Y[
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MT.6)KJU>[  !>N[G[;]B:CM;=.W[?5KZYBU:T L8381VUO9Y22VV:(35SG5
M=,]H;1C<222HWI>-WC98;FK0]75NFSD1?MY;6J+^6L5D6@W=0<3BSZ,DYDS(
MD7(!/1ZL,\+Y-),Z:Z*Z0CV5"FZ!QNQ;;?FJ:=OK;^T[6RN+34=>O[=TDTQB
M-L92]DDA;D=UK#&[P0TAS7MK0@T7*[^NNSS2=0[/]R;QN[^VO=,V[IURR."
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MOM*U"\C]KAT_1].M#<75Q(USQ'&#2C6,Q>\^$0*@4:XUJ #\'3O(*ZWJ[/\
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M3_FEZ$KP;Y0PD5)3,GJ]\UC8A@\DY!R:7@#%;L6#91T[7,5.4.<Q4FZ1C"
M(CT\ 9K7G8'VKV%I+?7>DR-M88W2//60^"UC2YQPDK@ 2MJR_B(['M0NXM/M
M-8C?=SR-C8WJIQF>]P:T5,8&)(&*U,+XOF]!SQ[D7M8'.KRT!Q_O?(:[M:A3
MVPH-"'35L5H=(+J0M8C1!0YGD@HB7Z)=8J)BMD $IW"O0O4I>T<O?^SKLYW!
MVE:\S1=$9EA!!FG<TF*!F)S/(Y30AC 07NH*@5</.^TKM,VYV7;>?KNO/S3$
M$06[7 2W$F RL!X-%09'D$,;4T)HUWZ=='Z2I6A*)'T6E,BI-D@([F)10H^F
M%AFS-T$'DS('$Z@^6<@@4"D >PBF4"%  #/U7V#L/0NSO;T>W]"C#8Q1TLA\
M>:4M =*_CBZ@H!@T4:, OR)[0^T'<':5N.7<6X)"935L48\2"+,7-B9@,&U-
M32KB2YV)7UW7X8(,?D:VM8?^<],'.V'],;_AN^LU=#_#^+YU96;*R3")A$PB
M81,(F$3")A%7-O\ LRU1]L]A]@%JS6E^VB\\_4<JW>.WI/R%6-FRK$PB81,(
MF$3")A$PB811*OC_ )=O(?\ 7\=[$ZY^WE,?CR></JA8-\9W2/D"EN7+-,(F
M$3")A$PB81,(F$4$J/V0;1^WN/\ Q9ZZRB+[27SQ]1BK9Q=YWS!3O+U8F$3"
M)A$PB81,(F$3"*L8+\+6QOEU'60_.>[##-:/]*D\QGRO58^T=T#YU9V;*L5"
M;RX_U7>3&+3FW#J/DX0SD8N1:G$?)E=@F#A%9 3 FJFIY$H]? 8!#P#TZ]?"
M>VSL&V_VTVEJ=0N)K+6+'K!#-& X99<I>Q\9(#FDL8ZH(<"T4=0N!D4X.%0M
M7&O=Y5Q,_P#TR\/G!!/U$J4<5 Q4Q'^Y*(N5 $W3T?!\S/FJW_@-MP\&[W&]
MS [\"T#33I=.['NTIW$I'S.[X^A6E4.$NMJA(M)AG-VA249J>50=I/O,3)F
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M<X4HX'*<"<J^BOX=AO:'7=0U'L^U"P@W%!9@^QW/"_B+JNBCK0!['-80<S7
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M<"8X(S^$\X5)H0Q@(<\@TH YS?V)[3>TW;G9;M]^NZ\\.F=F;;V[7 2W$@_
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M"/Q/C/RE3[+U8F$3")A$PB81,(F$3")A$PB81,(F$3")A%P]_20PZ]RKS?\
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M0T"CNJMF7'36QJ;M/7\NO!7*AV".LE?DT#=/(OXUP5<J2Y!^A<,G:93(N$3
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MK;&GRW9NM/$<PGBC&<E@<XC-U7&/,2V4&,N-*G:3C5>N=UFO+UCR3U5QYIE
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M:=_U*S_N<?\ Q)E^P7_]N\__ +I-:'_^RR__ $-@N!.>>K[Z3")A%^BKN%>
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MS5!T8L8F0B")P.BH4%SE'C= ACAW-#IT,<<-C=6CA)$R;K0_\6\@R. #>L-
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M,2E%(>)F4UR*$6AC2+\BSA+H/ER(^1-] H;.*U;2;;6&0PW>,,4[9<O(XM!
M:[^;X53STHN\[$[0-=[.[R^U+;CA'J=[ID]D):D.B9<%G621D<),K"UCOP2[
M.,6A7R0A2!T+UZ= #IZ =/%T#T,Y2E%T<DDU/%>>2H3")A$PB81,(JU=?A@@
M_P#9K:O913<UC^F-_P -WUFK#_>#S3\H5E9LK-,(F$3")A$PB81,(F$5<V_[
M,M4?;/8?8!:LUI?MHO//U'*MWCMZ3\A5C9LJQ,(F$3")A$PB81,(F$42K_\
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MWY$?IGU$K)S#OGU4],=K^L[7_NCV/WK<9KOR(_3/J)63F'?/JIZ8[7]9VO\
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M1'Z9]1,TG,WOGU5GTQVOZSM?^Z/8_>MQFN_(C],^HE9.8=\^JGICM?UG:_\
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M)[P"WP7&E[6T-J\B^[7Y.:8U/(\@ VO>[77.--S0F]E4BS;1O4@<WWX%(^M
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@U_V.?2G_ #8Y_P \_P"@_P"X_P ]?_TW_._*R%*__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
